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Chapter 1
General introduction
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Assuming that the average age of the readership of this thesis is 35 years, and that 49% is male,
given the number of theses printed (n=500) and the average life expectancy (78 years for men, 82.3
years for women), nine [95% confidence interval (95% CI): 8 - 10] readers (1.8%) will get a form
of facial pain as studied in this thesis. 1, 2
Despite its low frequency the severity and debilitating nature of certain facial pain conditions is an
important motivator for scientific research in this field. 3-5
Facial pain comprises many different disease entities, which differ in aetiology, presentation, sever-
ity, frequency of occurrence and natural course of disease. In this thesis, we studied eight different
forms of facial pain, including trigeminal neuralgia, postherpetic neuralgia in the facial area, clus-
ter headache, occipital neuralgia with referred facial pain, local facial neuralgias, persistent idio-
pathic facial pain, glossopharyngeal neuralgia and paroxysmal hemicrania. These diseases share
some clinical features and are often considered together in the differential diagnosis of a general
practitioner. Facial pain conditions can be divided into primary (idiopathic) and secondary (symp-
tomatic) facial pain based on the disease aetiology. 6-13 While the aetiology of primary forms is
largely unknown, secondary forms can be due to tumors, infarctions, arterio-venous malformations,
multiple sclerosis and many other diseases. 6-13
Two of the most frequent forms of facial pain are trigeminal neuralgia and cluster headache. 2
Trigeminal neuralgia is a severe form of facial pain presenting mostly with unilateral, stabbing,
paroxysmal pain in one or more branches of the fifth cranial nerve (trigeminal nerve). 14 Cluster
headache is also a unilateral, paroxysmal pain in the first branch of the fifth cranial nerve. 14 It may
be accompanied with ipsilateral lacrimation, conjunctival injection, photophobia, nasal stuffiness
and / or rhinorrhea. 14
Until now, research into facial pain is scanty and often limited to a secondary or tertiary care set-
ting. Recent publications reported a higher incidence of trigeminal neuralgia in primary care com-
pared to secondary care. 15-17 This finding suggests that not every patient with facial pain is referred
to secondary care. Patients treated in primary care might differ substantially from patients treated
in secondary and tertiary care. Reports on patients treated in secondary or tertiary care might not
be representative for all patients with facial pain. The lack of recent epidemiological data from pri-
mary care and the need for more accurate and comprehensive knowledge about the frequency, ae-
tiology and risk factors, and treatment of facial pain conditions motivated the studies included in
this thesis.
Aims and outline of this thesis
In this thesis we aimed to gather epidemiological data on the incidence, risk factors and treatment
of eight different forms of facial pain.
In chapter two we describe the incidence rate by age, calendar year, sex and season for trigeminal
neuralgia, postherpetic neuralgia in the facial area, cluster headache, occipital neuralgia with referred
facial pain, local facial neuralgias, persistent idiopathic facial pain, glossopharyngeal neuralgia and
paroxysmal hemicrania. 
To study possible aetiological mechanisms we evaluated both known and unknown risk factors for
the development of trigeminal neuralgia and cluster headache (chapter 3). Since trigeminal neural-
gia and cluster headache may present as relapsing diseases, we also studied risk factors for exacer-
bation (chapter 3). 
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Chapter 4 focuses on treatment patterns and treatment outcomes. We described healthcare use and
the diagnostic work-up of patients with facial pain. Furthermore, we analyzed drug utilization pat-
terns in general practice including type of drug prescribed, dosage regimen, type of prescriber, treat-
ment delay and failure rates. If patients are refractory to pharmacological treatment, invasive
intervention may be considered. In chapter 4 we studied the three most commonly used invasive pro-
cedures for trigeminal neuralgia, including percutaneous radiofrequency thermocoagulation, partial
sensory rhizotomy and microvascular decompression. To be able to better predict treatment success,
we modelled possible predictors of failure of pharmacological treatment in patients with trigemi-
nal neuralgia and cluster headache. Knowledge about predictors for treatment failure or success
may facilitate the development of tailor-made medicine which should lead to an improvement of out-
come, fewer adverse events and better patient satisfaction. The meaning an limitations of the stud-
ies are discussed in chapter 5 of this thesis and recommendations are made for future research.
9
Seppe proefschrift boek:Opmaak 1  01-04-2010  20:09  Pagina 9
10
Seppe proefschrift boek:Opmaak 1  01-04-2010  20:09  Pagina 10
Chapter 2
Incidence
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2.1
Incidence of facial pain in the general population
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Abstract
Background: Facial pain has a considerable impact on quality of life. Accurate incidence estimates
in the general population are scanty. The aim was therefore to estimate the incidence rate (IR) of
trigeminal neuralgia (TGN), postherpetic neuralgia (PHN), cluster headache (CH), occipital neu-
ralgia (ON) with referred facial pain, local facial neuralgia (LoN), atypical facial pain (AFP), glos-
sopharyngeal neuralgia (GPN) and paroxysmal hemicrania (PH) in the Netherlands. 
Methods: In the population-based Integrated Primary Care Information (IPCI) medical record data-
base potential facial pain cases were identified from codes and narratives. Two medical doctors re-
viewed medical records, questionnaires from general practitioners and specialist letters using criteria
of the International Association for the Study of Pain. A pain specialist arbitrated if necessary and
a random sample of all cases was evaluated by a neurologist. The date of onset was defined as date
of first specific symptoms. The IR was calculated per 100,000 person years. 
Results: 362 incident cases were ascertained. The overall IR [95% confidence interval] was 38.7
[34.9 - 42.9]. It was more common among women compared to men. Trigeminal neuralgia and
cluster headache were the most common forms among the studied diseases. Paroxysmal hemicra-
nia and glossopharyngeal neuralgia were among the rarer syndromes. The IR increased with age for
all diseases except CH and ON, peaking in the 4th and 7th decade respectively. 
Conclusions: Postherpetic neuralgia, CH and LoN were more common in men than women. From
this we can conclude that facial pain is relatively rare, although more common than estimated pre-
viously based on hospital data.
14
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Introduction
Facial pain is a rare but severe condition affecting the facial area which can have a considerable im-
pact on the quality of life. 3-5 Two of the most severe and debilitating facial pain conditions are
trigeminal neuralgia and cluster headache. Facial pain may either be primary (idiopathic) or sec-
ondary to diseases such as tumors, multiple sclerosis and cerebrovascular infarctions. 8, 11-13, 18, 19
Due to lack of objective diagnostic tools, diagnosis and classification of facial pain is made on clin-
ical judgment using criteria of the International Association for the Study of Pain (IASP) or the cri-
teria of the International Headache Society (IHS). 20, 21 Establishing the correct diagnosis and
differentiating between types of facial pain is complicated because different types of facial pain
share signs and symptoms and are often considered together in the differential diagnoses at first pres-
entation. The precise underlying pathophysiological mechanisms are not yet completely under-
stood, which further complicates diagnosis. Diseases often considered together in the differential
diagnosis of a general practitioner include trigeminal neuralgia, cluster headache, postherpetic neu-
ralgia in the facial area, occipital neuralgia with referred facial pain, glossopharyngeal neuralgia,
local facial neuralgias, glossopharyngeal neuralgia and atypical facial pain. Because of the appar-
ent difficulty of the general practitioner (GP) to differentiate these diseases and based on our clin-
ical judgment, we decided to study them together. 
Little is known about the exact incidence of these forms of facial pain in the general population. Re-
cent investigations in general practitioner (GP)-databases showed a considerably higher incidence
rate of trigeminal neuralgia compared to estimations from hospital data in the early nineties (26.8
to 28.9 per 100,000 person years (PY) versus 4.7 per 100,000 persons). 15, 16, 22, 23 However, the re-
cent studies relied on diagnosis codes in electronic patient records without additional external con-
firmation and might therefore have included false positive cases. More accurate population-based
incidence estimates are important to better understand the risk of developing the disease. The aim
of this study was to investigate the incidence rate and patterns of different types of facial pain in the
Netherlands.
Methods
The study was conducted in the Integrated Primary Care Information (IPCI)-database, a GP re-
search database with electronic patient records of more than one million patients throughout the
Netherlands. The source population of the IPCI database is representative of the general Dutch pop-
ulation regarding age and sex and has been proven valid for pharmacoepidemiological research. 24,
25 In the Dutch health care system, everyone is registered with one GP who acts as gatekeeper for,
and receiver of information from secondary care. 26
Electronic records contain anonymous and coded information on patient demographics, symptoms
and diagnoses (using the International Classification for Primary Care (ICPC)-codes) and free text
narratives, referrals, clinical findings, laboratory assessments, drug prescriptions and hospitaliza-
tions. 27 Summaries of hospital discharge letters or additional information from medical specialists
are entered as narratives and hard copies can be requested from the GP. To maximize completeness
of electronic data, GPs participating in the IPCI-project are requested not to use additional paper-
based records. The system complies with European Union guidelines on the use of medical data for
research. The scientific and ethical advisory board of the IPCI project approved this study (project
number 07/03).
15
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Source population
The source population comprised of persons with at least one year of valid history in the IPCI-data-
base and contributing person time to the database during the study period (January 1996–Septem-
ber 2006). One year of valid history meant that a practice had been contributing data to the
IPCI-database for at least one year and that the person had been registered with the GP for at least
one year. The one year run-in period was required to have sufficient background information on all
subjects and to exclude existing (prevalent) studied facial pain syndromes. Follow-up started at the
beginning of the study period or on the date that one year of valid history was available, whichever
date was latest. Follow-up ended upon transferring out of practice, date of last data supply by the
GP, first occurrence of facial pain, death or end of the study period, whichever came first. Since ad-
ditional data collection was required for validation of diagnoses, we excluded practices from the
source population that could not be contacted for additional data collection. In addition, we ex-
cluded non-responding practices and patients with a diagnosis of facial pain prior to the start of fol-
low-up (prevalent cases) from the source population.
Identification and validation of cases
Among facial pain conditions we included trigeminal neuralgia, cluster headache, postherpetic neu-
ralgia in the facial area, occipital neuralgia with referred facial pain, local facial neuralgias, glos-
sopharyngeal neuralgia and atypical facial pain as facial pain conditions. Local facial neuralgias
comprised of individual neuralgias of divisions of the trigeminal nerve such as nervus infra- or
supra-orbital neuralgia. Although cluster headache and paroxysmal hemicrania are classified as
trigemino-autonomic cephalalgia (TAC), they can be considered facial pain because of the possi-
ble involvement of the first trigeminal branch. 21 The case definitions were obtained from the IASP
criteria since the amount of detail of our database did not allow the application of the IHS criteria.
21
Potential cases were identified from computerized records by free text searches while taking into
account diagnoses, symptoms, specific treatments, abbreviations, lay terms and spelling errors for
each different type of facial pain. This was a broad, sensitive search to minimize false negative
findings. We relied on a three step approach for case ascertainment. Firstly, in order to exclude false
positive records and to assess the index date (date of first symptoms), all potential cases were man-
ually evaluated by a medical doctor (JK) by reviewing the complete electronic medical records ac-
cording to IASP criteria. 21 A case was defined as ‘probable’ if either a specialist had diagnosed the
disease or if a patient had two or more well documented episodes in the GP-records. A case was de-
fined as ‘possible’ if there was only one episode with a GP-diagnosis or if specific symptoms were
mentioned in the patient records. A case was defined as ‘no case’ if symptoms were not specific or
if the diagnosis was only mentioned as part of a differential diagnosis and no further details sug-
gesting the facial pain condition were found in the record subsequently. Furthermore, if a more
likely alternative diagnosis was present (e.g. complaints related to the cervical facet joint, C2 root,
ophthalmic conditions, oto-rhino-laryngical conditions, dental status or temporomandibular joint re-
lated pains) a case was defined as no-case. All ‘probable’ cases were evaluated by a second med-
ical doctor (MM) and discrepancies were arbitrated by a pain specialist (FH). 
Secondly, for ’possible’ cases additional information was requested from the GP. This was achieved
using a questionnaire, in which the criteria of the IASP were specified for each specific facial pain
condition. 21 The GP was asked to confirm or reject the diagnosis while taking into account the
IASP criteria and send anonymized specialist letters if available. IASP criteria were used rather
than the IHS criteria to ensure consistency with criteria used in the beginning of the case validation
process. All completed questionnaires and specialist letters were independently evaluated by two
medical doctors (JK, MM). Based on the medical record and the GP questionnaire the ‘possible’
16
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cases were classified as ’probable’ or ‘no case’. Patients with missing questionnaires were evalu-
ated by two medical doctors (JK, MM) using all available patient data. Discrepancies were arbitrated
by a pain specialist (FH). 
Thirdly, to further ensure validity of diagnoses, a random sample of 250 patients of all initial ‘prob-
able’ and ‘possible’ cases from step 1 was reviewed by a neurologist with ample experience in pain
treatment (CM). In case of disagreement, a case was discussed between JK and CM until agreement
was reached. Non-responding practices were excluded from the source population and could nei-
ther contribute cases nor person years to the analyses. Prevalent cases were identified in all three
steps by carefully reading the entire patient materials. Date of first symptoms as mentioned in pa-
tient records and prior use of drugs for pain treatment were taken into account in this assessment.
At the end of the three case validation steps each potential case was classified as either ’case’ or ‘no
case’. If multiple facial pain conditions occurred in a patient, the first confirmed condition was con-
sidered yielding mutually exclusive groups of facial pain. Concordance was estimated by means of
observer agreement.
Analyses
Incidence rates were calculated by dividing the total number of incident cases of each disease by
the total number of person years at risk in the study population. Incidence rates were calculated per
type of facial pain and stratified by sex, age category and calendar year. The incidence rate per cal-
endar year was weighted by taking a three year moving average to avoid fluctuations due to small
numbers. This means that the incidence rate of one year is the average of the previous, present and
next year. To investigate seasonal influences, incidence rates were also calculated by dividing the
number of cases occurring in winter (21 Dec -20 March), spring (21 March – 20 June), summer (21
June – 20 Sept) and fall (21 Sept – 20 Dec) by the total accumulated person time in each season.
Ninety-five percent confidence intervals (95% CI) were calculated using a Poisson distribution. 28
Results
Case description
In the source population of 479,949 (1,898,417 PY) patients in the IPCI-database who had at least
one year of valid history, 1466 potential cases were identified (appendix A). Of these, 319 were
considered ‘no case’ after the first validation step and 742 were considered incident (180 ‘proba-
ble’, 562 ‘possible’). For 481 ‘possible’ cases additional information was provided by the GP (re-
sponse rate 86%). GPs confirmed 247 patients as an incident case of facial pain, 34 were confirmed
but prevalent cases of facial pain and 200 were denied as case. After additional validation steps and
exclusion of prevalent cases, 368 confirmed possible and probable incident cases of facial pain re-
mained. After validation of the random sample (250 patients) by an experienced neurologist, six fur-
ther cases were excluded (4 probable, 2 possible), leaving 362 incident cases. These cases consisted
of 78 possible cases of trigeminal neuralgia, 16 cases of postherpetic neuralgia in the facial area,
94 possible cases of cluster headache, 15 cases of occipital neuralgia with referred facial pain, 26
possible cases of local facial neuralgias, 14 cases of atypical facial pain, 1 case of glossopharyngeal
neuralgia and 2 cases of paroxysmal hemicrania. The reduction of identified records from the au-
tomatic search via manual and external validation to our final case set is displayed in the appendix
A.
The false positive rate after the first validation step (manual validation of electronic patient records
without additional information from GP) was estimated to be 42.0% (266 prevalent or non cases out
of 634 potential incident cases from responding practices). The positive predictive value was 57.6%
17
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(362/(362+266)). The positive predictive value was 57.3% for trigeminal neuralgia, 83.7% for post-
herpetic neuralgia in the facial area, 49.4% for cluster headache, 61.2% for occipital neuralgia with
referred facial pain, 26.6% for local facial neuralgias, 66.7% for glossopharyngeal neuralgia and
50.0% for paroxysmal hemicrania. Atypical facial pain was initially underreported and yielded more
cases after completing the validation process. The observed investigator agreement in the second
step was 83% while the observed agreement in the third step was 78%.
The 362 incident cases comprised 118 cases of trigeminal neuralgia, 36 cases of postherpetic neu-
ralgia in the facial area, 117 cases of cluster headache, 30 cases of occipital neuralgia with referred
facial pain, 17 cases of local facial neuralgias, 41 cases of atypical facial pain, two cases of glos-
sopharyngeal neuralgia and one case of paroxysmal hemicrania. Overall, 44% of the cases were
men, varying between 0% and 61% across the different diagnoses (Table 1). The average age at di-
agnosis was 49.1 years, ranging between 24.0 and 68.0 years (Table 1).
Incidence rates
After excluding non-responding practices from the source population, the total accumulated person
time was 934,716 years for 193,838 persons (average 4.8 years per person). The overall incidence
rate of facial pain was 38.7 [95% CI: 34.9 - 42.9] per 100,000 PY. Cluster headache and trigeminal
neuralgia were the most frequent types of facial pain with an incidence rate of 12.5 [95% CI: 10.4
- 14.9] and 12.6 per 100,000 PY [95% CI: 10.5 - 15.1] respectively (Table 2 and 3). Before exter-
nal validation, the incidence rate of trigeminal neuralgia was 21.7 per 100,000 PY [95% CI: 18.9 -
24.9]. For non-responding (and thus non-validated) practices this was 26.1 [23.0 - 29.5], indicating
a small difference between excluded and included practices. Disease specific incidence rates were
3.9 [95% CI: 2.7 - 5.3] for postherpetic neuralgia in the facial area, 3.2 [95% CI: 2.2 - 4.5] for oc-
cipital neuralgia with referred facial pain, 1.8 [95% CI: 1.1 - 2.8] for local facial neuralgias, 0.2 [95%
CI: 0.0 - 0.7] for glossopharyngeal neuralgia, 4.4 [95% CI: 3.2 - 5.9] for atypical facial pain and 0.1
[95% CI: 0.0 - 0.5] per 100,000 PY for paroxysmal hemicrania.
The incidence rates increased with age for all types of facial pain, except for cluster headache and
occipital neuralgia with referred facial pain (Table 2). Cluster headache showed a peak incidence
in the 4th decade for men and in the 5th decade for women after which it declined. Occipital neural-
gia with referred facial pain had a peak incidence rate in the 7th decade for women (Table 2). 
18
Table 1: Sex and age distribution of patients with facial pain 
 
Diagnosis* Cases (%) Male (%) Mean age at diagnosis in years, (SD) 
Trigeminal neuralgia 118 (32.6) 34 (28.8) 51.5 (17.6) 
Postherpetic neuralgia 36 (9.9) 19 (52.8) 68.0 (17.7) 
Occipital neuralgia 30 (8.3) 13 (43.3) 54.1 (16.2) 
Local neuralgia 17 (4.7) 10 (58.8) 45.2 (15.7) 
Glossopharyngeal neuralgia 2 (0.6) 1 (50.0) 54.0 (5.7) 
Cluster headache 117 (32.3) 71 (60.7) 41.7 (13.4) 
Atypical facial pain 41 (11.3) 10 (24.4) 45.4 (19.6) 
Paroxysmal hemicrania 1 (0.3) 0 (0) 24.0 (0) 
    
Total facial pain 362 (100) 158 (43.6) 49.1 (18.0) 
 
SD: Standard deviation 
* Mutually exclusive groups 
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The overall incidence rate was lower in men than in women (34.1 [95% CI: 29.1 - 39.7] versus
43.3 per 100,000 PY [95% CI: 37.7 - 49.6]). The sex difference was, however, not consistent across
all specific types of facial pain. Female predominance was observed in trigeminal neuralgia and
atypical facial pain and was present but not significant in occipital neuralgia with referred facial pain
and paroxysmal hemicrania, based on overlapping confidence intervals. In cluster headache, post-
herpetic neuralgia in the facial area and local facial neuralgias, a trend towards male predominance
could be seen (Table 3).
Time trends
All types of facial pain showed a stable incidence rate over time, except for cluster headache and
trigeminal neuralgia where the incidence decreased from 13.6 in 1997 [95% CI: 5.2 - 29.8] to 10.4
[95% CI: 4.9 - 19.6] (cluster headache) and from 16.3 [95% CI: 6.8 - 33.6] to 11.1 per 100,000 PY
[95% CI: 5.3 - 20.5] (trigeminal neuralgia) (Figure 1a). 
Seasonal time trend analysis showed an increasing incidence of trigeminal neuralgia between spring
and winter time (Figure 1b). Cluster headache had a markedly but not significant decreased inci-
dence rate during the summer. For the other diseases, the incidence did not demonstrate a clear sea-
sonal pattern.
19
Table 2: Age specific incidence rates of facial pain in the general population 
 
Diagnosis: TGN PHN ON LoN GPN CH AFP PH 
<18: 0.5 [0.0-2.4] 0.0 [0.0-1.3] 0.0 [0.0-1.3] 0.0 [0.0-1.3] 0.0 [0.0-1.3] 1.6 [0.4-4.1] 2.1 [0.7-4.9] 0.0 [0.0-1.3] 
18-29: 6.8 [3.5-12.0] 1.4 [0.3-4.3] 0.7 [0.1-3.2] 1.4 [0.3-4.3] 0.0 [0.0-1.7] 12.2 [7.5-18.8] 2.0 [0.6-5.4] 0.7 [0.1-3.2] 
30-39: 16.5 [10.9-24.0] 0.7 [0.1-3.1] 5.3 [2.5-10.0] 3.3 [1.3-7.2] 0.0 [0.0-1.6] 25.1 [18.0-34.1] 7.3 [3.9-12.6] 0.0 [0.0-1.6] 
40-49: 16.3 [10.7-23.9] 2.0 [0.6-5.5] 1.4 [0.3-4.4] 2.0 [0.6-5.5] 0.0 [0.0-1.7] 19.7 [13.5-28.0] 4.1 [1.7-8.4] 0.0 [0.0-1.7] 
50-59: 17.6 [11.3-26.2] 2.4 [0.7-6.4] 5.6 [2.5-11.0] 2.4 [0.7-6.4] 1.6 [0.3-5.1] 12.8 [7.6-20.3] 6.4 [3.0-12.1] 0.0 [0.0-2.0] 
60-69: 14.6 [7.9-24.7] 8.5 [3.8-16.7] 9.7 [4.6-18.3] 4.9 [1.6-11.5] 0.0 [0.0-3.0] 10.9 [5.4-19.9] 3.6 [1.0-9.7] 0.0 [0.0-3.0] 
70-79: 25.6 [14.9-41.1] 11.9 [5.3-23.4] 3.4 [0.7-10.9] 0.0 [0.0-4.2] 0.0 [0.0-4.2] 5.1 [1.4-13.6] 6.8 [2.3-16.2] 0.0 [0.0-4.2] 
80: 30.6 [15.1-55.8] 44.2 [24.7-73.4] 6.8 [1.4-21.8] 0.0 [0.0-8.4] 0.0 [0.0-8.4] 3.4 [0.3-15.8] 6.8 [1.4-21.8] 0.0 [0.0-8.4] 
Total: 12.6 [10.5-15.1] 3.9 [2.7-5.3] 3.2 [2.2-4.5] 1.8 [1.1-2.8] 0.2 [0.0-0.7] 12.5 [10.4-14.9] 4.4 [3.2-5.9] 0.1 [0.0-0.5] 
 
TGN: Trigeminal neuralgia; PHN: Postherpetic neuralgia; ON: Occipital neuralgia; LoN: Local facial 
neuralgia; GPN: Glossopharyngeal neuralgia; CH: Cluster headache; AFP: Atypical facial pain; PH: 
Paroxysmal hemicrania 
Table 3: Sex specific incidence rates of facial pain in the general population 
 
Diagnosis Men Women Total: 
Trigeminal Neuralgia 7.3 [5.2-10.1] 17.8 [14.3-22.0] 12.6 [10.5-15.1] 
Post-herpetic Neuralgia 4.1 [2.5-6.3] 3.6 [2.2-5.6] 3.9 [2.7-5.3] 
Occipital Neuralgia 2.8 [1.6-4.7] 3.6 [2.2-5.6] 3.2 [2.2-4.5] 
Local Neuralgia 2.2 [1.1-3.8] 1.5 [0.7-2.9] 1.8 [1.1-2.8] 
Glossopharyngeal 
Neuralgia 
0.2 [0.0-1.0] 0.2 [0.0-1.0] 0.2 [0.0-0.7] 
Cluster Headache 15.3 [12.1-19.2] 9.8 [7.2-12.9] 12.5 [10.4-14.9] 
Atypical Facial Pain 2.2 [1.1-3.8] 6.6 [4.6-9.2] 4.4 [3.2-5.9] 
Paroxysmal Hemicrania 0.0 [0.0-0.5] 0.2 [0.0-1.0] 0.1 [0.0-0.5] 
    
Total: 34.1 [29.1-39.7] 43.3 [37.7-49.6] 38.7 [34.9-42.9] 
 
Between brackets: 95% confidence interval 
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Figure 1a: Incidence rate of facial pain per calendar year 
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TGN: Trigeminal neuralgia; PHN: Postherpetic neuralgia; ON: 
Occipital neuralgia; LoN: Local facial neuralgia; GPN: 
Glossopharyngeal neuralgia; CH: Cluster headache; AFP: Atypical 
facial pain; PH: Paroxysmal hemicrania; IR: incidence rate per 
100,000 person years; 95% CI: 95% confidence interval 
Figure 1b: Incidence rate of facial by season  
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facial pain; PH: Paroxysmal hemicrania; IR: incidence rate per 
100,000 person years; 95% CI: 95% confidence interval 
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Discussion
In this study, we found an overall incidence rate of facial pain of 38.7 per 100,000 PY, which is ten
times lower than the incidence of for example ischemic stroke in the Netherlands. 29 Cluster
headache and trigeminal neuralgia were the most common types of facial pain each occurring in
more than 12 persons per 100,000 PY. Age was an important risk factor for facial pain, whereas gen-
der altered the risk in trigeminal neuralgia, atypical facial pain and CH, each to a different extent
and direction.
Literature on the incidence of facial pain is scanty and mainly concerns trigeminal neuralgia. Pre-
vious studies that were conducted in the seventies reported an incidence of ~4,5 per 100,000 per-
sons for trigeminal neuralgia based on hospital data. 22, 30 More recently, incidence rates of 28.9 to
26,8 per 100,000 PY were reported from the IPCI database and the General Practice Research Data-
base. 15, 16, 23 Since not all patients are referred to a hospital by the GP, the estimates based on GP-
databases may be considered a more reliable estimate and will be higher than rates based on hospital
admissions. However, if rates are based on GP diagnoses without further validation (such as previ-
ous studies), the substantial false positive rate will lead to overestimation of the incidence. In our
study we tried to reduce the false positive rate by extensive review of the patients. In the present
study, we found a much lower incidence of 12.7 per 100,000 PY, which is a result of the stricter case
definition, validation and removal of false positively identified cases. The previous studies based
their estimates on an electronic medical record review without additional GP confirmation. We re-
ported an incidence rate of 21.7 per 100,000 PY before external validation, which is close to the pre-
viously reported estimates from GP databases presented in other primary care studies without
external validation. 15, 16, 23 As can be seen in appendix A, many potential cases turned out to be false
positive cases after validation with the GP. This indicates a high percentage of misclassification in
automatic screening of medical records for cases and illustrates the importance of cross-validation
with the full medical record, certainly from a research perspective. The low predictive value may
also be indicative of the difficulty of correctly diagnosing these forms of facial pain during a sin-
gle GP visit. The incidence of glossopharyngeal neuralgia was previously reported to be 0.7 per
100,000 persons based on hospital data, whereas we here report an incidence rate of 0.2 per 100,000
PY [95%CI: 0.0 - 0.7]. 22, 31 The incidence of cluster headache (12.5 per 100,000 PY) is slightly
higher than the previously reported 9.8 per 100,000 persons which was based on hospital data in
Minnesota. 32 This difference can be explained by the fact that not all patients may be referred to
secondary care. Researchers from the Mayo Clinic reported a decrease in incidence from 9.8 per
100,000 persons in 1979-1981 to 2.07 in 1989-1990. 32 In our data, a small but non-significant de-
crease in incidence rate of cluster headache was observed from 13.6 in 1997 to 10.4 in 2007. One
previous study explained the drop in incidence rate of cluster headache by a better differentiation
between different forms of facial pain at the end of the study period. 32 This explanation will, how-
ever, not be fully applicable to our study since all patients were evaluated retrospectively taking into
account the current IASP criteria. Nevertheless, diagnostic skills of the GP may have evolved over
time, either by more experience or better training. The (non-significant) decrease in the incidence
rate of trigeminal neuralgia, although not described in literature before, might have the same ex-
planation. For postherpetic neuralgia in the facial area, occipital neuralgia with referred facial pain,
local facial neuralgias of the face, atypical facial pain and paroxysmal hemicrania, no reports on in-
cidence rates are available in literature.
The seasonal trend we described for cluster headache, exhibiting a lower rate during summer, is
something that has been described before. 33 The incidence has been reported to decrease after clock
resetting for daylight saving time in april and october. 34 Although this finding concerned the num-
ber of attacks per day rather than the onset, the same mechanism might play a role in onset and re-
21
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currence. 34 These findings suggest involvement of the suprachiasmatic nucleus in the hypothala-
mic grey area. 33 For trigeminal neuralgia we observed a linear but non significant increase in inci-
dence from spring towards winter time. Such a seasonal trend has not been described in literature
for trigeminal neuralgia so far and we cannot explain the mechanism by which this might occur. In
view of the lack of statistical significance the observed seasonal trends may be spurious.
Being an observational study relying on retrospective analysis of electronic patient records, mis-
classification of the outcome is our main concern. False positive misclassification would lead to an
overestimation of the incidence rate while the opposite also holds. To minimize the effect of false
positive misclassification we employed a strict case definition and an extensive case ascertainment
process in which we requested additional GP confirmation for patients for whom the electronic pa-
tient records were inconclusive. In our case definition we assumed that the patients classified as
‘probable’ based on the electronic patient record (first validation step) were true positive cases. We
did not request additional information from the GP for these patients because of cost considera-
tions. However, all cases were reviewed by two medical doctors who had to agree on the diagno-
sis. During this process, additional information requested from the GP was used to further evaluate
the possible cases. The GP usually has more background information and additional information on
the course of disease. Considering the false positive cases that were excluded during the case as-
certainment process, the positive predictive value of the diagnosis based on review of electronic pa-
tient records was 57.6%. To further ensure validity of cases, a random sample (250 patients) of all
probable and possible cases was evaluated by a neurologist. There was substantial agreement be-
tween the neurologist and previous case review (observer agreement 78%). 35 False negative mis-
classification might be a problem leading to a potential underestimation of the incidence rate. We
tried to minimize this by using a broad, sensitive search algorithm including common symptoms,
specific treatments and spelling errors. As can be seen in appendix A, the amount of identified
records was extensive (111,810). We believe that our extensive search strategy and case validation
procedure has reduced the number of false positive cases accurately without increasing the number
of false negative cases. Therefore the presented incidence rates should be close to the actual inci-
dence in the general population and better than previous estimates that did not apply extensive val-
idation. Another limitation may be the types of facial pain conditions selected for this study. This
selection was based on our clinical judgment and the place of these syndromes in the differential
diagnosis of a GP. As a result this study describes several well known facial pain syndromes while
leaving out others such as burning mouth syndrome and hemicrania continua. It would have been
stronger if we had made a choice based on pathophysiology; however the unclear aetiology of al-
most all studied diseases makes any classification arbitrary.
In conclusion, we report the incidence of eight forms of facial pain using the Integrated Primary Care
Information (IPCI) database. Facial pain is a rare condition occurring in the general population at
a rate of 38.7 per 100,000 PY. Trigeminal neuralgia and cluster headache were the most common
forms of facial pain studied.
22
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Chapter 3
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3.1
Risk factors for development and exacerbation of trigeminal neuralgia
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Abstract
Background: Trigeminal neuralgia is a severe form of facial pain with a paroxysmal disease course.
To identify risk factor for first occurrence and exacerbations we performed a case-control and case-
crossover study in a general practice research database.
Methods: Patients with trigeminal neuralgia were identified in the Integrated Primary Care Infor-
mation-database with electronic medical records. We matched cases to up to ten random controls
by sex, age and general practitioner’s (GP) practice. Known risk factors and broad disease categories
were evaluated as risk factors for first occurrence of trigeminal neuralgia. To evaluate risk factors
for exacerbations we performed a case-crossover study in trigeminal neuralgia cases who had at least
one exacerbation (n=34). We evaluated weather conditions, solstices, daylight saving time and treat-
ment regimes as time-varying risk factors (triggers).
Results: We identified 114 cases with idiopathic trigeminal neuralgia and we matched them to 1032
controls. Hypertension was associated with the onset of trigeminal neuralgia (OR: 1.63; [95% CI:
1.02 - 2.60]). Furthermore, diseases of the lipid and glucose metabolism, benign neoplasm and
mixed infections were associated with onset of trigeminal neuralgia. By using the case crossover
design we could not identify time-varying triggers for exacerbations of trigeminal neuralgia.
Conclusions: We showed that hypertension and other comorbid conditions are associated with
onset of trigeminal neuralgia. No triggers for exacerbation of trigeminal neuralgia could be identi-
fied in this dataset.
28
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Introduction
Trigeminal neuralgia is a rare but severe form of facial pain with an estimated incidence rate of
12.6 per 100,000 person years. 2 It is a paroxysmal pain presenting with sudden, stabbing pain in
one or more branches of the fifth cranial nerve. 14 Most patients who present with trigeminal neu-
ralgia (71%) have more than one exacerbation. 36 Although the exact aetiology of primary trigem-
inal neuralgia is unknown, it is hypothesized to be due to neurovascular compression at the root
entry zone. 37, 38 Occasionally trigeminal neuralgia develops secondary to tumors, infarctions, mul-
tiple sclerosis etc. 39 Some risk factors have been identified including hypertension, race, religion,
a previous history of surgery and smoking. 17, 22, 40 Most of these findings arise from an epidemio-
logical study that was conducted in the early eighties in a secondary care setting. 40 Attacks can be
triggered by heat, cold, eating or a tactile stimulus of certain areas. 36 Identification of risk factors
and triggers for development of trigeminal neuralgia and subsequent exacerbations is important to
develop primary and secondary prevention strategies.
To identify risk factors for first occurrence and first exacerbation of trigeminal neuralgia, we per-
formed a matched case-control and case-crossover study in a general practice research database
Methods
Source population
Data for this study were derived from the Integrated Primary Care Information (IPCI)-database, a
longitudinal observational database, containing data from computer based medical records of gen-
eral practitioners (GPs) throughout the Netherlands. In the Netherlands a GP acts as the gatekeeper
for and receiver of information from secondary care. The database contains anonymized records of
over one million patients in 141 practices throughout the Netherlands. The source population has a
similar age and sex distribution as the general Dutch population. Participating GPs do not keep
paper records to maximize completeness of the database. The records contain coded information on
patient demographics, symptoms and diagnoses (coded using the International Classification for
Primary Care (ICPC)-codes) as well as free text. 27, 41 It includes referrals, clinical findings, labo-
ratory assessments, drug prescriptions with anatomical, therapeutical and chemical codes (ATC-
code) as defined by the World Health Organization (WHO), dose, duration and primary ICPC-coded
indication and hospitalizations. 42 Summaries of the hospital discharge letters and information from
specialists are entered in a free text format and hard copies can be provided on request. The IPCI-
database has been proven valid for pharmacoepidemiological research. 24, 25 The system complies
with European Union guidelines on the use of medical data for research. The scientific and ethical
advisory board of the IPCI project approved this study (project number 07/03). The source popu-
lation comprised of persons with at least one year of valid history in the IPCI-database and con-
tributing person time to the database during the study period (January 1996–September 2006). The
one year history period was required to have sufficient and valid background information on each
study subject.
Case selection
Case selection and validation was part of a larger project on facial pain, details of which have been
described elsewhere. 2 In brief, potential cases of facial pain were identified using a broad and sen-
sitive free text search in the computerized records followed by a three step approach for case as-
certainment. Firstly, in order to exclude false positive records and to assess the index date (date of
first symptoms), all potential cases were manually evaluated by a medical doctor (JK) using the
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complete electronic medical records and criteria of the International Association for the Study of
Pain (IASP). 21 They were classified as trigeminal neuralgia, cluster headache, postherpetic neuralgia
in the facial area, occipital neuralgia with referred facial pain, local facial neuralgia, persistent id-
iopathic facial pain, glossopharyngeal neuralgia or paroxysmal hemicrania. Potential cases were
divided into ‘probable’, ‘possible’ or ‘improbable’ depending on the number of episodes, mentioned
symptoms and specialist confirmation. Improbable cases were excluded as a case. Secondly, addi-
tional information was requested from the GP for all ‘possible’ cases. This was achieved using a
questionnaire, in which criteria from the IASP were mentioned per facial pain condition. 21 The GP
was asked to confirm or reject the diagnosis. If specialist letters were present, anonymized hard
copies were requested. All case information (including returned questionnaires) of all ‘probable’ and
‘possible’ cases was independently evaluated by two medical doctors. Discrepancies were arbi-
trated by a pain specialist (FH). Thirdly, to further ensure validity of the diagnosis, a random sam-
ple of 250 patients of all initial cases from step one was reviewed by a neurologist with ample
experience in pain treatment. In case of disagreement, a case was discussed until agreement was
reached. At the end of the case validation each subject was classified as either ’case’ or ‘no case’.
Cases with a date of diagnosis before study entry (prevalent cases) were excluded from the source
population. In addition, we excluded non-responding practices. For the present study we included
only patients who were classified as trigeminal neuralgia. The index-date (start) was set at the date
of first symptoms of trigeminal neuralgia. Cases with a secondary form of trigeminal neuralgia (p.e.
tumors) were excluded from the study cohort.
Case-control study
For each new case of trigeminal neuralgia we randomly selected up to ten controls from the source
population, matched on GP-practice, gender, age and calendar time (controls received the same
index date as the case). As possible risk factors we investigated hypertension and smoking, which
have been described as risk factors for trigeminal neuralgia before. 17, 22, 40 Hypertension was ex-
tracted from the electronic records based on ICPC-codes and elevated average blood pressure val-
ues in the year before the index date (i.e. systolic >140 mmHg or diastolic >90 mmHg). Smoking
and alcohol abuse were extracted from the electronic records based on a free text search and ICPC-
codes. As additional potential risk factor in the analysis we considered comorbidity (derived man-
ually from the full electronic medical records). Comorbidity was categorized as described before
for complex regional pain syndrome into mutually exclusive disease categories based on underly-
ing aetiological pathways into anatomical, degenerative, metabolic, neoplasmatic, infectious, in-
flammatory, psychological and traumatic disease (appendix B). 43 Diseases were categorized into
categories independently by two medical doctors. Acute and episodic diseases were only assumed
present if they occurred in the year before the index date, whereas chronic diseases were accepted
any time before the index date. Disease categories that were associated with the onset of trigemi-
nal neuralgia in the univariate analysis were further divided into subgroups and individual diseases
(appendix B).
Case-crossover study
To study risk factors for exacerbations of trigeminal neuralgia subsequent to the first diagnosis, we
applied a case-crossover design using only patients with trigeminal neuralgia who experienced an
exacerbation to avoid for confounding by stable factors. Exacerbations were defined as a specifi-
cally recorded exacerbation or start of a new drug therapy specifically for pain treatment. The index
date was set at the date of first symptoms of an exacerbation which was assessed upon manual re-
view of the full electronic medical record. Only the first exacerbation was included in the analysis.
Up to four three month control periods were defined based on the duration between the onset of
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trigeminal neuralgia and the first exacerbation, the three months just prior to the exacerbation date
were considered the ‘case’ risk window. To ensure that patients had at least one control period, we
excluded exacerbations which occurred less than six months after the first diagnosis of trigeminal
neuralgia. Risk factors were present in a control or case period if the date of occurrence fell within
the respective three month risk window. Binomial risk factors included vaccinations, infections,
asthma exacerbations, changes in pain medication (stop or switch), type of pain treatment received
and switch of anti-hypertensive drugs. Furthermore we evaluated daylight saving time (i.e. date of
changing to summer time or winter time during three month) or solstices (i.e. the date that the earth
axis is most tilted towards (summer) or away from (winter) the sun, resulting in the longest and
shortest day respectively) as binomial risk factors. Weather conditions including a maximum, min-
imum and average temperature (°C), air humidity (%) and air pressure (millibars) during the three
month period (provided by the Royal Netherlands Meteorological Institute (KNMI)) were analyzed
as continuous factors. 44 As weather changes may trigger exacerbations we also considered the di-
rection (increase or decrease) of change in temperature, humidity and pressure during the three
month period. 
Statistical Data analysis
Odds ratios (OR) and 95% confidence intervals (CI) were calculated using conditional logistic re-
gression. Factors were included in the multivariable analysis if they were univariately associated
with a P < 0.05. Statistical significance was assumed for two-sided p-values < 0.05. All statistical
analyses were conducted using SPSS software version 15.0 (SPSS inc, Chicago, III).
Results
The source population for this study comprised 479,949 (1,898,417 PY) subjects from the IPCI-data-
base who had at least one year of valid history in the database. Within this population 118 incident
cases of trigeminal neuralgia were identified. Four cases with secondary trigeminal neuralgia were
excluded leaving 114 patients for analysis. 
Risk factors for first development of trigeminal neuralgia
The 114 remaining cases were matched to 1032 controls by sex, age, GP practice and calendar time.
The minimum number of controls per case was one. Cases had an average age of 51.3 years (stan-
dard deviation (SD) 17.9) and were mostly female (71%) (Table 1). Hypertension was univariately
associated with the development of trigeminal neuralgia (OR: 1.63; [95% CI: 1.02 - 2.60]) (Table
1). Based on data from the medical records, smoking was not associated with trigeminal neuralgia.
Metabolic diseases, neoplasm and infectious diseases were associated with an increased risk of
trigeminal neuralgia development (Table 1). More specifically, these associations were confined to
diseases of the lipid and glucose mechanism, benign neoplasm and mixed infections. As most dis-
eases occurred infrequently we could not validly estimate odds ratios for individual diseases. Dia-
betes mellitus type II and hypercholesterolemia were the most frequently occurring diseases of the
lipid and glucose metabolism diseases followed by angina pectoris and other cardiovascular dis-
eases. Benign naevi and myomas were the most common benign tumors. Bronchitis, upper airway
tract infections, otitis externa and sinusitis were the most frequent infectious diseases. The study was
not powered to demonstrate significant associations for the individual diseases (Table 1).
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Risk factors for exacerbation of previous trigeminal neuralgia
Of all 114 cases with primary trigeminal neuralgia, 34 patients experienced at least one exacerba-
tion during follow-up, of whom 25 (73.5%) had six months of follow-up and were included in the
case-crossover analysis. This group was on average 53.0 years old (SD: 18.2) and mostly female
(56%). Almost no case received a vaccination or suffered from an asthma exacerbation their case
or control risk windows (Table 2). Infections were associated with a 6-fold increased risk of exac-
erbations, but do to lack of power this was not significant from a statistical perspective. Daylight
saving time, solstices, weather conditions and type of pain medication were not associated with ex-
acerbations of trigeminal neuralgia. 
Discussion
In this study we identified several risk factors for first occurrence of trigeminal neuralgia. In addi-
tion to hypertension, lipid and glucose metabolism disorders, benign neoplasm and infections were
associated with developing trigeminal neuralgia. With the limited power available no statistically
significant triggers or risk factors for subsequent exacerbations could be identified, although the
point estimates suggest an effect of infections (OR=6-) and increased in air humidity (OR=2.78).
Previous studies reported a 2-fold increased risk of developing trigeminal neuralgia with hyper-
tension. 17, 22 Our point estimate (OR: 1.63 [95% CI: 1.02 - 2.60]) is completely in line with this find-
ing. Smoking was previously reported to be protective for the development of trigeminal neuralgia
(OR for non smoking: 1.69; [95% CI: 1.22 - 2.34]). 40 We found the opposite, namely an increased
risk associated with smoking (OR: 1.64; [95% CI: 0.94 - 2.87]) although this did not reach statis-
tical significance. The previous report however used patients with cervical osteoarthritis or a rup-
tured cervical disc as control group. Although no definite association between smoking and
osteoarthritis has been found, several reports suggest an association (negatively as well as posi-
tively). 45-48 Furthermore, smoking is strongly associated with disc degeneration. 49 If smoking is pos-
itively associated with the disease of patients chosen as control group, a negative association
between trigeminal neuralgia and smoking may be erroneously found. In our study non-differential
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Table 1: Risk factors for first occurrence 
 
 Cases Controls Univariable OR [95% CI] Multivariable OR [95% CI] 
N 114 1032   
Age (SD) 51.3 (17.9) 49.5 (17.0) Matched Matched 
Male gender 33 (29%) 288 (28%) Matched Matched 
Known risk factors     
  Smoking 19 (17%) 115 (11%) 1.64 [0.94; 2.87]  
  Alcohol abuse 0 (0%) 3 (0%) NA  
  Hypertension 63 (55%) 467 (45%) 1.63 [1.02; 2.60] 1.48 [0.91; 2.40] 
Disease categories     
  Anatomical 14 (12%) 83 (8%) 1.55 [0.83; 2.90]  
  Degenerative 15 (13%) 96 (9%) 1.20 [0.63; 2.29]  
  Metabolic 22 (19%) 95 (9%) 2.28 [1.30; 4.02]  
    Lipid and Glucose Metabolism 19 (17%) 71 (7%) 2.55 [1.40; 4.66] 2.23 [1.20; 4.13] 
    Excesses or Deficiencies 2 (2%) 13 (1%) NA  
    Intoxications 0 (0%) 2 (0%) NA  
    Other 2 (2%) 13 (1%) NA  
  Neoplasmatic 21 (18%) 105 (10%) 1.76 [1.01; 3.07]  
    Benign 16 (14%) 69 (7%) 1.97 [1.08; 3.60] 1.85 [0.98; 3.47] 
    Malignant 6 (5%) 39 (4%) 1.15 [0.43; 3.06]  
  Infectious 45 (39%) 282 (27%) 1.73 [1.15; 2.60]  
    Commonly Bacterial 10 (9%) 83 (8%) 1.05 [0.53; 2.10]  
    Commonly Viral 9 (8%) 63 (6%) 1.37 [0.65; 2.89]  
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misclassification of smoking might have occurred since we applied an automated search algorithm
to extract smoking status. This may have diluted the effect of smoking towards the null. Other pre-
viously reported risk factors, including being a non-Jew (OR of 2.86), being non-tonsillectomized
(OR of 1.88), being native American (OR of 1.78) and non drinking (OR of 1.22) could not be eval-
uated in our database. 40
The association between trigeminal neuralgia, diseases of the lipid and glucose metabolism, be-
nign neoplasm and infectious diseases have not been described in literature before. Primary (idio-
pathic) trigeminal neuralgia is hypothesized to be caused by compression of the trigeminal nerve
at the root entry zone by an aberrant blood vessel (neurovascular contact). This may lead to local
demyelinisation provoking development of spontaneous action potentials. 50-54 Action potentials
can reflect at locations with a higher thickness, such as demyelinated locations causing resonation
of the large αβ-fibers (sensitive fibres). The dorsal root reflex can then activate the αδ-fibers (pain
fibres) if enough presynaptic discharge takes place. 55
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Table 2: Risk factors for exacerbation of trigeminal neuralgia (case-crossover design) 
Risk factors* Cases Control periods OR [95% CI] 
N 25 90 NA 
Age (SD) 53 (18.2) 51.9 (17.8) NA 
Male gender 11 (44%) 43 (48%) NA 
Vaccination 2 (8%) 1 (4%) NA 
Infection 3 (12%) 4 (4%) 6.00 [0.60; 60.44] 
Astma exacerbation 0 (0%) 2 (2%) NA 
Daylight saving time (winter) 7 (28%) 22 (24%) 1.24 [0.50; 3.07] 
Daylight saving time (summer) 9 (36%) 22 (24%) 1.53 [0.65; 3.58] 
Solstice winter 7 (28%) 24 (27%) 0.99 [0.40; 2.44] 
Solstice summer 6 (24%) 21 (23%) 1.09 [0.42; 2.81] 
Definite stop of pain medication 0 (0%) 3 (3%) NA 
Switch in pain medication 0 (0%) 4 (4%) NA 
Treatment received 8 (32%) 31 (34%) 0.89 [0.26; 3.08] 
Stop in anti-hypertensives 1 (4%) 2 (2%) 1.19 [0.09; 14.86] 
Temperature (°C)#    
Maximum temperature 25.8 (6.4) 25.1 (6.7) 1.02 [0.96; 1.08] 
Minimum temperature -3.8 (5.1) -3.1 (5.1) 0.98 [0.90; 1.07] 
Average temperature 10.1 (5) 10.4 (4.7) 0.99 [0.91; 1.08] 
Increase in temperature 14 (56%) 54 (60%) 0.80 [0.34; 1.88] 
Humidity    
 
 
 
 
 
 
 
 
 
 
 
* assessed during three month period before the index date 
# national figures obtained from Royal Netherlands Meteorological Institute (KNMI) in the Netherlands 
NA: not assessable (if less than three cases or controls exposed) 
Maximum humidity 98.9 (0.3) 98.9 (0.3) 1.39 [0.27; 7.22] 
Minimum humidity 32.9 (8.9) 35.3 (10.1) 0.98 [0.94; 1.02] 
Average humidity 81.2 (4.8) 82.5 (4.8) 0.96 [0.88; 1.04] 
Increase in humidity 4 (16%) 6 (7%) 2.78 [0.73; 10.51] 
Pressure    
Maximum pressure 1036 (4.1) 1035 (4.4) 1.04 [0.95; 1.14] 
Minimum pressure 988.5 (8.2) 988.7 (7.5) 1.00 [0.94; 1.06] 
Average pressure 1015.7 (2.5) 1015.3 (2.3) 1.08 [0.88; 1.33] 
Increase in pressure 13 (52%) 49 (54%) 0.95 [0.37; 2.41] 
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Diabetes mellitus type 2 can cause chronic inflammatory demyelinating polyneuropathy. 56-60 This
process might cause central demyelinisation and thus play a role in the aetiology of trigeminal neu-
ralgia. If idiopathic trigeminal neuralgia is indeed caused by neurovascular contact due to sacking
of cerebral arteries, one could argue that cardiovascular diseases such as atherosclerosis will speed
up this process. The association between benign tumors and trigeminal neuralgia is less clear. Given
that trigeminal neuralgia can be secondary to benign cerebral tumors this association might reflect
missed secondary forms of trigeminal neuralgia. Since we defined the index date of trigeminal neu-
ralgia as the date of first symptoms and assessed the presence of comorbidity before the index date,
it is unlikely that tumors were discovered during the diagnostic work-up for trigeminal neuralgia.
Recently, the role of neuropeptides, more specifically substance P, in trigeminal neuralgia has been
highlighted. 61, 62 Benign prostatic hyperplasia has been associated with elevated plasma levels of
neuropeptides including substance P. 63 Although a definite conclusion is preliminary it might be an
alternative hypothesis. The association we found between infections and trigeminal neuralgia might
have the same aetiology. No risk factors for exacerbations have been reported in the literature al-
though attacks may be triggered by heat or cold. 36 In our study no significant risk factors for ex-
acerbation could be identified. Among the various meteorological factors studied (temperature,
humidity and air pressure) only humidity increase was associated with a non-significant three-fold
exacerbation risk increase. Vaccinations and asthma exacerbations might trigger an inflammatory
response possibly leading to an increased exacerbation rate. These factors could not be evaluated
due to a low prevalence in our study. We did observe a 6-fold exacerbation risk increase following
infections, but the prevalence of infections was too low to reach statistical significance. Changes in
preventive pain medication may affect exacerbation risk but they could not be evaluated due to low
numbers. There are several alternative reasons why we could not find any significant trigger for ex-
acerbations apart from absence of a true association. Firstly, misclassification of risk factors. Al-
though weather conditions were very accurately measured by the Royal Netherlands Meteorological
Institute, they are national averages and may not adequately represent the individual circumstances.
64 Vaccinations, asthma exacerbations and infections were manually assessed to ensure maximum
validity. Any remaining misclassification might result from under recording by the GP and is likely
to be non-differential which may explain lack of effect. Despite the above mentioned limitations,
our findings may provide some direction into the search of the aetiology of trigeminal neuralgia, es-
pecially since very little data is actually available. Our results may point to a potential role of neu-
ropeptides and demyelinization in the pathophysiology of trigeminal neuralgia.
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3.2
Risk factors for development and exacerbation of cluster headache
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Abstract
Background: Cluster headache is a severe form of facial pain with a paroxysmal disease course.
To identify risk factor for first occurrence and exacerbations we performed a case-control and case-
crossover study in a general practice database.
Methods: Patients with cluster headache were identified in the Integrated Primary Care Informa-
tion-database with electronic GP records using an extensive validation procedure. We matched cases
to up to ten random controls by sex, age and GP practice. Known risk factors and broad disease cat-
egories were evaluated as risk factors for first occurrence. To evaluate risk factors for exacerbations
we performed a case-crossover study in cluster headache cases undergoing at least one exacerba-
tion. We evaluated weather conditions, solstices, daylight saving time, treatment regimes and oral
contraceptive use as risk factors.
Results: We identified 115 cases with idiopathic cluster headache and we matched them to 1123
controls. Smoking was significantly associated with onset of cluster headache (OR: 2.93; [95% CI:
1.71 - 5.00]). Furthermore, diseases of the internal organs, of the musculoskeletal tract, mycoses,
mixed infections, allergies, menstrual cycle and climacterium related disorders were significantly
associated with first occurrence of cluster headache. We could not identify any risk factors for ex-
acerbations of cluster headache.
Conclusions: We confirmed that smoking is a risk factor for cluster headache and we identified sev-
eral potential new risk factors. The power of the study was too limited to identify risk factors for
exacerbation of cluster headache.
36
Seppe proefschrift boek:Opmaak 1  01-04-2010  20:09  Pagina 36
Introduction
Cluster headache (CH) is a rare but severe type of paroxysmal headache presenting with severe, uni-
lateral pain in the orbito-temporal region accompanied with autonomic symptoms such as lacrimation,
nasal stuffiness, rhinorrhea, miosis, ptosis or scleral injection. 65 In some patients, cluster headache is
secondary to other diseases such as aneurysms, arteriovenous malformations, subarachnoid cysts and
dissection of the internal carotid artery. 13, 66-76 In most patients however no precipitating cause can be
found. Although the exact pathway of (primary) cluster headache is unknown, neurovascular disor-
ders in the hypothalamus are presumed to play a major role. 65, 77 Several factors have been reported
to be associated with either the development of cluster headache or with exacerbations, including head
trauma, smoking and alcohol consumption. 78-87 Hypertension has been suggested as a risk factor for
development of severe headache but its risk for development of cluster headache has not yet been in-
vestigated. 88 Furthermore, there is a male predominance which could point at hormonal influence, but
on the other hand, in females, menstrual cycle, oral contraceptive use, menopause and hormone re-
placement therapy have never been shown to influence the attack rate. Genetic susceptibility in clus-
ter headache patients has also been suggested. 85, 89-91 Finally, there are some indications that daylight
changes such as solstices and daylight saving time can trigger cluster headache attacks. 34 Most of the
currently available studies include populations recruited from secondary care clinics. These patients
may differ from those treated in primary care settings regarding characteristics severity and exacer-
bation frequency. 86 Valid risk estimates for development and exacerbation of cluster headache based
on primary care data may help improving treatment strategies. To evaluate known risk factors for first
development and to identify new risk factors we performed a population based matched case-control
study using a general practitioner (GP) database. For identification and quantification of risk factors
for exacerbations we performed a case-crossover study. 
Methods
Source population
Data for this study were derived from the Integrated Primary Care Information (IPCI)-database, a lon-
gitudinal observational database, containing data from computer based patient records of general
practitioners (GPs) throughout the Netherlands. In the Netherlands a GP acts as the gatekeeper for
and receiver of information from secondary care. The database contains anonymized records of more
than one million patients in 141 practices throughout the Netherlands. The source population has a
similar age and sex distribution as the general Dutch population. Participating GPs do not keep paper
records to maximize completeness of the database. The records contain coded information on patient
demographics, symptoms and diagnoses (coded using the International Classification for Primary
Care (ICPC)-codes) as well as free text. 27, 41 It includes referrals, clinical findings, laboratory as-
sessments, drug prescriptions with anatomical, therapeutic and chemical codes (ATC-code) as defined
by the World Health Organization (WHO), dose, duration and primary ICPC-coded indication and
hospitalizations. 42 Summaries of the hospital discharge letters and information from specialists are
entered in a free text format and hard copies can be provided on request. The IPCI-database has been
proven valid for pharmacoepidemiological research. 24, 25 The system complies with European Union
guidelines on the use of medical data for research. The scientific and ethical advisory board of the
IPCI project approved this study (project number 07/03). The source population comprised of per-
sons with at least one year of valid history in the IPCI-database and contributing person time to the
database during the study period (January 1996–September 2006). The one year history period was
required to have sufficient background information on each study subject.
37
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Case ascertainment
Case selection and validation was part of a larger project on facial pain, details of which have been
described elsewhere. 2 In brief, potential cases of facial pain were identified using a broad and sen-
sitive free text search in the computerized records followed by a three step approach for case as-
certainment. Firstly, in order to exclude false positive records and to assess the index date (date of
first symptoms), all potential cases were manually evaluated by a medical doctor (JK) using the
complete electronic medical records and criteria of the International Association for the Study of
Pain (IASP). 21 They were classified as trigeminal neuralgia, cluster headache, postherpetic neuralgia
in the facial area, occipital neuralgia with referred facial pain, local facial neuralgia, persistent id-
iopathic facial pain, glossopharyngeal neuralgia or paroxysmal hemicrania. Potential cases were
divided into ‘probable’, ‘possible’ or ‘improbable’ depending on the number of episodes, mentioned
symptoms and specialist confirmation. Improbable cases were excluded as a case. Secondly, addi-
tional information was requested from the GP for all ‘possible’ cases. This was achieved using a
questionnaire, in which criteria from the IASP were mentioned per facial pain condition. 21 The GP
was asked to confirm or reject the diagnosis. If specialist letters were present, anonymized hard
copies were requested. All case information (including returned questionnaires) of all ‘probable’ and
‘possible’ cases was independently evaluated by two medical doctors. Discrepancies were arbi-
trated by a pain specialist (FH). Thirdly, to further ensure validity of the diagnosis, a random sam-
ple of 250 patients of all initial cases from step one was reviewed by a neurologist with ample
experience in pain treatment. In case of disagreement, a case was discussed until agreement was
reached. At the end of the case validation each case was classified as either ’case’ or ‘no case’.
Cases with a date of diagnosis before study entry (prevalent cases) were excluded from the source
population. In addition, we excluded non-responding practices. For the present study we included
only patients who were classified as cluster headache. The index-date was set at the date of first
symptoms of cluster headache. Furthermore, cases with a secondary form of cluster headache (p.e.
multiple sclerosis) were excluded from the study cohort.
Case-control study
For each case we randomly selected up to ten controls from the source population, matched on GP-
practice, sex, age and calendar time (controls received the same index date as the case). As possi-
ble risk factors we included specific risk factors of interest including head trauma, hypertension,
alcohol consumption, smoking, oral contraceptive and hormonal replacement therapy use. 83, 88 Hy-
pertension was based on ICPC-codes and average blood pressure values in the year preceding the
index date. An average blood pressure higher than 140 (systolic) or 90 (diastolic) was considered
as hypertension. Smoking was assessed from free text search in the medical record and ICPC-codes.
Oral contraceptive use and use of hormone replacement therapy were evaluated together and based
on ATC-codes in the prescription records. Furthermore we evaluated several broad disease cate-
gories as possible new risk factors for first occurrence of cluster headache. Disease categories were
based on underlying aetiological mechanisms and included an anatomical, degenerative, metabolic,
neoplasmatic, infectious, inflammatory, psychological and traumatic disease category (see appen-
dix B). 43 Occurrence of chronic diseases was assessed using the entire medical history prior to the
index date. Acute diseases were assessed in the year prior to index date. Firstly, the overall diseases
categories were used. Disease categories which were statistically significant associated were fur-
ther examined in subgroups (appendix B). These subgroups in turn were, if associated with first oc-
currence, divided in individual diseases.
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Case-crossover study
To study risk factors for exacerbations of cluster headache subsequent to the first diagnosis, we ap-
plied a case-crossover design using only patients with cluster headache who experienced an exac-
erbation to avoid for confounding by stable factors. Exacerbations were defined as a specifically
recorded exacerbation or start of a new drug therapy specifically for pain treatment. The index date
was set at the date of first symptoms of an exacerbation which were assessed upon manual review
of the full electronic medical record. Only the first exacerbation was included in the analysis. Up
to four three month control periods were defined based on the duration between the onset of clus-
ter headache and the first exacerbation, the three months just prior to the exacerbation date were con-
sidered the ‘case’ risk window. To ensure that patients had at least one control period, we excluded
exacerbations which occurred less than six months after the first diagnosis of cluster headache. Risk
factors were present in a control or case period if the date of occurrence fell within the respective
three month risk window. Binomial risk factors included vaccinations, infections, asthma exacer-
bations, changes in pain medication (stop or switch), type of pain treatment received and switch of
anti-hypertensive drugs. Furthermore we evaluated daylight saving time (i.e. date of changing to
summer time or winter time during three month) or solstices (i.e. the date that the earth axis is most
tilted towards (summer) or away from (winter) the sun, resulting in the longest and shortest day re-
spectively) as binomial risk factors. Weather conditions including a maximum, minimum and av-
erage temperature (°C), air humidity (%) and air pressure (millibars) during the three month period
(provided by the Royal Netherlands Meteorological Institute (KNMI)) were analyzed as continu-
ous factors. 44 As weather changes may trigger exacerbations we also considered the direction (in-
crease or decrease) of change in temperature, humidity and pressure during the three month period. 
Statistical Data analysis
Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated using conditional logis-
tic regression. Factors were included in the multivariable analysis if they were univariately associ-
ated with a P < 0.05. Statistical significance was assumed for two-sided p-values < 0.05. All
statistical analyses were conducted using SPSS software version 15.0 (SPSS inc, Chicago, III).
Results
The source population for this study contained 479,949 (1,898,417 PY) subjects from the IPCI-
database who had at least one year of valid history in the database. Within this population 117 in-
cident cases of cluster headache were identified. Two cases with secondary cluster headache were
excluded leaving 115 cases for analysis.
Risk factors for development of cluster headache
The 115 cases of cluster headache were matched to 1123 controls by sex, age, GP practice and cal-
endar time. The minimum number of controls per case was five. Cases had an average age of 41.7
years (standard deviation (SD) 13.4) and were mostly male (61%) (Table 1). 
Of the specifically evaluated risk factors (head trauma, smoking, alcohol consumption and hyper-
tension) only smoking was associated with cluster headache occurrence (OR: 2.93; [95% CI: 1.71
- 5.00]) (Table 1). Regarding the larger disease categories; anatomical diseases, infections, inflam-
matory diseases and hormonal diseases were associated with the development of cluster headache.
More specifically, anatomical diseases of internal organs and the locomotoric tract, mycoses, mixed
infectious diseases, allergies, menstrual cycle related diseases and climacterium related diseases
were significantly associated with first cluster headache occurrence (Table 1). Most diseases oc-
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curred infrequently. We therefore did not calculate odds ratios for individual diseases. Among these
broad disease categories, gastro-esophageal reflux disease (4 cases, 4 controls) and urolithiasis (2
cases, 6 controls) were the most common diseases of the internal organs followed by diaphragmatic
hernias (2 cases, 3 controls). Cervicobrachial syndrome (4 cases, 9 controls) was the most frequent
locomotoric tract disease. The most common mycoses were dermatomycoses (4 cases, 12 controls),
tinea pedis (4 cases, 17 controls), candida (1 case, 13 controls) and onychomycoses (1 case, 11 con-
trols). Bronchitis (1 case, 18 controls), upper airway tract infections (1 case, 22 controls), otitis ex-
terna (4 cases, 15 controls), otitis media (1 case, 12 controls) and sinusitis (10 cases, 27 controls)
were the most frequent infectious diseases. Allergic diseases consisted mainly of allergic rhinitis (8
cases, 31 controls) and allergic conjunctivitis (5 cases, 5 controls). Metro- or menorrhagie con-
tributed mainly (2 cases, 10 controls) to menstrual cycle related diseases. Atrophic vaginitis (3 con-
trols), climacterial symptoms (1 case, 2 controls) and osteoporosis (2 cases) contributed equally to
climacterium related diseases. The multivariable analyses are shown in table 1. Although some fac-
tors do not retain statistical significance, the trend is retained. 
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Table 1: Risk factors for first occurrence 
 
 Cases Controls Univariable OR [95% CI] Multivariable OR [95% CI] 
N 115 1123   
Age (SD) 41.7 (13.4) 41.2 (12.9) Matched Matched 
Male gender 70 (61%) 686 (61%) Matched Matched 
Known risk factors     
    Smoking 24 (21%) 106 (9%) 2.93 [1.71; 5.00] 2.65 [1.52; 4.62] 
    Alcohol 0 (0%) 4 (0%) NA  
    Hypertension 47 (41%) 380 (34%) 1.43 [0.92; 2.23]  
    Head trauma 6 (5%) 31 (3%) 1.93 [0.78; 4.77]  
Disease categories     
Anatomical 17 (15%) 64 (6%) 3.03 [1.67; 5.50]  
    Internal Organs 8 (7%) 18 (2%) 4.86 [2.01; 11.73] 4.80 [1.83; 12.64] 
    Neurological Tract 4 (3%) 14 (1%) 2.91 [0.94; 8.97]  
    Locomotoric Tract 4 (3%) 9 (1%) 4.69 [1.35; 16.26] 3.84 [1.06; 13.96] 
    Vascular Tract 1 (1%) 21 (2%) 0.45 [0.06; 3.35]  
    Other 0 (0%) 3 (0%) NA  
  Degenerative 4 (3%) 41 (4%) 0.91 [0.32; 2.61]  
  Metabolic 9 (8%) 64 (6%) 1.40 [0.65; 3.01]  
  Neoplasmatic 6 (5%) 77 (7%) 0.70 [0.30; 1.67]  
  Infectious 45 (39%) 275 (24%) 1.96 [1.32; 2.93]  
    Commonly Bacterial 12 (10%) 75 (7%) 1.58 [0.83; 3]  
    Commonly Viral 9 (8%) 64 (6%) 1.42 [0.68; 2.96]  
    Mycoses 12 (10%) 63 (6%) 1.99 [1.03; 3.81] 1.60 [0.79; 3.22] 
    Several Types of Microorganisms Possible 23 (20%) 116 (10%) 2.19 [1.33; 3.60] 1.65 [0.96; 2.83] 
    Other 0 (0%) 1 (0%) NA  
  Inflammatory 32 (28%) 192 (17%) 1.88 [1.21; 2.93]  
    Hypersensitivity 26 (23%) 129 (11%) 2.25 [1.39; 3.63]  
      Auto-immune 4 (3%) 22 (2%) 1.80 [0.61; 5.33]  
      Asthma 4 (3%) 26 (2%) 1.47 [0.50; 4.33]  
      Allergy 13 (11%) 50 (4%) 2.87 [1.48; 5.59] 2.15 [1.05; 4.43] 
      Eczema 7 (6%) 37 (3%) 1.92 [0.82; 4.51]  
    Locomotoric Tract 8 (7%) 56 (5%) 1.46 [0.65; 3.26]  
    Other 5 (4%) 19 (2%) 2.58 [0.95; 7.04]  
  Hormonal 9 (8%) 32 (3%) 3.05 [1.37; 6.78]  
    Sex Hormones 7 (6%) 23 (2%) 3.40 [1.35; 8.59]  
      Menstrual Cycle Related 5 (4%) 18 (2%) 3.15 [1.07; 9.30] 2.98 [0.97; 9.14] 
      Climacterium Related 3 (3%) 5 (0%) 5.54 [1.32; 23.3] 3.96 [0.75; 20.86] 
      Other 0 (0%) 0 (0%) NA  
    Thyroid Hormones 1 (1%) 7 (1%) NA  
    Other 1 (1%) 1 (0%) NA  
  Psychological 12 (10%) 84 (7%) 1.45 [0.75; 2.79]  
  Traumatic 10 (9%) 84 (7%) 1.18 [0.60; 2.34]  
Oral contraceptives / hormone replacement therapy 23 (20%) 240 (21%) 0.87 [0.45; 1.67]  
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Risk factors for exacerbation
Of all 115 cases with primary cluster headache, 47 underwent at least one exacerbation during fol-
low-up. Twenty-nine had at least six months of follow-up and were included in the case-crossover
analysis. This group was 40.5 years old (SD: 12.7) on the date of first exacerbation and mostly male
(59%). Almost no one received a vaccination or suffered from an infection or asthma exacerbation
during follow-up (Table 2). There were no differences between case and control periods regarding
daylight saving time and solstices. Characteristics of received pain medication as well as weather
conditions did not differ between case and control periods. Overall, no predictors for exacerbations
could be identified.
Discussion
In our study we found an association between smoking and development of cluster headache . Hy-
pertension was not associated with cluster headache. We could not evaluate the influence of alco-
hol consumption as risk factor due to the low exposure prevalence. Despite the low prevalence of
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Table 2: Risk factors for exacerbations 
 
 Case periods Control periods OR [95% CI] 
N 29 87 NA 
Age (SD) 40.5 (12.8) NA 
Male gender 17 (59%) NA 
Vaccin 0 (0%) 1 (3%) NA 
Infection 1 (3%) 4 (5%) NA 
Astma exacerbation 0 (0%) 0 (0%) NA 
Daylight saving time (winter) 7 (24%) 22 (25%) 1.06 [0.43; 2.63] 
Daylight saving time (summer) 9 (31%) 20 (23%) 1.34 [0.57; 3.11] 
Solstice winter 9 (31%) 21 (24%) 1.28 [0.56; 2.95] 
Solstice summer 9 (31%) 22 (25%) 1.20 [0.53; 2.73] 
Definite stop of pain medication 1 (3%) 0 (0%) NA 
Switch in pain medication 0 (0%) 2 (2%) NA 
Treatment received 29 (100%) 87 (100%) NA 
Stop in anti-hypertensives 0 (0%) 3 (3%) NA 
Temperature    
Maximum temperature 25.3 (7) 25.6 (6.8) 1.00 [0.95; 1.05] 
Minimum temperature -3.2 (5.2) -3 (5.1) 1.00 [0.93; 1.08] 
Average temperature 10.3 (4.7) 10.7 (4.8) 0.99 [0.92; 1.08] 
Increase in temperature 15 (52%) 49 (56%) 0.72 [0.31; 1.67] 
Humidity    
Maximum humidity 99 (0.2) 99 (0.2) 1.09 [0.11; 10.77] 
Minimum humidity 35.4 (11.2) 35.1 (10.8) 1.00 [0.97; 1.04] 
Average humidity 82.8 (5.2) 82.5 (5.1) 1.01 [0.94; 1.09] 
Increase in humidity 3 (10%) 12 (14%) 0.74 [0.19; 2.87] 
Pressure    
Maximum pressure 1034 (4.5) 1034.8 (5.1) 0.96 [0.88; 1.05] 
Minimum pressure 986.7 (7.2) 988.2 (7.9) 0.98 [0.93; 1.04] 
Average pressure 1014.8 (2.7) 1015 (3) 0.96 [0.83; 1.11] 
Increase in pressure 13 (45%) 48 (55%) 0.69 [0.30; 1.60] 
Oral contraceptives / hormone replacement therapy 2 (7%) 6 (7%) 0,78 [0,1; 5,85] 
 
* assessed during three month period before the index date 
# national figures obtained from Royal Netherlands Meteorological Institute (KNMI) in the Netherlands 
NA: not assessable (if less than three cases or controls exposed) 
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smokers in our study (i.e. 21% versus 80-97% in others) we confirmed the presence of an almost
three-fold increased risk of cluster headache in smokers 83, 86, 87 Most other studies included patients
seen in secondary care, and their study population might not be comparable to ours. Patients seen
in secondary care could be more severe patients with a higher percentage of smokers. Also these
studies used questionnaires to study the prevalence of smoking. This might lead to recall bias and
thus selective over- or underreporting. Since our data is collected independently of the research
question, recall bias is of no major concern. A plausible explanation for the effect of smoking on
cluster headache might be the influence on the cerebrovascular blood flow 33, 92 Another possible fac-
tor playing a role in smoking is a reduced level of melatonin, which is reduced in smokers and clus-
ter headache patients. 33, 93 Hypertension has been associated with severe headache but an association
with cluster headache has not been shown yet. 88 In this study we could not demonstrate an associ-
ation between cluster headache and hypertension, which brings further support to the fact that it is
not associated. 
In a more hypothesis generating approach, that requires confirmation, we found possible new risk
factors for cluster headache occurrence, including diseases of the internal organs or locomotoric
tracts, mycoses, mixed type infections, allergies and menstrual cycle or climacterium related dis-
eases. The association with these diseases may point at a role for neuropeptides in the aetiology of
cluster headache. Substance P, calcitonin gene related peptide and neurokinase play an important
role in the activation of the cerebral blood vessels and dura mater. 33 Substance P and other neu-
ropeptides are mentioned in the pathogenesis of gastro-esophageal reflux disease and atopic der-
matitis. 94-96 In addition, the association of smoking and irregular menstrual cycle with cluster
headache suggests a role for melatonin in the pathophysiology of cluster headache. An association
between irregular menstrual cycle and reduced melatonin levels was shown in a Japanese study.
Both were identified as a risk factor for cluster headache in our study. 33, 97
Previously, we demonstrated a decreasing incidence of cluster headache during the summer. 2 This
might be due to weather conditions such as temperature, humidity or air pressure. These weather
conditions may be associated with the onset of cluster headache which we could not further verify
due to matching on calendar time, but they were not associated with an increased exacerbation fre-
quency. None of the other investigated factors was significantly associated with an increased ex-
acerbation rate, however, this might be due to lack of power only. Apart from power, there are
several other reasons why we may not have been able to find risk factors for exacerbations of clus-
ter headache. Firstly, the risk factors we evaluated might simply be unrelated to the exacerbation
risk. Secondly, there could be misclassification of risk factors. The extent of this is probably mini-
mal for weather conditions since these are very accurately measured by the Royal Netherlands Me-
teorological Institute. 64 Nevertheless, national averages may not adequately represent individual
local circumstances. Vaccinations, asthma exacerbations and infections are manually validated to
ensure maximum validity. 
Besides the above mentioned limitations regarding the case crossover study on exacerbation trig-
gers there are some others to be discussed for the risk factors of cluster headache onset. As we used
observational data our main concern is misclassification of covariates (exposures) and disease. Mis-
classification of the outcome was minimized by an extensive validation process following a broad
sensitive search algorithm. Misclassification of covariates is of a larger concern. Hypertension,
smoking and chronic alcohol consumption were automatically assessed. Smoking and chronic al-
cohol consumption might be underestimated due to under recording by GPs. 
Despite the described limitations, we identified some potential new risk factors for first occurrence
of cluster headache. These associations, however, must be further studied in future research.
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Cluster headache and head trauma: A Dutch population-based study
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Abstract
Background: There remains controversy regarding head trauma and cluster headache (CH). 
Methods: We performed a case-control study using the IPCI database to clarify the association.
Incident cases were matched to ten controls by age, sex, GP and index date. Patients with a history
of eye/brain surgery, cervical spine surgery or mastoidectomy were excluded. Head trauma was
manually assessed and included trauma details. Multivariate conditional logistic regression was
used for analyses. 
Results: 117 cases were identified and matched to 1143 controls. Head trauma was present in 5%
of cluster headache patients and in 3% of controls. The median latency period between head trauma
and CH was 2.83 years. The ORadj was 1.93 (95%CI 0.78 - 4.75). Recent head trauma ( < 2.83
years) revealed a 3.5-fold increased risk [95% CI: 1.25 - 9.96]. 
Conclusions: We were unable to show an association between head trauma and cluster headache
but showed a 3.5-fold risk increase of CH with recent head trauma.
44
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Introduction
Cluster headache (CH) is a rare but severe type of headache which has a prevalence varying from
59 to 279 per 100,000 and an incidence rate of 12.5 per 100,000 person years (PY). 2, 98 Most pa-
tients present with severe, unilateral pain in the orbito-temporal region accompanied with auto-
nomic symptoms such as lacrimation, nasal stuffiness, rhinorrhea, meiosis, ptosis or scleral injection.
65 Neurovascular disorders in the hypothalamus are postulated to play a major role in the develop-
ment of cluster headache. 65, 77 The exact pathway, however, is not known. 65, 77 Many factors are re-
ported to be associated with cluster headache such as arterial dissection of the internal carotid artery,
enucleation, removal of a subarachnoid cyst and smoking. 73, 75, 76, 82 Furthermore, there is a male pre-
dominance and possibly a genetic susceptibility. 85, 89 Alcohol use, and in women, menstrual cycle,
oral contraceptives, pregnancy and menopause were found to trigger attacks in some although the
effect of female hormones was smaller in cluster headache patients compared to migraine patients.
86, 91, 99
Several studies addressed the risk of cluster headache after head trauma. 78-81 Two case-control stud-
ies reported a significant association between head trauma and cluster headache with a reported
history of head trauma in 36% of cases versus 17% of controls. 82, 83 The latent period ranged be-
tween 6.4 and 12.7 years but longer latency periods have been described. 79, 83 Although these find-
ings are consistent, controversy remains regarding the relation between head trauma and cluster
headache. 84 The findings might be (partly) explained by behavioral or lifestyle characteristics such
as alcohol and coffee consumption or cigarette smoking making cluster headache patients more
prone to also have experienced head trauma. 84 Furthermore, the reported long latency periods and
the usually minor traumata preceding the cluster headache occurrence make head trauma seem an
implausible explanation for cluster headache. 84 To further elucidate and quantify the association be-
tween cluster headache and head trauma, we performed a population based matched case-control
study using a general practitioner (GP) database.
Methods
Data for this study were derived from the Integrated Primary Care Information (IPCI)-database, a
longitudinal observational database, containing data from computer based medical records of gen-
eral practitioners (GPs) throughout the Netherlands. In the Netherlands a GP acts as the gatekeeper
for and receiver of information from secondary care. The database contains anonymized records of
more than 1 million patients in 141 practices throughout the Netherlands. The source population has
a similar age and sex distribution as the general Dutch population. Participating GPs do not keep
paper records to maximize completeness of the database. The records contain coded information on
patient demographics, symptoms and diagnoses (coded using the International Classification for
Primary Care (ICPC)-codes) as well as free text. 27, 41 It includes referrals, clinical findings, labo-
ratory assessments, drug prescriptions with anatomical, therapeutical and chemical codes (ATC-
code) as defined by the World Health Organization (WHO), dose, duration and primary ICPC-coded
indication and hospitalizations. 42 Summaries of the hospital discharge letters and information from
specialists are entered in a free text format and hard copies can be provided on request. The IPCI-
database has been proven valid for pharmaco-epidemiological research. 24, 25 The system complies
with European Union guidelines on the use of medical data for research. The scientific and ethical
advisory board of the IPCI project approved this study (project number 07/03). 
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Cases and controls
The source population comprised of persons with at least one year of valid history in the IPCI-data-
base and contributing person time to the database during the study period (January 1996–Septem-
ber 2006). The one year history period was required to have sufficient background information on
each study subject. Case selection and validation was part of a larger project facial pain, details of
which have been described elsewhere. 2 In brief, potential cases of facial pain were identified using
a broad and sensitive free text search in the computerized records followed by a three step approach
for case ascertainment. Firstly, in order to exclude false positive records and to assess the index
date (date of first symptoms), all potential cases were manually evaluated by a medical doctor (JK)
using the complete electronic medical records and criteria of the International Association for the
Study of Pain (IASP). 21 They were classified as trigeminal neuralgia, cluster headache, postherpetic
neuralgia in the facial area, occipital neuralgia with referred facial pain, local facial neuralgia, per-
sistent idiopathic facial pain, glossopharyngeal neuralgia or paroxysmal hemicrania. Potential cases
were divided into ‘probable’, ‘possible’ or ‘improbable’ depending on the number of episodes, men-
tioned symptoms and specialist confirmation. Improbable cases were excluded as a case. Secondly,
additional information was requested from the GP for all ‘possible’ cases. This was achieved using
a questionnaire, in which criteria from the IASP were mentioned per facial pain condition. 21 The
GP was asked to confirm or reject the diagnosis. If specialist letters were present, anonymized hard
copies were requested. All case information (including returned questionnaires) of all ‘probable’ and
‘possible’ cases was independently evaluated by two medical doctors. Discrepancies were arbi-
trated by a pain specialist (FH). Thirdly, to further ensure validity of the diagnosis, a random sam-
ple of 250 patients of all initial cases from step one was reviewed by a neurologist with ample
experience in pain treatment. In case of disagreement, a case was discussed until agreement was
reached. At the end of the case validation each case was classified as either ’case’ or ‘no case’. For
the present study we included patients who were classified as cluster headache. The index-date was
set at the date of first symptoms of cluster headache. Cases with a date of diagnosis before study
entry (prevalent cases) were excluded from the source population. In addition, we excluded non-re-
sponding practices. To avoid influence of obvious known risk factors for cluster headache we also
excluded from the source population subjects with mastoidectomy, brain surgery, eye surgery or cer-
vical spine surgery from the source population. For each case we randomly selected up to ten con-
trols from the source population, matched on GP-practice, gender, age and calendar time (controls
received the same index date as the case). 
Exposure and confounders
The primary exposure of interest was a history of head trauma as mentioned in the patient records.
Head trauma was defined as any trauma to the supracervical area. Type of trauma (fall, traffic ac-
cident or blunt trauma) and clinical aspect such as contusion, loss of consciousness and post trau-
matic deficit (amnesia, visual deficit, concentration problems, lethargia or whiplash) were manually
assessed. The investigator assessing exposure was blinded for the case status. The time to occurrence
of cluster headache was defined as the time lapse between head trauma and index date. To evalu-
ate the exposure window, we classified time lapse as below and above the median of cases and con-
trols together. The prevalence on the index date of smoking, alcohol abuse, cerebro- and
cardiovascular disease (stroke, transient ischemic attack, heart failure, ischemic heart disease, acute
myocardial infarction, angina pectoris or peripheral artery disease), atrial fibrillation / flutter, heart
failure, hypertension (i.e. diagnosis of hypertension), diabetes mellitus (i.e. diagnosis of diabetes
mellitus or prescription of drugs used in diabetes (ATC-code A10)), hypercholesterolemia (i.e. di-
agnosis of hypercholesterolemia and/or the use of lipid modifying treatment (ATC-code C10)) and
oral contraceptive use (including hormonal replacement therapy use and contraceptive use) were as-
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sessed automatically from the medical journal by free text search for lay terms, ICPC-codes, med-
ical abbreviations and ATC-codes. 41, 42
Statistical Data analysis
Means were compared using a student’s T-test, proportions by chi-square statistics. We used Mann-
Whitney U for comparison of time lapse between head trauma and occurrence of cluster headache
in cases and controls. The association between cluster headache and head trauma was analyzed
using a conditional logistic regression analysis with absence of head trauma as the reference expo-
sure category. Potential confounders were included into the final analysis if they were associated
with cluster headache (p ≤ 0.05) and if they changed the crude point estimate of the association be-
tween head trauma and cluster headache by 10%. We explored the effect of duration by adding du-
ration as a dichotomous variable based on the overall median of cases and controls. To evaluate
effect modification by age and gender, we repeated the analysis stratified for gender and age (below
and over median). An adjusted odds ratio (OR) and 95% confidence intervals (95% CI) was derived
from the final model. Point estimates were only calculated if there were more than three exposed
cases. All statistical analyses were conducted using SPSS software version 15.0 (SPSS inc, Chicago,
III). Statistical significance was accepted at a p-value equal to or below 0.05.
Results 
The source population for this study comprised 479,949 (1,898,417 PY) subjects from the IPCI-data-
base who had at least one year of valid history in the database. Within this population 117 incident
cases of cluster headache were identified and matched to 1143 controls by sex, age, GP practice and
calendar time. Cases had an average age of 41.6 years (standard deviation (SD) 13.3) and were
mostly male (61%) (Table 1). Smoking and hypercholesterolemia were significantly more common
in cases compared to controls (p<0.05). Cases slightly more often had cardiovascular disease than
controls, but this was borderline statistically significant (p=0.052). The prevalence of diabetes mel-
litus, alcohol abuse, oral contraceptive use and hypertension did not differ significantly between
cases and controls (p>0.05). 
A history of head trauma preceding the index date was more common in cases (5%) than in con-
trols (3%), but this difference was not statistically significant (p=0.14) (Table 2). Traffic accidents
were the main cause. The median duration from head trauma until the index date (date of cluster
headache in cases) was 1.57 years (inter quartile range (IQR): 0.99 – 3.08) in cases and 3.09 years
(IQR: 1.61 – 5.09) in controls (p=0.15). Overall, it was 2.83 years (IQR): 1.37 – 4.52). In controls,
the time lapse between head trauma and cluster headache ranged between 66 days to 38 years and
in cases between 58 days and 4.6 years. The majority of head trauma was without contusion (99%)
and loss of consciousness (99%). A minority of patients had post traumatic deficits (1%) most com-
monly consisting of amnesia (Table 2). The crude analyses showed a statistically non-significant as-
sociation between head trauma and cluster headache (ORmatched: 1.93; [95% CI: 0.78 - 4.75],
p=0.15) (Table 2). Numbers did not allow for analysis of associations between individual aspects
of head trauma (contusion or loss of consciousness, deficit etc) and cluster headache. Analysis of
head trauma with different categories of time lapse until cluster headache (latency period) did yield
different odds ratios for the separate categories. Head trauma occurring before the median latency
period (2.83 years) was statistically significant associated with cluster headache (ORmatched: 3.53;
[95% CI: 1.25 - 9.96]) (Table 2). 
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Adding smoking, hypercholesterolemia and heart failure to the model did not change the point es-
timates (Table 2). Stratification for age below and above 37 (median age) suggested effect modifi-
cation between age and head trauma in the risk of cluster headache. People aged under 37 had a
higher risk for cluster headache after head trauma (ORadj: 3.09; [95% CI: 0.98 - 9.77] vs ORadj:
1.01; [95% CI: 0.22 - 4.71]) although the difference was not statistically significant. Stratification
for gender showed that the association was slightly but non-significantly stronger in men as com-
pared to women (ORadj: 2.16; [95% CI: 0.67 - 6.95] vs ORadj: 1.64; [95% CI: 0.32 - 8.46]). 
Discussion
In this study, we did not find a statistically significant association between cluster headache and head
trauma, although the risk of cluster headache tended to be increased with head trauma (ORadj: 1.92;
[95% CI: 0.77 - 4.82]). Only smoking, hypercholesterolemia and heart failure were statistically sig-
nificant associated with the development of cluster headache but did not affect the point estimate
for head trauma. The lag time between head trauma and first occurrence of cluster headache was
not statistically different between cases and controls but the variation was smaller in cases (58 days
to 4.6 years) than in controls (66 days to 38 years). Recent head trauma (< 2.83 years) was signif-
icantly associated with a 3.5-fold increased risk for cluster headache. Furthermore, patients younger
than 37 years seemed to have a higher risk compared to older patients. This might reflect a differ-
ent or more severe head trauma in younger patients or a different mechanism of action.
Although the exact pathway underlying cluster headache remains unknown, head trauma may play
a role by causing damage to relevant neurovascular structures. 33, 79 Literature describing the asso-
ciation between head trauma and cluster headache consists of several case reports and case-control
studies. 78-83 A case control study performed in Italy revealed that head trauma was significantly as-
sociated with cluster headache (OR: 2.50; [95% CI: 1.28 - 4.88]). 82 Whereas more objective ex-
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Table 1: Baseline characteristics of the study population 
 
 Cases Controls OR [95% CI] P-value 
Total 117 1137   
Age (SD) * 41.6 (13.3) 41.1 (12.8) Matched Matched 
Below 37 years (%) 49 (42%) 472 (42%)   
Above 37 years (%) 68 (58%) 665 (58%)   
Male Sex (%) * 71 (61%) 694 (61%) Matched Matched 
Comorbidity     
Diabetes Mellitus (%) 6 (5%) 30 (3%) 2.03 [0.79; 5.2] 0.12 
Ischemic Cerebro-cardiovascular Disease (%) ** 8 (7%) 48 (4%) 1.64 [0.73; 3.68] 0.23 
Heart Failure (%)  3 (3%) 3 (0.3%) 10.36 [1.7; 62.93] 0.01 
Atrial fibrillation / flutter (%) 3 (3%) 11 (1%) 2.71 [0.71; 10.4] 0.15 
Hypertension (%) 10 (9%) 57 (5%) 1.79 [0.83; 3.88] 0.11 
Hypercholesterolaemia (%) 20 (17%) 121 (11%) 1.89 [1.06; 3.36] 0.04 
Smoking (%) 37 (32%) 195 (17%) 2.42 [1.55; 3.78] <0.01 
Alcohol abuse (%) 0 (0%) 4 (0.4%) 0.04 [0.00; 140523.38] 0.52 
OC use (%) 24 (21%) 245 (22%) 0.9 [0.47; 1.72] 0.80 
 
*Age and sex are matching factors thus showing similar distributions.  
** Includes stroke, transient ischemic attack, ischemic heart disease, acute myocardial infarction, angina and 
peripheral artery disease. 
SD: standard deviation, OR: odds ratio, CI: confidence interval, OC: oral contraceptives and hormone 
replacement therapy  
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posure such as previous head trauma with loss of consciousness was not significantly associated with
cluster headache (OR: 1.57; [95% CI: 0.63 - 4.00]) which could point at differential misclassifica-
tion of head trauma without loss of consciousness. 82 Alternatively, there could be a lack of power.
A major difference between this study and ours is that the prevalence of head trauma in our study
population is much lower (3-5% versus 16-36%). 83 In our study there may be underreporting of head
trauma because patients may omit reporting it and GPs may omit registering it. The Italian study
on the other hand, may have over reporting of head trauma because of a wider definition of head
trauma. Furthermore, since exposure in these studies was assessed retrospectively using question-
naires this might lead to information bias and selective misclassification of exposure. In our study
all cases of head trauma were registered by the GP before the first symptoms of cluster headache
occurred. Our exposure is thus less likely to be biased. The duration until cluster headache in liter-
ature ranged from 2 to 30 years which is comparable to our findings. 79 We explored the effect of
longer latency periods between head trauma and cluster headache and found that head trauma with
a latency periods longer than 2.83 years were not associated with cluster headache. Head trauma
with a latency period of less than 2.83 years was associated.
49
Table 2: Head trauma and the risk of cluster headache 
 
  Cases Controls OR * (95% CI) OR adjusted * ^ (95% CI) 
 (n=117) (n=1137)   
Head trauma (%) 6 (5%) 31 (3%) 1.93 [0.78; 4.75] 1.92 [0.77; 4.82] 
Fall (%) 1 (1%) 12 (1%) NA NA 
Traffic accident (%) 4 (3%) 16 (1%) 2.44 [0.81; 7.39] 2.63 [0.85; 8.14] 
Blunt trauma (%) 0 (0%) 2 (0.2%) NA NA 
     
Median duration until Cluster headache 
in years (IQR): * 1.57 (2.08) 3.09 (3.47)  
 
   0-2.83 years 5 (83%) 14 (46%) 3.53 [1.25; 9.96] 3.26 [1.13; 9.43] 
   >=2.84 years 1 (17%) 17 (54%) NA NA 
   0-1.37 years 2 (33%) 7 (23%) NA NA 
   >=1.37 years 4 (67%) 24 (77%) 1.67 [0.56; 4.94] 1.68 [0.56; 5.07] 
     
Clinical aspect: #, +     
   No serious aspect reported (%) 4 (67%) 22 (73%) 1.82 [0.62; 5.35] 1.65 [0.55; 4.97] 
   Contusion (%) 2 (33%) 8 (26%) NA NA 
   Loss of consciousness (%) 0 (0%) 1 (3%) NA NA 
     
Post traumatic deficit: #     
   Non reported (%) 4 (67%) 22 (7%) 1.83 [0.62; 5.39] 1.89 [0.63; 5.65] 
   Amnesia (%) 1 (17%) 5 (16%) NA NA 
   Visual deficit (%) 1 (17%) 0 (0%) NA NA 
   Concentration problems (%) 0 (0%) 1 (3%) NA NA 
   Whiplash (%) 0 (0%) 2 (6%) NA NA 
   Lethargia (%) 0 (0%) 0 (0%) NA NA 
 
# 1 missing / unknown 
* ‘no head trauma’ as reference category; median duration calculated in total population 
^ Adjusted for smoking, hypercholesterolemia and heart failure 
+ One patient had both a contusion as well as loss of consciousness 
The characteristics of head traumata and the duration until occurrence of cluster headache are displayed. Post 
traumatic deficits are also displayed.  
OR: odds ratio, CI: Confidence interval, IQR: Interquartile range, NA: not assessable; there are not enough 
cases to calculate an association. 
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In the literature debate remains regarding the association between head trauma and cluster headache
and the influence by life style factors or information bias. 79, 84 Social lifestyle such as smoking and
alcohol consumption or coffee drinking are associated with cluster headache. 100 Up to 90% of clus-
ter headache patients are smokers or former smokers and 90% are drinkers. 83 Furthermore, 84.9%
of cluster headache patients were current or past drinkers while alcohol use could trigger attacks in
80% of patients. 99 We also found smoking to be more common among cases (32%) compared to
controls (17%). Social lifestyle factors confounding the association between head trauma and clus-
ter headache may also explain the higher incidence of cluster headache in men who are possibly
more prone to head trauma due to more risky behavior. 2
There might be several reasons why we could not show an association between head trauma and
cluster headache. Since we performed an observational study, residual confounding may be an issue.
Information bias is an important source of spurious associations, especially misclassification of
outcome, exposure and confounders. To minimize false negative and false positive misclassifica-
tion of the outcome, we performed a broad, sensitive search including ICPC-codes, lay terms, spe-
cific treatment and symptoms which were manually validated while blinded for exposure. Manual
validation of exposure blinded for case status was done to avoid (differential) misclassification of
exposure. Despite this, there might be a considerable underestimation of head trauma in our study.
This is illustrated by our much lower prevalence of head trauma compared to previous studies (36%
vs. 5%). 83 This difference might, in part, be explained by different exposure measurements (ques-
tionnaires vs. electronic patient records). Cases sent directly to the emergency department might be
missed if no communication is sent to the general practitioner or if the communication is not digi-
tally available. This underestimation is probably non-differential among case status, as it occurred
before occurrence of cluster headache. It will therefore lead to an underestimation of the effect.
Our measurement of confounders was done automatically. This might also have led to underesti-
mation of confounder status although standardized search algorithms were used to minimize this.
The effect of this on the point estimate depends on the relation of the confounder with exposure and
outcome and might lead to either an underestimation or overestimation of the association. Given the
prospective nature of the database and the fact that general practitioners record data irrespectively
of the research question, recall bias is not an issue in our study as is selection bias. Probably the main
cause of concern in our study is the lack of power. The low number of exposed cases may explain
the statistically non-significant elevated risk of cluster headache after head trauma in this study.
This is partly due to the low prevalence of head trauma. 
Despite these limitations we report an epidemiologically sound study revealing no statistically sig-
nificant association between head trauma and cluster headache. This might be caused by lack of
power and underestimation of exposure. An alternative hypothesis might be that there is no asso-
ciation between cluster headache and head trauma. We did, however, find an 3.5-fold increased risk
for cluster headache in patients with a recent head trauma. This might be due to (selective) under-
reporting of head trauma occurring longer ago. It might also indicate subacute mechanisms under-
lying the relationship between head trauma and cluster headache. Future research on this subject
should thus focus on recent head trauma and should have an objective definition of head trauma.
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Abstract
Background: Few drugs are registered for treatment of neuropathic facial pain (NFP) and not much
is known about treatment choices for NFP in daily practice. 
Methods: Patients with NFP were identified in the Integrated Primary Care Information-database
with longitudinal electronic general practitioner (GP) records. We described prescription patterns
of pain medication following first symptoms. Off-label, off-guideline use, failure and reasons for
failure were assessed. Failure was defined as treatment switch, exacerbation, adverse event or in-
vasive treatment for NFP. 
Results: Of 203 NFP cases, 160 (79%) received pharmacological pain treatment. Most patients
(90%) were initially treated by a GP with anti-epileptic drugs (55%) or NSAIDs (16%) as monother-
apy. The median treatment delay was 0 days (range 0-2478 days). Adverse events were experienced
by 16 (10%) of patients. Sixty-two percent of first prescriptions were in adherence to guidelines and
59% were considered on-label while 34% of prescriptions were both off-label and off-guideline. Of
the first therapy, 38% failed within three months. The median duration until failure was 251 days. 
Conclusions: General practitioners usually are the first to treat NFP. They usually prescribe drugs
licensed for NFP and according to guidelines, but the extent of off-label use is substantial. Initial
treatment often failed within a short period after starting therapy. 
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Introduction
Neuropathic facial pain represents a group of neuropathic conditions which affect the facial area.
Though relatively rare, the nature of the pain and its location cause a considerable impact on the
quality of life and the daily functioning. Each year, 21.7 out of 100,000 persons are newly diagnosed
with one of these diseases according to recent data. 101
The most common type of neuropathic facial pain is trigeminal neuralgia, which presents with
paroxysmal, unilateral facial pain in one or more branches of the fifth cranial nerve. Other forms
include postherpetic neuralgia in the facial area, occipital neuralgia with referred facial pain, local
facial neuralgias and glossopharyngeal neuralgia. It is generally assumed that all forms of neuro-
pathic facial pain share a common aetiology involving demyelinisation of cranial nerves in the root
entry zone. However the cause of this demyelinisation may differ between the different types of neu-
ralgias. 37, 102-105
Many different pharmacological strategies have a proven efficacy but studies evaluating effective-
ness in real clinical practice are scanty. The European Federation of Neurological Societies (EFNS)
has developed guidelines for the pharmacological treatments of trigeminal neuralgia and posther-
petic neuralgia. 106 For trigeminal neuralgia the guidelines recommend carbamazepine (level A level
of evidence (LOE)) but also oxcarbazepine (level B LOE) and even baclofen and lamotrigine (level
C LOE). 106 For postherpetic neuralgia they recommend tricyclic antidepressants, gabapentine, pre-
gabalin and opioids (level A LOE). 106 Capsaicin, tramadol, topical lidocaine and valproate have a
lower efficacy or are less well evaluated (level B LOE). 106 In the Netherlands only carbamazepine
is officially registered for trigeminal neuralgia. Gabapentine is registered for peripheral neuralgia
which might include postherpetic neuralgia in the facial area and local facial neuralgias. 107 Prega-
balin is registered for peripheral and central neuropathic pain which covers all forms of neuropathic
facial pain. 107 The discrepancy between guideline recommendation and formal indication may af-
fect the treatment approach in real life practice.
Drug utilization studies evaluating real life pharmacological treatment patterns of neuropathic fa-
cial pain are scarce. The extent of off-label and off-guideline drug use in the treatment of these
painful conditions has not been quantified to date. The aim of this study was to investigate drug pre-
scription patterns in patients with trigeminal neuralgia, postherpetic neuralgia in the facial area, oc-
cipital neuralgia with referred facial pain, local facial neuralgias and glossopharyngeal neuralgia in
a primary care setting. Additionally, we quantified the extent of off-label and off-guideline treatment
as well as treatment failure. 
Methods
Setting
The study was conducted within the Integrated Primary Care Information (IPCI) database, a gen-
eral practitioners (GP) research database with longitudinal electronic patient records of more than
one million patients throughout the Netherlands. The patient population is representative of the
general Dutch population regarding age and sex. In the Dutch health care system, everyone is reg-
istered with a GP who acts as gatekeeper for medical care. Information from secondary care is col-
lected in the patient records of the GP. 26 Electronic records contain anonymous and coded
information on patient demographics, symptoms and diagnoses (using the International Classifica-
tion for Primary Care (ICPC-codes) and free text terminology), referrals, clinical findings, labora-
tory assessments, drug prescriptions and hospitalizations. 27 Summaries of hospital discharge letters
and additional information from medical specialists are entered in a free text format and hard copies
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can be requested. Information on drug prescriptions comprised amount, strength, ICPC-coded in-
dication, prescribed daily dose and Anatomical Therapeutic Chemical (ATC) classification code. 42
To maximize completeness of electronic data, GPs participating in the IPCI project are not allowed
to use additional paper-based records. The system complies with European Union guidelines on
the use of medical data for research and has been proven valid for pharmacoepidemiological re-
search. 24, 25 The scientific and ethical advisory board of the IPCI project approved this study (pro-
ject number 07/03).
Source population
The source population comprised all persons contributing person time to the database during the
study period (January 1996–September 2006) with at least one year of valid history in the IPCI
database. Since extra data collection was required for the validation of diagnoses, we excluded
practices from the source population that could not be contacted for data collection. In addition, we
excluded non-responding practices. Follow-up started at the beginning of the study period or the date
that one year of valid history was available and ended upon transferring out of practice, date of last
data supply by the GP, death or end of the study period, whichever came first.
Cohort definition
This study was conducted in a cohort of patients with incident neuropathic facial pain, which is
part of a larger project on facial pain in general. The overall study cohort for the project included
all persons from the source population who were newly diagnosed with facial pain according to the
criteria of the International Association for the Study of Pain (IASP). 14 Facial pain was identified
from the computerized records by a sensitive search on codes and free text comprising specialist re-
ported diagnoses and synonyms / abbreviations. Identification was followed by a three step ap-
proach for case ascertainment. Firstly, in order to exclude false positive records and to label the
probability and type of diagnosis, all potential cases were manually reviewed by a medical doctor
(JK) using the complete electronic medical records. Facial pain was classified as ‘probable’ if di-
agnosed by a specialist or if more than one episode of typical symptoms was recorded in the records,
and as ‘possible’ if only one episode was recorded or specific symptoms were mentioned in the pa-
tient records. Patients for whom no typical symptoms or specialist diagnosis were recorded were
classified as ‘no case’. Secondly, GPs were requested to confirm the presence and type of facial pain
of all ‘possible’ cases. In addition, they were asked to send the anonymized hard copies of all spe-
cialist letters regarding this diagnosis. All returned information was independently evaluated by
two medical doctors (JK, MM) to classify cases as ‘probable’ or ‘no case’. Discrepancies were ar-
bitrated by a pain specialist (FH). Thirdly, to further ensure the validity of the diagnosis, a random
sample of 250 patients of all initial ‘probable’ and ‘possible’ cases (742) from step one was re-
viewed by a neurologist with ample experience in pain treatment. In case of disagreement with the
previous classification, a case was discussed. Agreement was reached in all discussed cases.
At the end of the case validation process each potential case was classified as either ’case’ or ‘no
case’ by type of facial pain. The index date was set at the date of first symptoms of facial pain. If
multiple facial pain conditions occurred in a patient only the first was considered, yielding mutu-
ally exclusive groups of facial pain. Patients having a diagnosis of facial pain before the start of fol-
low-up (prevalent cases) were excluded in order to retain a cohort of incident (newly diagnosed)
patients. Within the cohort we made a distinction between neuropathic facial pain and other facial
pain, because of fundamental differences in treatment approaches. For the present analysis we ex-
cluded all patients with vascular facial pain resulting in a cohort of patients with incident neuropathic
facial pain.
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Treatment
Drug prescribing patterns were evaluated using the electronic prescription records from the IPCI
database and using full specialist letters requested from the GPs. As study drugs we included parac-
etamol, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, anti-epileptics, anti-migraine
drugs, anti-depressants, benzodiazepines, calcium-antagonists, clonidin and oxygen. The electronic
prescription records were manually evaluated to assess whether a drug was prescribed for an episode
of neuropathic facial pain. If no indication for drug prescription was recorded in free-text and no
indication code was entered by the GP, the first indication for prescribing the drug was used for sub-
sequent prescriptions until otherwise mentioned. If the drug was started before the index date, the
drug was considered not to be prescribed for facial pain. If a prescription started after the index
date and no indication could be found, it was considered as prescribed for facial pain to avoid false
negative misclassification.
Legend durations were calculated by dividing the total number of prescribed tablets by the pre-
scribed daily number of tablets to be taken. Drugs were assumed to be concomitant if they were pre-
scribed on the same day. Episodes of use were defined as periods of continuous drug (based on full
ATC-codes) use with gaps of 30 days or less. To evaluate whether the definition of the gap influ-
enced failure parameters we conducted several sensitivity analyses in which the gap width was var-
ied between 15 and 60 days.
Dosage regimens were classified as titration, fixed or as needed based on the prescribed regimens.
The prescribed daily dosage (PDD) was expressed as the number of defined daily dosages (DDD)
as defined by the World Health Organisation (WHO) taken per day. 108, 109 If no dosage regimen was
recorded and no regimen was available from follow-up treatment prescribed by the GP, the PDD was
calculated based on the prescribed total amount and the prescribed duration. If the prescribed du-
ration was missing, the average dosage regimen for the same drug and prescriber (GP or specific
specialist) were imputed. If this was not available, average dosage regimens were imputed not con-
sidering prescriber. Remaining empty variable were filled using guidelines and DDD. The total
PDD for concomitant medications was calculated as the sum of the individual PDDs. For combi-
nation products, (e.g. paracetamol with codeine), the DDD of the main component was used (e.g.
paracetamol). 
Outcome parameters
Various outcome parameters were considered comprising: patient demographics, the average num-
ber of study drug prescriptions and treatment episodes per patient, proportion of treated patients and
patients in follow-up, treatment delay between index date and first study drug, type of prescriber
(GP or specialist), guideline adherence, on- and off-label treatment, type of pain medication, treat-
ment regimen, failure of first therapy, reported adverse events and treatment switches during the first
episode. On- or off-label use was evaluated using the summary of product characteristics (SPC)
from the Medicines Evaluation Board in the Netherlands. 107 Drugs were considered on-label for a
certain diagnosis if that diagnosis was specifically mentioned as an indication in the SPC or if a drug
had a broader indication for pain (i.e. ‘severe pain’ or ‘chronic pain’). All other use was classified
as off-label. For trigeminal neuralgia and glossopharyngeal this meant that carbamazepine, prega-
balin and gabapentin were classified as on-label. For postherpetic neuralgia in the facial area, oc-
cipital neuralgia with referred facial pain and local facial neuralgias pregabalin and gabapentin were
considered as on-label.
Adherence to guidelines was assessed by making use of the EFNS guidelines on treatment of trigem-
inal neuralgia and postherpetic neuralgia. 106 There is no EFNS guideline available for local facial
neuralgias, occipital neuralgia with referred facial pain and glossopharyngeal neuralgia. As a result
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guideline adherence for these subtypes was not assessed. Furthermore, these diseases were cen-
sored while calculating percentage of patients treated with on-guideline drugs. 
Failure was classified through the following outcomes: 
a) Specific reason stated in the records (invasive pain treatment, adverse events leading to cessa-
tion of therapy, exacerbations, suicide or dose adjustment (excluding titration regimens)).
b) No specific reason stated in the records (drug switch without mentioned cause). 
Failures were attributed to the drug if it occurred during its legend duration or within the carryover
period of 30 days. The date of failure was defined as the date of starting the new episode (in case
of switch) or the date of recorded event, whichever came first. Sensitivity analyses were performed
with a carryover period of 15, 45 and 60 days. Only failure of the first treatment episode was con-
sidered. In this analysis follow-up was right censored upon the end of the treatment episode plus 30
days (carryover period). 
Analyses
Standard descriptive statistics were used to describe utilization patterns (percentages, means and me-
dians). Median time until first treatment was calculated as the total accumulated number of days be-
tween the index date and date of first treatment divided by the number of persons receiving treatment
during follow-up. Comparisons in treatment delays were tested using the Mann-Whitney U-test.
Within treated persons, median time till first failure and absolute risk of failure at three months was
assessed by a Kaplan-Meier analysis. In these analyses the start of follow-up was defined as the date
of first treatment start. All statistical analyses were conducted using SPSS 15.0 (SPSS inc, Chicago,
III).
Results
The source population comprised 479,949 persons who contributed 1,898,417 person years of total
follow-up. We identified 203 incident patients with neuropathic facial pain of who 118 suffered
from trigeminal neuralgia, 36 from postherpetic neuralgia in the facial area, 30 from occipital neu-
ralgia with referred facial pain, 17 from local facial neuralgias and two from glossopharyngeal neu-
ralgia. The mean follow-up after disease onset was 3.39 years (SD 0.18) and accumulated to a total
of 688.5 person years. Patients were on average 54.3 years old (SD 18.3) at first diagnosis of neu-
ropathic facial pain and 77 (37.9%) were male (Table 1). 
First line pharmacological treatment
During the follow-up 160 out of 203 (79%) patients with neuropathic facial pain were treated with
some kind of pharmacological pain treatment, 86% of patients with trigeminal neuralgia, 78% of
patients with postherpetic neuralgia in the facial area, 67% of patients with occipital neuralgia with
referred facial pain, 47% of patients with local facial neuralgia and 100% of patients with patients
with glossopharyngeal neuralgia. 
The median delay till first treatment was 0 days (ranging 0 to 2478 days). The median treatment
delay was much longer for patients with glossopharyngeal neuralgia (315 days) than for patients
with postherpetic neuralgia in the facial area (0 days), although this was not statistically significant
(p=0.12). Most patients were treated by a general practitioner (90%), the remaining part mostly by
a neurologist (6%), usually with a single drug treatment (Table 1). The distribution was equal for
men and women (p > 0.05).
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Figure 1: Drug use in neuropathic facial pain 
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Type of drugs
Anti-epileptic drugs were by far the most frequently prescribed drug for the first treatment of neu-
ropathic facial pain (55% of patients) followed by NSAIDs (16%) (Figure 1). This distribution was
observed for trigeminal and occipital neuralgia with referred facial pain but not for other types of
facial neuropathic pain. Patients with postherpetic neuralgia in the facial area received mostly anti-
depressant (38%) and anti-epileptic drugs (24%) as first prescription (Figure 2). Patients with local
or glossopharyngeal neuralgia received mostly anti-epileptic drugs or opioids as first prescription.
No statistically significant differences in first line therapy were observed between sexes (P > 0.05).
Subsequent use of anti-migraine drugs or calcium-antagonist was more common in men (p ≤ 0.05). 
In total, 42 of all treatment episodes in a total of 28 people contained a combination of two drugs
and two contained a combination of three drugs. The most common combination was an opioid
with an anti-epileptic drug (14%), followed by an opioid or paracetamol with an anti-depressant drug
(both 10%). Drugs were mostly prescribed in a fixed regimen (Table 2). Combination therapy and
dosage regimen did not differ between men and women (p > 0.05). As needed prescribing was most
common with conventional analgesics such as paracetamol (28%) and NSAIDs (23%). Titration to
a fixed regimen occurred with anti-epileptics and anti-depressants. Anti-migraine drugs and opioids
were rarely used but if used they were prescribed ‘as needed’. 
Off label/off guideline
Regarding guidelines, 61% of patients were first treated with a level A LOE drug. Fifty-nine per-
cent received a drug with a labelled indication (42% narrow +17% broad) (Table 2). Together, 55
(34%) of patients received initial treatment with an off-label and off-guideline drug. Subsequent
treatment episodes included level A LOE drugs in 58% of cases. Adherence to guidelines or regis-
tration labels did not differ between men and women for both the first and subsequent treatment 
(p > 0.05).
Treatment persistence /failure
The neuropathic facial pain patients received a total of 745 study drug prescriptions for facial pain
with an average of 4.1 prescriptions (SD 6.3) per patient, 96 patients (47%) had gaps between pre-
scriptions or failed and therefore had multiple treatment episodes during follow-up (Table 1). The
average number of different treatment episodes was 2.6 (SD 3.5). The median duration of the first
treatment episode was 20 days (inter-quartile range (IQR): 12-47 days). Initially a high proportion
of patients received treatment however the proportion persisting on treatment stabilized to approx-
imately 20% of patients after 6 months (Figure 3). 
One hundred and four out of 160 treated patients successfully completed the first treatment episode
or continued this treatment uneventfully within the first year after starting therapy. First treatment
of neuropathic facial pain failed in 57 patients out of 160, of who 38 failed because of unspecified
reasons and 19 because of specified reasons (adverse events, exacerbation, invasive treatment or
dose adjustment). Failure rates and Kaplan Meier analysis are displayed in table 3 and figure 4.
The median duration till first failure was 251 days overall (IQR: 20-353 days). Sensitivity analy-
ses with varying carryover periods showed a range of 50-60 cases failing treatment overall with sim-
ilar distributions for each individual type of neuropathic facial pain. Patients mostly switched to
anti-epileptic agents or a combination of drugs (Table 4). 
Adverse events occurred in 16 of first treatment episodes (10%) leading to a treatment switch in 9
patients (56%) (Table 2). In total 31 adverse events were recorded, including mostly central nerv-
ous system adverse events such as dizziness (2), hallucinations (3), headaches (1) or drowsiness (4)
and gastro-intestinal adverse events such as elevated liver enzymes (2), nausea (1), vomiting (1) and
dry mouth (1). There was no significant difference in frequency of treatment failure or the occur-
rence of adverse events between sexes (p > 0.05).
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Figure 3: Percentage of people on-treatment during follow-up 
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The largest percentage of patients receives a prescription during the 
first six months. After that, the percentage treated drops considerably. 
Figure 4: Failure rate 
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Discussion
This study showed that neuropathic facial pain was often treated at short notice using either anti-
epileptic drugs or NSAIDs, mostly by a general practitioner. The three months failure rate terms of
switching, necessity to increase dose or necessity to stop because of reported adverse events was
almost 40%. Almost 60% of prescriptions were labeled for the indication and 62% were in line with
recommendations from the EFNS guidelines. One third (34%) of treatment was off-label and off-
guideline. Most treatment was given during the first six months after which the number of treated
patients dropped considerably. The reduction in treatment can be explained by the natural history
of, for example, trigeminal and glossopharyngeal neuralgia with patients having prolonged painfree
remissions for months to years. 17, 31, 110 Furthermore it could be caused by lack of effectiveness or
side effects. Although it seems alarming that paracetamol and NSAIDs add up to 25% of first treat-
ment regimens this might be due to initial misclassification of the diagnosis or latency period be-
tween onset of symptoms and definite diagnosis. On the other hand we cannot exclude the
inappropriate use of medication because of lack of education or unfamiliarity with the treatment
guidelines. By defining the index date as date of first symptoms instead of as date of first diagno-
sis, possible false negative misclassification of drug exposure is prevented with little chance of in-
troducing false positive misclassification. 111-113 For our definition of on- and off-label, we considered
drugs prescribed for central and peripheral neuropathic pain to be on-label for all studied diseases
since these can be classified as central or peripheral. Drugs with ‘severe pain’ or ‘chronic pain’
listed as indication can be considered drugs for chronic pain syndromes but not specifically regis-
tered for neuropathic pain. These are therefore defined as having a broad indication. It is as of yet
unclear whether being off-label or off-guideline is a prognostic factor for failure.
The results of our study on prescription behavior are comparable to previous reports although lit-
erature is not available for all types of facial pain. One previous study performed in the United
Kingdom showed that the mean duration of treatment was 49.1 (Sd 84.7) days for trigeminal neu-
ralgia and 47.3 (SD 93.4) days for postherpetic neuralgia. 16 In the UK carbamazepine was the drug
of choice for trigeminal neuralgia (in line with our results) and coproxamol was the drug of choice
(24.9%) in postherpetic neuralgia. 16
A study surveying the impact of chronic pain in general on quality of life also reported similar treat-
ment patterns. 114 Of all chronic pain patients, 2% were currently treated by a pain management
specialist while one-third did not receive treatment anymore. Two-thirds were taking prescription
drugs, 44% NSAIDs, 28% opioids and 18% paracetamol. 114 Management was inadequate in 40%.
114 These findings are in agreement with our results although they do not specifically concern neu-
ropathic facial pain.
Two more recent papers reported that postherpetic neuralgia was most often treated with amitripty-
line while anti-epileptics were less used.23, 115 Our results show a slightly higher use of anti-epilep-
tic drugs (24%) and a lower use of anti-depressants (38%). Similarly for trigeminal neuralgia we
showed a higher amount of first treatments with anti-epileptics (65% vs. 55.3%) and lower per-
centages treated with paracetamol (5% vs. 11.3%) and amitriptyline (6% vs. 26.1%). 23
Our study possibly has some limitations. As we used observational data our main concern is false
positive and false negative misclassification of the diagnosis, outcome and the exposure. The lower
incidence rate of trigeminal neuralgia in our study as compared to other studies might indicate an
underestimation of the incidence rate in our study. 15, 23 To ensure maximum sensitivity and thereby
avoid false negative misclassification we performed a very broad search. To maximize specificity
and thereby avoid false positive misclassification we performed an extensive manual validation.
Nevertheless our incidence rate might be an underestimation. This could have led to an overesti-
mation of drug usage, adverse events and failure since patients requiring drug treatment, experi-
67
Seppe proefschrift boek:Opmaak 1  01-04-2010  20:10  Pagina 67
encing adverse events and failure of therapy are most likely to be seen by a GP and thus be identi-
fied by our search algorithm. Misclassification of exposure might occur due to over-the-counter
use of paracetamol and NSAIDs leading to an underestimation of its use. Similarly, since we based
our exposure date on a GP database we might miss specialist prescriptions. To ensure maximum
completeness of our data, manual review of specialist letters (electronic and hard copy) was per-
formed. The extent of omitting specialist prescriptions is probably minimal since GPs usually take
responsibility for repeat prescriptions. The uncommon use of combination therapy might likewise
be an underestimation of the actual use since most combinations are prescribed by specialists. In ad-
dition, we may have missed adverse events and exacerbations which were not reported by the pa-
tient or GP leading to an underestimation of our reporting of adverse events and to a possible
underestimation of the failure rate. To compensate for this, we considered any switch in treatment
regimen as failure of treatment assuming a switch to be due to adverse events or loss of effective-
ness. Cost considerations played a minor role since all drugs studied are reimbursed in the Nether-
lands. Misclassification of the treatment outcome due to errors in assessing legend durations was
further minimized by taking a 30 day carryover effect. After 30 days a drug was considered to be
prescribed for a new exacerbation of the disease rather than a failure of treatment. Although this 30
day period is chosen arbitrarily, sensitivity analyses were performed with a 15, 45 and 60 day pe-
riod showing minor chances. 
This study showed that the extent of off-label treatment in neuropathic facial pain conditions is sub-
stantial but less than 50%. Patients are treated rapidly, mostly by a GP, but treatment failure occurs
rapidly as well. Prescriptions that are both off-label and off-guideline occur in 34% of the first treat-
ment episodes. Whether or not this is a prognostic factor for failure has to be determined in further
studies. Reasons for off-label and off-guideline prescriptions are, although not yet clarified, of pos-
sible interest and may direct future action towards improving the effectiveness of treatment of neu-
ropathic facial pain.
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4.2
Predictors of carbamazepine treatment failure in trigeminal neuralgia
Submitted
Joseph SHA Koopman, MD 1, Jeanne P Dieleman, PhD 1, Frank. J Huygen, PhD 2, Ewout W. Steyer-
berg, PhD 3, Miriam CJM Sturkenboom, PhD 1,4
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Abstract
Background: Trigeminal neuralgia (TN) is a severe form of facial pain for which carbamazepine
is the first choice of treatment. Carbamazepine treatment is known to fail in 1 of 3 patients. We
aimed to identify predictors for failure of first carbamazepine treatment in patients with trigeminal
neuralgia.
Methods: Patients with validated incident TN were identified in the Integrated Primary Care In-
formation (IPCI)-database. TN patients were included in the analysis upon first start of carba-
mazepine treatment. Failure was defined as a change in treatment regimen, adverse event, surgical
procedure or TN exacerbation. Age, sex, daily dose, treatment regimen, primary or symptomatic TN,
delay until carbamazepine treatment, prior use of pain treatment, prescriber, alcohol abuse, smok-
ing and comorbidity were evaluated as predictors. Predictors were analyzed using Cox regression
analyses with penalized maximum likelihood model estimation. Model performance was expressed
using a concordance (c) statistic.
Results: Out of 118 incident cases with TN, 76 (64%) received carbamazepine treatment (67% fe-
males. The median age was 47.5 years. The one month cumulative failure risk was 20%. Special-
ist prescriber, symptomatic TN, and alcohol abuse could not be evaluated due to a low prevalence.
In a multivariable model, a higher dose and a long treatment delay were significant predictors of fail-
ure. The c-statistic was 0.61 [95% CI: 0.47 - 0.74] reflecting poor ability to predict failure.
Conclusions: Although we identified several predictors of the carbamazepine treatment failure,
failure in individual patients cannot be predicted. Further studies are needed to identify stronger pre-
dictors for treatment failure.
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Introduction
Trigeminal neuralgia is a severe form of paroxysmal facial pain presenting in one or more divi-
sions of the fifth cranial nerve. 20 It is a rare disease with an incidence rate of 12.6 per 100.000 per-
son years but known as seriously debilitating. 2 It can be either primary or secondary (symptomatic)
to other causes such as multiple sclerosis and tumors. Although surgical interventions exist, the pri-
mary treatment is pharmacologically. 116 Recent guidelines advise carbamazepine (level A level of
evidence (LOE)) and oxcarbazepine (level B LOE) as primary treatment with lamotrigine or ba-
clofen as less well proven alternatives. 116 Only carbamazepine is specifically registered for trigem-
inal neuralgia in the Netherlands. 107 Other commonly used drugs for neuropathic pain such as
pregabalin, gabapentin and tricyclic antidepressants have an unknown efficacy although they are fre-
quently used in clinical practice. 101, 116 Pregabalin and gabapentin are registered for central and pe-
ripheral neuropathic pain which includes trigeminal neuralgia in the Netherlands. 107 A recent drug
utilization study showed that most patients are primarily treated with anti-epileptics in the primary
care setting. 101 Clinical experience and review of clinical data however revealed a high failure rate.
101 Given the seriousness of the condition, patients would benefit from an a priori estimation of the
probability of treatment success. If predictors could be identified for treatment failure, this could be
a first step towards more tailor-made medicine and prevention of unnecessary adverse events. Until
today, predictors for failure of carbamazepine treatment in trigeminal neuralgia have not been iden-
tified. 
In this hypothesis-generating study, we aimed to identify predictors for failure of first carbamazepine
treatment for trigeminal neuralgia using an electronic general practitioners database.
Methods
Setting
The study was conducted within the Integrated Primary Care Information (IPCI) database, a gen-
eral practitioners (GP) research database with longitudinal electronic patient records of over one mil-
lion patients throughout the Netherlands. The patient population is representative of the general
Dutch population regarding age and sex. In the Dutch health care system, everyone is registered with
a GP who acts as gatekeeper for medical care. Information from secondary care is recorded in the
patient records of the GP. 26 Electronic records contain anonymous and coded information on pa-
tient demographics, symptoms and diagnoses (using the International Classification for Primary
Care (ICPC-codes) and free text terminology), referrals, clinical findings, laboratory assessments,
drug prescriptions and hospitalizations. 27 Summaries of hospital discharge letters and additional in-
formation from medical specialists are entered in a free text format and hard copies can be re-
quested. Information on drug prescription comprises amount, strength, ICPC-coded indication,
prescribed daily dose and Anatomical Therapeutic Chemical (ATC) classification code. 42 To max-
imize completeness of electronic data, GPs participating in the IPCI project do not use additional
paper-based records. The system complies with European Union guidelines on the use of medical
data for research and has been proven valid for pharmacoepidemiological research. 24 The scientific
and ethical advisory board of the IPCI project approved this study (project number 07/03).
Source population
The source population comprised all persons contributing person time to the IPCI database during
the study period (January 1996–September 2006) and with at least one year of valid history in the
database. Since extra data collection was required for the validation of diagnoses, we excluded
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practices from the source population that could not be contacted for additional data collection. In
addition, we excluded non-responding practices. Follow-up started at the beginning of the study pe-
riod or the date that one year of valid history was available and ended upon transferring out of prac-
tice, date of last data supply by the GP, death or end of the study period, whichever came first.
Study population
Within the source population we identified all patients with an incident diagnosis of trigeminal neu-
ralgia, as part of a wider project on facial pain using criteria of the International Association for the
Study of Pain (IASP). 2, 14 Case validation is prescribed in detail elsewhere. 2 In brief, facial pain was
identified from the computerized records by a sensitive search followed by a three step approach
for case ascertainment. Firstly, all potential cases were manually reviewed by a medical doctor (JK)
using the complete electronic medical records. Facial pain was classified as ‘probable’ if diagnosed
by a specialist or if more than one episode of typical symptoms was recorded in the records and as
‘possible’ if only one episode was recorded or specific symptoms were mentioned in the patient
records. Patients for whom no typical symptoms or specialist diagnosis were recorded were classi-
fied as ‘no case’. Secondly, GPs were requested to confirm the presence and type of facial pain of
all ‘possible’ cases. In addition, they were asked to send the anonymized hard copies of all spe-
cialist letters regarding this diagnosis. All returned information was independently evaluated by
two medical doctors to classify cases as ‘probable’ or ‘no case’. Thirdly, to further ensure the va-
lidity of the diagnosis, a random sample of 250 patients of all initial ‘probable’ and ‘possible’ cases
(n=742) from step one was reviewed by a neurologist with ample experience in pain treatment. At
the end of the case validation process each potential case was classified as either ’case’ or ‘no case’
by type of facial pain. The index date was set at the date of first symptoms of facial pain. If multi-
ple facial pain conditions occurred in a patient only the first was considered, yielding mutually ex-
clusive groups of facial pain. Patients having a diagnosis of facial pain before the start of follow-up
(prevalent cases) were excluded in order to retain a cohort of incident (newly diagnosed) patients.
For this study we only selected patients with incident trigeminal neuralgia who were treated with
carbamazepine. Follow-up started on the date of first carbamazepine prescription and ended upon
treatment failure, end of first carbamazepine treatment episode (including a 30 day carryover pe-
riod) or end of follow-up, whichever was earliest. Carbamazepine was chosen since it is the only
drug with a level A recommendation of the American Association of Neurologists and the European
Federation of Neurological Societies. 116
Treatment
Ascertainment of carbamazepine prescribing patterns is described in detail elsewhere. 101 In brief,
we manually evaluated study drugs using the electronic prescription records from the IPCI database
and using full specialist letters available in the free text of the database or requested from the GPs.
We manually ascertained strength, dosing regimen, titration regimen, as-needed prescription and in-
dication of use. Legend durations were calculated by dividing the total number of prescribed tablets
by the prescribed daily number of tablets to be taken. Episodes of use were defined as periods of
continuous drug (based on full ATC-codes) use with gaps of 30 days or less. 
Outcome
The primary outcome was treatment failure, defined as invasive pain treatment, adverse events lead-
ing to cessation or switch of treatment, exacerbations, suicide or drug switch without mentioned
cause or dose adjustment (excluding titration regimes). 
Treatment failure was attributed to the drug if it occurred during its legend duration or within the
carryover period of 30 days. The date of failure was defined as the date of starting a new treatment
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episode (in case of switch) or the date of recorded event, whichever came first. Only failure of the
first treatment episode with carbamazepine was considered. For calculation of the one month fail-
ure risk, follow-up was additionally right censored upon one month after start of treatment. 
Predictors
Various predictors for failure were considered, including sex, age, comorbidity, smoking, alcohol
abuse, prescriber, primary or symptomatic trigeminal neuralgia, dosage and treatment regimen dur-
ing the first episode of carbamazepine treatment. Furthermore, we considered as predictor for fail-
ure the delay between the date of first symptoms (index date) and start of first carbamazepine
treatment and treatment naivety (i.e. naive if carbamazepine treatment was the first pain treatment
received for trigeminal neuralgia). We classified comorbidity according to the number of unique
ATC-codes prescribed in the year preceding (not including) the date of first symptoms (i.e. comor-
bidity index). This score is used as a proxy for illness using drug prescription data instead of clin-
ical diagnoses. Predictors were assessed using automated search algorithms (alcohol abuse,
smoking, comorbidity index and treatment delay) or manual validation (prescriber, dosage and treat-
ment regime). Dosage regimens were classified as flexible (titration regimen or as-needed) or fixed
(exact regimen). The dosage was defined as the dosage taken per day expressed as the prescribed
daily dosage (PDD) divided by the defined daily dosages (DDD), as set by the World Health Or-
ganisation (WHO), yielding a PDD / DDD-ratio. 42 The DDD for carbamazepine is 1000 milligram
per day for the main indication (anti-epileptic). Age, treatment delay, the PDD / DDD-ratio and co-
morbidity index were entered as continuous variables after checking for non-linearity. Non-linear-
ity was checked by adding a quadratic term in a univariate Cox proportional hazards model. 117
Categorization might have led to a loss of power and residual confounding. 118
Analyses
Standard descriptive statistics were used to describe baseline characteristics (percentages, means and
medians) with standard deviation (SD; for means) and interquartile range (IQR; for medians). The
one month failure risk was derived from Kaplan-Meier analysis in which duration till failure was
right censored at three months. 
The association of predictors with the outcome was analyzed using a Cox proportional hazards
model. Hazard ratios (HR) and adjusted hazard ratios (HRadj) were reported with 95% confidence
intervals (95% CI). The hazard ratio of age was reported per ten year band, treatment delay per
week, the PDD / DDD-ratio per decimal and the comorbidity index per whole point (i.e. additional
ATC-code). To be considered for the multivariable analyses, variables had to have a reasonable
spread (at least 5% prevalence). A penalized maximum likelihood model was used to deal with pos-
sible overfitting. 119 We used an absolute (“Lasso”) and quadratic (“Ridge”) penalty to simultane-
ously select and shrink the coefficients and reduce potential overfitting. 120 This method has been
described before as a solution to a large number of evaluated predictors compared to the number of
events or cases. 121 By applying the proper penalties, which can be selected by maximizing the pe-
nalized likelihood of the model, coefficients of individual prognostic factors are reduced towards
zero. Any variables with a coefficient of zero (after penalizing) were dropped out of the model.
Since the penalized model does not return standard errors we did not provide 95% CI for factors in
the final model but only their HR. Predictors of failure from this model were used as penalized
maximum likelihood HRs (HRpml). Model performance was tested using the concordance statis-
tic (c-statistic) with 95% CI which is equivalent to the area under the curve (AUC) for binary out-
comes. 122 Statistical analyses were conducted using SPSS 15.0 (SPSS inc, Chicago, III) and R
(version 2.7.12) using the packages Penalized and Design. 123
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Results
The source population comprised 479,949 persons who contributed 1,898,417 person years of total
follow-up. We identified 118 incident patients with trigeminal neuralgia. The mean follow-up after
disease onset was 4.21 years (SD: 2.67). In total, 76 patients with trigeminal neuralgia used carba-
mazepine. Patients were on average 50 years old (SD: 18) at first diagnosis of trigeminal neuralgia
and 25 (33%) were male (Table 1). Three people had secondary trigeminal neuralgia. 
The median delay was 0.9 weeks (IQR: 0.0 – 10.8 weeks) until the first treatment with carba-
mazepine. Patients failing treatment had a significantly longer treatment delay than patients not
failing their first carbamazepine treatment (p = 0.02). Carbamazepine was mostly initiated by a GP
(86%) and as fixed dosage regimes (87%). Dosages were usually lower than the DDD as defined
by the WHO for treatment of epilepsy (PDD / DDD-ratio 0.3, IQR 0.2-0.4), but it did not differ sig-
nificantly between people failing and not failing treatment (p = 0.47). People were, on average,
healthy with a median comorbidity index of 2.0 (IQR: 1.0-7.0). Patients failing were equally healthy
as non-failing patients as proxied by the comorbidity index (p = 0.17). Most patients received car-
bamazepine as first treatment (78%) while a minority received it subsequent to other treatment
(22%). Failure risk was equal for treatment naïve and treatment experience patients. The one month
failure risk was 20% [95% CI: 10% - 30%] (Table 1). Failure occurred after a median duration of
25.0 days (IQR: 12.0-70.0 days). 
Alcohol abuse, primary or symptomatic trigeminal neuralgia and prescriber could not be evaluated
because of too little spread (prevalence <5%). Univariately, longer delay (weeks) till first carba-
mazepine treatment (HR: 1.01; [95% CI: 1.00 - 1.01]) and a higher PDD / DDD – ratio (HR: 1.3;
[95% CI: 1.0 - 1.7]) were associated with failure (p < 0.05). In the multivariate Cox proportional
hazard model, delay till first carbamazepine treatment (HRadj: 1.01; [95% CI: 1.00 - 1.01]) was sig-
nificantly associated with treatment failure (Table 1). PDD / DDD ratio was no longer statistically
significant but the point estimate remained stable. 
Penalized model
After shrinkage using the penalized model, two variables were retained: delay until carbamazepine
treatment and PDD / DDD-ratio. Longer delay until carbamazepine treatment (HRpml: 1.01) and
higher PDD / DDD – ratio (HRpml: 1.16) were associated with an increased risk of failure. Since
the penalized model does not provide standard errors we cannot report 95% CIs around the HRpml.
Overall, the c-statistic of the final model was 0.61 [95% CI: 0.47 - 0.74], which is poor. 117
Discussion
In this study we identified several predictors for failure of the first carbamazepine treatment for
trigeminal neuralgia. In a penalized multivariable model we found longer delay until carbamazepine
treatment and a higher daily dosage to be most predictive of the risk of failure of carbamazepine
treatment. Overall, the model with these two variables performed poorly with a c-statistic of 0.61.
117
The finding that a higher dosage leads to increased failure might seem contra-intuitively but this may
be explained by confounding by severity. More severe trigeminal neuralgia might be treated with
higher dosages and have a higher a priori failure risk. Alternatively, the increased risk may be caused
by an increased risk of adverse effects at higher dosages. 
The one month failure rate was 20% which is in line with the 70 to 89% success rate of carba-
mazepine for treatment of trigeminal neuralgia reported elsewhere. 124 Other studies had however
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a longer follow-up and therefore probably have a much lower failure rate at one month than our
study. The difference in failure rate can have several explanations. For one, patients in our study re-
ceived a median dosage of 300 mg compared to up to 2400 mg in clinical trials. 124 Furthermore,
there were methodological issues such as the lack of a washout period and allowing of concurrent
interventions. 125-127 Also, since these studies were randomized clinical trials the patient population
might have been more homogenous and more closely supervised than in our study. All these issues
lead to incomparable results. To our knowledge, no reports exist regarding the identification of pre-
dictors of failure of carbamazepine treatment for trigeminal neuralgia in routine clinical practice.
Some studies report predictors for carbamazepine failure in epilepsy patients but most of the pre-
dictors in that setting are not applicable to our situation. 128
Our study has several limitations. As we used observational data our main concern is misclassifi-
cation of the exposure and outcome. False negative misclassification of carbamazepine use might
occur because we miss some specialist prescriptions. To ensure maximum completeness of our data,
manual review of specialist letters (electronic and hard copy) was performed. The extent of omit-
ting specialist prescriptions is probably minimal since GPs usually take responsibility for repeat
prescriptions. In addition, we may have missed adverse events and exacerbations which were not
reported by the patient or GP leading to an underestimation of our reporting of adverse events and
to a possible underestimation of the failure rate. To compensate for this, we considered any switch
in treatment regimen within 30 days of cessation of the last prescription as failure of treatment as-
suming a switch to be due to adverse events or lack of effectiveness. This is an assumption which
may not fully compensate for the underestimation of treatment failure or which may even lead to
an overestimation of the outcome. Misclassification of our predictors is another limitation. There
is probably no or little misclassification of sex, age, prescriber, dosage and treatment regimen, treat-
ment delay and treatment naivety. Since comorbidity is ascertained based on drug use our study
probably underestimates the presence of comorbidity although this is likely to be non-differential.
The presence of smoking, alcohol abuse and primary or symptomatic trigeminal neuralgia might be
severely underestimated in our study. False negative misclassification of these predictors will most
likely lead to an underestimation of their effect and residual confounding. This might cause certain
factors to drop out of our model while they might be important predictors for treatment failure. The
main limitation of this study is the small sample size. This leads to optimistic estimations of model
performance and limited power for selection of important predictors. Using a p-value of 0.05 for
predictor selection would have been too strict. We therefore used a penalized model to shrink the
coefficients and reduce the optimism of the model and performed bootstrapping for validation.
Despite these limitations, this study tried to identify potential predictors for failure of first carba-
mazepine treatment for trigeminal neuralgia. Given the hypothesis generating nature of this study
and the poor predictability of our model, no clinical judgment can yet be made based on our results.
Further studies should be performed in a larger dataset to identify stronger predictors and ideally
include severity at baseline in addition to dose and dosing regimen. Building of a clinical predic-
tion model might enable tailor made medicine and avert the trial and error approach in daily prac-
tice. 
76
Seppe proefschrift boek:Opmaak 1  01-04-2010  20:10  Pagina 76
4.3
Pharmacological treatment of cluster headache in the general population
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Abstract
Background: Few drugs are registered for treatment cluster headache (CH) and not much is known
about treatment choices in daily practice. We evaluated treatment patterns, treatment failure, off-
label, off-guideline use and predictors for treatment failure.
Methods: Cases were identified in the population-based Integrated Primary Care Information-data-
base. First and ever prescription of pain medication following index date were assessed in terms of
off-label and off-guideline use. Treatment failure was defined as switching of pain medication, ex-
acerbation of cluster headache, recorded adverse events and referral for invasive treatment. Pre-
dictors of failure were evaluated in first time users of sumatriptan, oxygen or zolmitriptan. Age,
sex, dose, treatment regimen, treatment delay until treatment, prior use of pain treatment, prescriber,
alcohol abuse, smoking and comorbidity were evaluated. Predictors were analyzed using Cox re-
gression analyses with penalized maximum likelihood estimation. 
Results: Of the 117 confirmed incident cases of CH, 105 (90%) received pharmacological pain
treatment. Most of these patients (95%) were initially treated by a GP with anti-migraine drugs
(49%) or NSAIDs (17%) as monotherapy. Fifty-five percent of first prescriptions were in adherence
to guidelines and 15% were considered on-label treatment while 34% of prescriptions were both off-
label and off-guideline. Based on type of first therapy, 31% [95% CI: 15% - 47%] failed within one
month. We identified 60 first time users of sumatriptan, oxygen or zolmitriptan. Dosage regimen
(strength and fixed dose), comorbidity, treatment delay, drug prescribed and age were statistically
significant predictors. 
Conclusions: General practitioners usually are the first to treat cluster headache. They regularly
choose drugs not licensed for this indication. A considerable percentage of these treatments failed
within the first month of treatment. We identified several predictors for treatment failure. Further
studies may consider these predictors to identify patients at increased risk of treatment failure.
78
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Introduction
Cluster headache is a chronic facial pain syndrome which has a serious impact on the quality of life.
5 Each year, 12.5 out of 100,000 persons are newly diagnosed with this disease. 2 Cluster headache
is considered to be a trigeminal-autonomal cephalalgia (TAC) which represents a distinct group of
facial pains together with paroxysmal hemicrania and short-lasting unilateral neuralgiform headache
with conjunctival injection and tearing (SUNCT). 65 Although cluster headache is a cephalalgia, it
can be considered as a form of facial pain given the involvement of the first branch of the trigem-
inal nerve. 14
The recommended drugs of the European Federation of Neurological Societies (EFNS) are often not
in agreement with the limited registered pharmacological treatment options for cluster headache. 107,
129 For instance, in the Netherlands subcutaneous sumatriptan is the only drug registered for acute
treatment of cluster headache and methysergide is the only drug registered for prophylaxis. 107 The
EFNS guidelines recommends not only sumatriptan but also oxygen and zolmitriptan for the treat-
ment of cluster headache attacks and verapamil or steroids for the prevention of relapses (all level
A level of evidence (LOE)). 129 Methysergide is only recommended at a level B. 129 The discordance
between drug licensing and treatment guidelines is likely to lead to extensive off-label treatment for
cluster headache. The extent of off-label use and the consequences in the general population are not
known. In fact, there is very limited insight in the use and effects of pharmacological treatment for
cluster headache in general practice. 
Treatment is only successful in a 60-75% of patients being treated with oxygen or sumatriptan. 65
Given the severity of cluster headache, it is important to identify patients at a higher risk for fail-
ure. Identifying predictors for treatment failure can help to develop tailor-made treatment approaches
thereby minimizing the risk of adverse events and delay till effective treatment. Smoking, alcohol
intake, age, nausea, vomiting and restlessness have been reported to influence treatment response
of various drugs in the treatment of cluster headache. 85, 87, 130, 131
To provide more data on drug utilization patterns and to identify new predictors of first sumatrip-
tan, oxygen or zolmitriptan treatment we performed a cohort study using the population-based In-
tegrated Primary Care Information (IPCI) database in the Netherlands. 
Methods
Setting
The study was conducted within the Integrated Primary Care Information (IPCI) database, a gen-
eral practitioners (GP) research database with longitudinal electronic medical records of currently
more than one million patients throughout the Netherlands (total population 17 million). The patient
population is representative of the general Dutch population regarding age and sex. In the Dutch
health care system, everyone is registered with a GP who acts as gatekeeper for medical care. In-
formation from secondary care is collected as narratives in the patient records of the GP. 26
Electronic medical records contain anonymous and coded information on patient demographics,
symptoms and diagnoses (using the International Classification for Primary Care (ICPC-codes) and
free text terminology), referrals, clinical findings, laboratory assessments, drug prescriptions and
hospitalizations. 27 Summaries of hospital discharge letters and additional information from med-
ical specialists are entered in a free text format and hard copies can be requested. Information on
drug prescription comprises amount, strength, ICPC-coded indication, prescribed daily dose and
Anatomical Therapeutic Chemical (ATC) classification code. 42 To maximize completeness of elec-
tronic data, GPs participating in the IPCI project are not allowed to use additional paper-based
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records. The system complies with European Union guidelines on the use of medical data for re-
search and has been proven valid for pharmacoepidemiological research. 24, 25 The scientific and
ethical advisory board of the IPCI project approved this study (project number 07/03).
Source population
The source population for the study comprised of all persons contributing person time to the IPCI
database during the study period (January 1996-September 2006) with at least one year of valid
history in the database. Since extra data collection was required for the validation of the cluster
headache diagnoses, we excluded all practices from the source population that could not be con-
tacted for additional data collection. In addition, we excluded non-responding practices. Follow-
up started at the beginning of the study period or the date that one year of valid history was available
and ended upon transferring out of practice, date of last data supply by the GP, death or end of the
study period, whichever came first.
Cohort definition
This study was conducted in a cohort of patients with incident cluster headache, which is part of a
larger project in which we study the epidemiology of facial pain in general. 2 The overall study co-
hort for the project included all persons from the source population who were newly diagnosed
with facial pain according to the criteria of the International Association for the Study of Pain
(IASP). 14 Cases were identified from the computerized records by a sensitive search on codes and
free text comprising specialist reported diagnoses. Identification was followed by a three step ap-
proach for case ascertainment. Firstly, the electronic medical records of all potential cases were
manually reviewed by a medical doctor (JK). Cases were classified as ‘probable’ if diagnosed by a
specialist or if more than one episode of typical symptoms was recorded in the records, and as ‘pos-
sible’ if only one episode was recorded or specific symptoms were mentioned in the patient records.
Patients for whom no typical symptoms or specialist diagnosis were recorded were classified as
‘no case’. Secondly, GPs were requested to confirm the presence and type of facial pain of all ‘pos-
sible’ cases and to send the anonymized hard copies of all specialist letters regarding this diagno-
sis. The information was independently evaluated by two medical doctors (JK, MM) to classify
cases as ‘probable’ or ‘no case’. Discrepancies were arbitrated by a pain specialist (FH). Thirdly,
to further ensure the validity of the diagnosis, a random sample of 250 patients of all initial ‘prob-
able’ and ‘possible’ cases (742) from step one was reviewed by a neurologist with ample experience
in pain treatment. In case of disagreement with the previous classification, a case was discussed. 
To identify possible predictors of treatment failure we only studied patients with incident cluster
headache who were treated with sumatriptan, oxygen or zolmitriptan, which are the level-of-
evidence (LOE) A drugs for acute treatment of abortion of cluster headache attacks according to the
guidelines of the European Federation of Neurological Societies. 129 These are mutually exclusive
groups meaning only the first treatment episode with one of the above mentioned drugs is analyzed.
Follow-up for this cohort started on the date of first drug prescription and ended upon treatment fail-
ure, end of treatment or end of follow-up, whichever was earliest.
Treatment
Drug prescribing patterns were evaluated using both the electronic prescription records from the
IPCI database and the medical specialist letters that were requested from the GPs. As study drugs
we included paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, anti-epileptics,
anti-migraine drugs (triptans and ergots), anti-depressants, benzodiazepines, calcium-antagonists,
clonidin and oxygen. Indications were obtained from linked or written indications and follow-up in-
dications if available. If the drug was started before the index date, the drug was not considered to
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be prescribed for cluster headache. If a prescription started after the index date and no indication
could be found, it was considered as probably prescribed for cluster headache to avoid underre-
porting of prescription rates.
Legend durations were calculated by dividing the total number of prescribed tablets by the pre-
scribed daily number of tablets to be taken. Drugs were assumed to be used concomitantly if they
were prescribed on the same day. Episodes of use were defined as periods of continuous drug (based
on full ATC-codes) use with refill gaps of 30 days or less. To evaluate as to whether the definition
of the gap width influenced failure parameters we conducted several sensitivity analyses in which
the gap width was varied between 15 and 60 days.
Dosage regimens were classified as titration, fixed or as needed based on the prescribed regimens
of the index and subsequent prescriptions. The prescribed daily dosage (PDD) was expressed as
the number of defined daily dosages (DDD) as defined by the World Health Organisation (WHO)
taken per day (PDD / DDD-ratio). 42
Outcome parameters
The primary outcome of interest of this study was the drug utilization patterns in cluster headache
patients’ first starting treatment. Parameters comprised: proportion of treated patients, the number
of study drug prescriptions and treatment episodes per patient, treatment delay, type of prescriber
(GP or specialist), type of pain medication, treatment regimen, labelling status, adherence to the
EFNS guideline and treatment switches. Labelling status was evaluated using the summary of prod-
uct characteristics (SPC) from the Medicines Evaluation Board in the Netherlands. 107 Drugs were
considered on-label if cluster headache was specifically mentioned or if a drug had a broader indi-
cation for pain (i.e. ‘severe pain’ or ‘chronic pain’). All other use was classified as off-label. The
secondary outcome was failure of first line treatment defined as: 
a) Failure mentioned in the electronic record (e.g. requirement of invasive pain treatment, adverse
events leading to cessation of therapy, exacerbations of pain, suicide or dose adjustment (exclud-
ing titration regimens)).
b) No specific reason stated in the records but a switch to another type of pain treatment. 
Failure was attributed to the drug if one of these events occurred during the legend duration or
within the carryover period of 30 days. 
Predictors
Various predictors for failure were considered, including sex, age, comorbidity, smoking, alcohol
abuse, prescriber, dosage and treatment regimen during the first episode of use. Furthermore, we
considered treatment delay between date of first symptoms (index date) and first level A LOE treat-
ment and treatment naivety (i.e. naïve means that there was no previous treatment) for cluster
headache. We classified comorbidity according to the number of unique prescriptions on ATC-7
level in the year preceding the index date. This score is a proxy for comorbidity using drug pre-
scription data instead of clinical diagnoses with zero indicating absence of comorbidity. Predictors
were abstracted from the electronic patient records using automated search algorithms (alcohol
abuse, smoking, comorbidity and treatment delay) and by manual validation (prescriber, dosage
and treatment regimen). Dosage regimens were classified as flexible (titration regimen or as-needed)
or fixed (exact regimen). The dosage was defined as the PDD / DDD-ratio.
Analyses
Standard descriptive statistics were used to describe utilization patters (percentages, means and me-
dians). Median time until first treatment was calculated as the total accumulated number of days be-
tween the index date and date of first treatment divided by the number of persons receiving treatment
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during follow-up. Treatment delay and treatment failure risk were estimated using Kaplan Meier
analysis and the Mann-Whitney U-test. The association of predictors with the outcome was analyzed
by applying a Cox proportional hazards model. Hazard ratios (HR) and adjusted hazard ratios
(HRadj) were reported with 95% confidence intervals (95% CI). Age, treatment delay (in weeks),
the PDD / DDD-ratio and chronic disease score were entered as continuous variables after check-
ing for absence of non-linearity. Non-linearity was checked by adding a quadratic term in a uni-
variate Cox proportional hazards model. Dichotomizing might have led to a loss of power and
residual confounding. 118 The hazard ratio of age was reported per ten year band, treatment delay
per week, the PDD / DDD-ratio per decimal point and the number of unique ATC-codes per whole
point. To be considered for the multivariable analyses, variables had to have a reasonable spread (at
least 3 positive events). A penalized maximum likelihood model was used to deal with possible
overfitting. 117, 119 We used an absolute (“Lasso”) and quadratic (“Ridge”) penalty to simultaneously
select and shrink the coefficients and reduce potential overfitting. 120 This method has been de-
scribed before as a solution to the presence of a large number of evaluated predictors compared to
the number of patients with the outcome. 121 By applying the proper penalties, which can be selected
by maximizing the penalized likelihood of the model, coefficients of individual prognostic factors are
reduced towards zero. Any variables with a coefficient of zero (after penalizing) were dropped out of
the model. Since the penalized model does not return standard errors we did not provide 95% CI for
factors in the final model but only their hazard ratios. Predictors of failure from this model were ex-
pressed as penalized maximum likelihood hazard ratios (HRpml). Model performance was tested
using the concordance statistic (c-statistic) with 95% CI which is equivalent to the area under the
curve (AUC) for binary outcomes. 122 Statistical analyses were conducted using SPSS 15.0 (SPSS inc,
Chicago, III) and R (version 2.7.12) using the packages Penalized and Design. 123
Results
The source population comprised 479,949 eligible persons who contributed 1,898,417 person years
of follow-up. We identified 117 patients with incident cluster headache. The mean follow-up after
disease onset was 3.48 years (SD 0.23) and accumulated to a total of 406.6 person years. Patients
were on average 41.7 years old (SD 13.4) at first diagnosis and 71 (61%) were male (Table 1). 
First line pharmacological treatment
During the follow-up 105 out of 117 (90%) patients with cluster headache were pharmacologically
treated. The median delay till first treatment was 0 days (range 0 to 2107 days). Most patients were
treated by a general practitioner (95%), the remaining part mostly by a neurologist (4%). Patients
were usually treated with a single drug (Table 1). 
Type of drugs
Anti-migraine drugs were the most frequently prescribed drugs for the first treatment of cluster
headache (49% of patients) followed by NSAIDs (17%) (Figure 1). In the studied patient a total of
665 medication prescriptions were made, 61 of these contained a combination of two drugs and
three contained a combination of three drugs. The most common combination was an anti-migraine
drug with a calcium channel blocker (61%), followed by an anti-migraine drug with either an
NSAID or an anti-epileptic drug (both 7%). As needed prescribing was most common with con-
ventional analgesics such as paracetamol (16%) and anti-migraine drugs (71%). Titration to a fixed
regimen occurred with anti-epileptics and calcium channel blockers. Oxygen was rarely used but
if used it was prescribed ‘as needed’.
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Off label / off guideline
Regarding guidelines, 54% of patients were first treated with a level A LOE drug. Fifteen percent
received a drug with a labelled indication (4% according to narrow definitions, 11% if broad defi-
nitions were applied) (Table 1). Together, 36 (34%) of patients received initial treatment with an off-
label and off-guideline drug. Second treatment episodes were slightly worse with 51% including a
level A drug. 
Treatment persistence / failure
The cluster headache patients received a total of 665 prescriptions of drugs (501 episodes) included
in this study with an average of 6.3 (SD 8.8) per patient. Sixty-nine patients (59%) had multiple treat-
ment episodes during follow-up (Table 1) with an average number of 4.8 (SD 6.2). The median dura-
tion of the first treatment episode was 10 days (inter-quartile range (IQR): 5.0 – 15.0). After six months
the proportion remaining on treatment stabilized to approximately 30% of patients (Figure 2).
First treatment of cluster headache failed in 34 patients out of 105, 28 because of unspecified rea-
sons (i.e. as approximated by treatment switch) and 6 because of specified reasons (adverse events,
83
Table 1: Patient and treatment characteristics 
 
Cluster Headache 
  First Episode Second Episode 
Number 117 
Mean age (SD) 41.7 (13.4) 
Male sex (%) 71 (61%) 
Number treated  
No of episodes 4.8 (6.2) 
   1 episode 105 (90%) 
2 episodes 69 (59%) 
>2 episodes 53 (45%) 
Number of drugs used   
Single drug 94 (90%) 59 (86%) 
Two Drugs Combined 11 (10%) 9 (13%) 
Three Drugs Combined 0 (0%) 1 (1%) 
Prescriber   
   General Practitioner 100 (95%) 60 (87%) 
Neurologist 4 (4%) 9 (13%) 
   Other Specialist 1 (1%) 0 (0%) 
EFNS guideline followed    
   Level A* 57 (54%) 35 (51%) 
   Level B* 1 (1%) 4 (6%) 
On-label treatment   
   Narrow indication 4 (4%) 6 (9%) 
   Broad indication 12 (11%) 6 (9%) 
Dosage regimen   
   PRN 48 (46%) 31 (45%) 
   Titration Regimen 3 (3%) 3 (4%) 
   Fixed Dose 54 (51%) 35 (51%) 
Off-guideline and off-label 36 (34%) 24 (35%) 
Adverse events 1 (1%) 2 (3%) 
 
The stated numbers are number of patients meaning that, for example, 
10 patients have been treated with any combination of drugs during 
their second treatment episode. SD = standard deviation. 
* This reflects the level-of-evidence for a drug as recommended by 
the guidelines of the European Federation for Neurological Societies. 
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exacerbation, invasive treatment or dose adjustment). The one month failure rate of treated patients
was 31% [95% confidence interval (95% CI): 15% - 47%], 27% [95% CI: 18% - 36%] for switch-
ing and 5% [95% CI: 0; 10%] for failure due to specific causes (Figure 3). Reported adverse events
leading to a treatment switch occurred once (1%) (Table 2). In total six adverse events were
recorded, including gastro-intestinal adverse events such as weight gain (n=1), restless legs (n=1),
unspecified (n=2), oedema (n=1) and dizziness (n=1). 
Sensitivity analyses with varying carryover periods showed a range of 31-37 cases failing treat-
ment overall. Patients mostly switched to anti-migraine drugs or a combination of drugs (Table 2). 
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Figure 2: Percentage of people on-treatment during follow-up 
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Figure 1: First and total type of drug prescribed 
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Predictors
During the study period, 60 (51%) used either oxygen (n=5, 8%), sumatriptan (n=54, 90%) or
zolmitriptan (n=1, 2%) as single drug treatment. The median treatment delay was 0.9 weeks (IQR:
0.0-17.9 weeks) until the first treatment (Table 3). Treatment was mostly initiated by a GP (n=56,
93%) and as a flexible dosage regimen (n=48, 60%). Doses were usually lower than the DDD as
defined by the WHO (PDD / DDD-ratio 0.6, SD 0.2-2.0). Patients used a median number of unique
ATC-codes of 3.0 (IQR: 2.0-6.0). Most treatment was given as the first cluster headache treatment
(66%) while only 33% was subsequent to another treatment for cluster headache.
Alcohol abuse and prescriber could not be evaluated because of too little spread. Univariately, treat-
ment with a fixed dosage regimen (HR: 0.2; [95% CI: 0.0 - 0.6]) was associated with failure. If all
variables were included in a cox proportional hazard model the number of unique ATC-codes was
associated too (HRadj: 1.4; [95% CI: 1.1 - 1.7]) (Table 3). After shrinkage using the penalized
model, six variables were retained namely age, fixed dosage regimen, treatment delay, the PDD /
DDD - ratio, the number of unique ATC-codes and treatment naivety for other pain treatments for
cluster headache. The number of unique ATC-codes (HRpml: 1.21) and being treatment experi-
enced for other pain treatments (HRpml: 1.25) were associated with an increased risk of failure.
Older age (HRpml: 0.88 per 10 year increase), receiving a fixed dose regimen (HRpml: 0.45), longer
treatment delay (HRpml: 0.999 per week delay) and a higher PDD / DDD – ratio (HRpml: 0.98 per
0.1 increase) were associated with a reduced risk of treatment failure. Overall, the c-statistic of the
final model was 0.72 [95% CI: 0.60 - 0.83].
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Figure 3: Failure rate of first treatment  
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Discussion
This study showed that cluster headache is often treated instantly and for a short duration using ei-
ther anti-migraine drugs or NSAIDs prescribed by a general practitioner. Although most drugs were
off-label a considerable part was used according to the EFNS guidelines. Only 33% of patients had
treatment for over six months. This might be explained by the natural history of cluster headache
with patients having painfree remissions for months to years. 132 First line treatment failure was
common and occurred early in treatment, mostly because patients needed a switch of their med-
ication. We found a younger age, flexible dose regimen, a shorter treatment delay, a lower PDD /
DDD-ratio, a higher comorbidity score and being treatment experienced to be associated with fail-
ure. Overall, our model with these six variables performed satisfactory with a c-statistic (= AUC)
of 0.72. 117 The higher risk in non-naive patients may be explained by the fact that these patients
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Table 3: Baseline characteristics, risks and hazard ratios 
 
  
Characteristic n Events one month risk (95% CI) Univariate HR Multivariate HR 
Sex      
  Male 38 14 0.32 [0.17; 0.46] Ref Ref 
  Female 22 7 0.33 [0.13; 0.53] 0.8 [0.3; 2.1] 1.1 [0.3; 3.3] 
Age* 
#
 39.5 (32.3 - 50.0)  36.0 (30.5 - 53.5)  1.0 [0.7; 1.4] 0.7 [0.4; 1.1] 
Prescriber      
  General practitioner 56 19 0.30 [0.18; 0.42] NA NA 
  Anaesthesiologist 0 0 NA NA NA 
  Neurologist 4 2 0.67 [0.13; 1.00] NA NA 
  Other 0 0 NA NA NA 
Dosage regimen      
  Flexible 48 20 0.38 [0.24; 0.52] Ref Ref 
  Fixed 12 1 0.08 [0.00; 0.24] 0.2 [0.0; 0.6] 0.1 [0.0; 0.8] 
Alcohol abuse      
  No 60 21 1.00 [0.88; 1.12] NA NA 
  Yes 0 0 NA NA NA 
Smoking      
  No 43 13 0.26 [0.13; 0.40] Ref Ref 
  Yes 17 8 0.47 [0.23; 0.71] 1.7 [0.7; 4.2] 0.7 [0.2; 2.0] 
Treatment Delay (weeks) * 0.9 (0.0 – 17.9) 2.0 (0.0 - 29.7)  1.00 [0.99; 1.01] 1.0 [0.98; 1.01] 
PDD / DDD - ratio* 
%
 0.6 (0.2 - 2.0) 0.2 (0.1 - 1.5)  0.99 [0.96; 1.02] 0.99 [0.96; 1.02] 
Chronic Disease Score* 
&
 3.0 (2.0 - 6.0) 4.0 (1.5 - 8.0)  1.13 [0.99; 1.29] 1.4 [1.1; 1.7] 
Treatment naive      
  Yes 40 11 0.28 [0.14; 0.42] Ref Ref 
  No 20 10 0.40 [0.18; 0.62] 1.8 [0.8; 4.3] 1.6 [0.5; 5.0] 
Total 69 22 0.32 [0.20; 0.44]   
 
 
This table displays the total number of treated patients per baseline characteristic (n) and the number of failures 
per category (events). Also, the one month failure risks (from Kaplan-Meier analysis) are displayed and 
the univariate and multivariable hazards ratios. 
* Age, treatment delay until first level A recommended treatment, the PDD / DDD-ratio and the number of 
unique ATC-codes in the year preceding the index date are entered as a continuous variable. The 
median is displayed with the interquartile range between brackets in total (n) and cases (events). 
# 
The HR of age displayed is per ten years. 
%
 The HR of the PDD / DDD-ratio displayed is per tenth of a point. 
&
 The HR of the number of unique ATC-codes is per point. 
** Mutually exclusive treatment groups 
PDD / DDD – ratio: prescribed daily dosage (PDD) divided by the defined daily dosage (DDD). The DDD 
indicates a standardized dose as defined by the World Health Organization. 
95% CI: 95% confidence intervals. 
HR: hazard ratio as derived from a cox proportional hazard model. 
NA: not assessable. It usually indicates there are not enough cases to do a calculation. 
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failed on previous treatment which may point at a higher a priori risk of failure. Patients receiving
a fixed dose might have a less severe form of cluster headache with a lower a priori failure risk. Al-
ternatively, a fixed dose itself might be more effective due to more stable blood levels. Similarly,
shorter treatment delay may point at a severe form of cluster headache with a higher a priori risk of
treatment failure. The lower failure risk in older people might have several explanations. Firstly, pa-
tients presenting with cluster headache at a higher age might generally have a less severe form of
cluster headache. Secondly, given their age and the natural course of cluster headache, older peo-
ple might have a lower risk of exacerbations. Thirdly, given a lower renal and hepatic function,
older patients might have higher plasma levels of prescribed drugs thus potentially leading to a
lower failure rate. Patients with a higher comorbidity score might be at a higher failure risk due to
the complexity of the circumstances (i.e. drug-drug interactions). In our study, smoking was not
associated with an increased risk of treatment failure.
Drug utilization studies in chronic pain syndromes in a primary care setting are rare. A recent sur-
vey under medical doctors found that 3% of neurologists prescribed gabapentine (GBP) for cluster
headache. 133 Analgetics were mostly used for a registered indication and in only 5% for scientifi-
cally unjustified off-label indications. 133 In contrast, we found 34% of first treatment episodes and
35% of second treatment episodes to be with off-label and off-guideline drugs. This difference can
be caused by a different patient population and a different on-label definition. We required the di-
agnosis or either ‘chronic pain’ or ‘severe pain’ to be explicitly mentioned in the SPC. If the men-
tion of ‘pain’ is considered as indication for all types of pain, most analgesics will be on-label. 
Another study performed in Canada assessed drug utilization and effectiveness in pain patients ret-
rospectively using questionnaires. 134 One third of patients with episodic cluster headache had used
anti-migraine drugs or oxygen. 134 Our study did not evaluate as to whether treatment was used pro-
phylactic or acute, but it showed a low rate of oxygen use compared to the use of calcium channel
blockers and anti-migraine drugs. The difference with our study might reflect a selection bias or dif-
ferent entry criteria in the Canadian study. Finally, we defined the start of follow-up as the date of
first symptoms rather than the date of diagnosis. As a consequence, the prescribed treatment as ob-
served in our study could partly reflect treatment during diagnostic work up. This could explain the
high rate of off-label and off-guideline drug prescription as well as the high failure rate.
Several studies have evaluated predictors for treatment failure in either migraine or cluster headache.
Smoking is associated with the development of cluster headache and might thus be associated with
exacerbations leading to more failure among smokers. 82 A previous study however found smoking
to be unrelated to triptan or oxygen treatment failure, which is in line with our study. 130 Alcohol was
found to be a trigger for exacerbations of cluster headache. 85-87 This could, however, not be con-
firmed in patients using triptans or oxygen. 130 Unfortunately, we could not evaluate alcohol con-
sumption as predictor of treatment failure due to low numbers of exposed patients. Other factors
such as the presence of autonomic features, the form of cluster headache and the absence of aura
could not be evaluated in our study. While age was not a factor of relevance in topiramate treatment,
older age was reported before to be predictive of triptan treatment failure in migraine patients, but
not in cluster headache patients. 130, 135, 136 We found age to have a positive influence on success of
therapy (HRpml: 0.88). Given our small dataset and the absence of confidence intervals after shrink-
age, no definite conclusion can be drawn regarding comparability of these findings. Although one
study in migraine found males to be more at risk for failure, the difference was minor (OR 1.27;
[95% CI: 1.10 - 1.50]). 136 Sex had no influence on failure in our final model, confirming findings
of a study about response to triptan and oxygen treatment in cluster headache patients and topira-
mate response in migraine patients. 130, 135
88
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Our study possibly has some limitations. As we used observational data our main concern is false
positive and false negative misclassification of the disease, outcome and the exposure. We aimed
to limit the extent of false negative misclassification of cluster headache by performing a broad, sen-
sitive search algorithm including common symptoms, specific treatments and spelling errors. Mis-
classification of the exposure might occur due to over-the-counter use of paracetamol and NSAIDs
leading to an underestimation of its use. Similarly, since we based our exposure data on a GP data-
base we might miss specialist prescriptions. To ensure maximum completeness of our data, man-
ual review of specialist letters (electronic and hard copy) was performed. Furthermore, since the GPs
usually take responsibility for repeat prescription the omission of specialist prescriptions was prob-
ably minimal. In addition, we may have missed adverse events and exacerbations which were not
reported by the patient or GP leading to an underestimation of our reporting of adverse events and
to a possible underestimation of the failure rate. To compensate for this, we considered any switch
in treatment regimen as failure of treatment assuming a switch to be due to adverse events or loss
of effectiveness. Cost considerations played a minor role since all drugs studied are reimbursed in
the Netherlands. Misclassification of the treatment outcome was further minimized by taking a 30
day carryover effect. After 30 days a new prescription was considered to be prescribed for a new
exacerbation of the disease rather than a failure of treatment. Although this 30 day period is cho-
sen arbitrarily, sensitivity analyses were performed with a 15, 45 and 60 day period showing minor
changes. There is no or little misclassification of sex, age, prescriber, dosage and treatment regimen,
treatment delay and treatment naivety. Since comorbidity was based on drug use our study proba-
bly underestimated the presence of comorbidity although the misclassification this is likely to be
non-differential. The presence of smoking and alcohol abuse is probably severely underestimated
in our study. False negative misclassification of these predictors will most likely lead to an under-
estimation of the effect. This might cause certain factors to drop out of our model while they in fact
are important predictors for treatment failure. The main limitation of this study is the small sample
size. This leads to optimistic estimates of model performance and limited power for selection of im-
portant predictors. Using a p-value of 0.05 for predictor selection would have been too strict. 121 We
therefore used a penalized model to shrink the coefficients and reduce the optimism of the model
and performed bootstrapping for validation. 
This study showed that the extent of off-label treatment in cluster headache in the Netherlands is
more than 80% whereas 55% is in agreement with the EFNS guidelines. One third of patients were
first treated with an off-guideline and off-label drug which might explain the high and rapid failure
rate (42%). Furthermore, this study represents a first step towards identifying potential predictors
for treatment failure of first sumatriptan, oxygen or zolmitriptan treatment for cluster headache.
Given the hypothesis generating nature of this study, no clinical judgment can yet be made based
on our results. The findings can be used to base further research on. Our findings should be repli-
cated preferably in a larger dataset and ideally include severity at baseline and presence of autonomic
features in addition to dose and dosing regimen. 
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Abstract
Background: Few drugs are registered for treatment of persistent idiopathic facial pain (PIFP) and
little is known about treatment choices for PIFP in daily practice. We therefore studied treatment
patterns, treatment failure, off-label and off-guideline use for PIFP.
Methods: PIFP cases were newly identified patients in the population-based Integrated Primary
Care Information-database containing electronic general practitioner (GP) records. All cases were
extensively validated to ensure the presence, type and onset of PIFP. Prescriptions of pain medica-
tion following the index date were evaluated by disease and prescriber. Furthermore, off-label use
of pain medication was assessed. Treatment failure included switching of drugs, visits for exacer-
bations of PIFP, reported adverse events or a referral for invasive treatment.
Results: Of 41 confirmed PIFP cases, 31 (76%) received pharmacological pain treatment. Most
(90%) were initially treated by a GP with anti-epileptic drugs (29%) or NSAIDs (21%) as monother-
apy. Seventy-one percent of pain medication was considered off-label PIFP. Of first line treatment
27% [95% CI: 11.2 - 43.4] failed within one month. 
Conclusions: First line PIFP treatment is most often started by the GP, but often with drugs not li-
censed for PIFP, one quarter of first line treatment failed.
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Introduction
Persistent idiopathic facial pain (PIFP), also referred to as atypical facial pain, is a rare chronic pain
syndrome affecting the facial area with a serious impact on the quality of life. 2 The pathophysiol-
ogy of PIFP is unclear but thought to be of neuropathic origin. 137 There are no guidelines for treat-
ment of PIFP and no drugs are currently registered for this specific indication in the Netherlands.
Not much is known about the actual treatment of PIFP in primary care. Therefore we investigated
drug prescription patterns in patients with PIFP in the general population by using the population-
based Integrated Primary Care Information (IPCI) database in the Netherlands. This study was part
of a larger study into facial pain conditions.
Methods
In brief, the study was conducted within the Integrated Primary Care Information (IPCI) database,
an anonymized population-based medical record database currently capturing data from more than
500 GPs and more than one million patients. Details of the source population and cohort definition
are described in detail elsewhere. 2
Since this study was retrospective and based on medical records we used the criteria of the Inter-
national Association for the Study of Pain (IASP) to classify PIFP cases. Detailed information on
case validation has been described before. 2, 14 The index date was the date of first symptoms and
represented the start of follow-up.
Drug prescribing patterns were manually evaluated using the electronic prescription records from
the IPCI database and using full specialist letters requested from the GPs. As study drugs for pain
treatment we included paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), acetyl-sali-
cylic acid, opioids, anti-epileptics, anti-migraine drugs (triptans and ergots), anti-depressants, ben-
zodiazepines, calcium-antagonists, clonidin and oxygen. Episodes of use were defined as periods
of continuous drug (based on full Anatomical Therapeutic and Chemical (ATC)-codes) use with
gaps of 30 days or less. 42
Outcome parameters
Various outcome parameters were considered including treatment persistence (number of treated pa-
tients divided by the number of patients in follow-up during each consecutive six months period),
treatment delay, type of prescriber and off-label use. Drugs were considered on-label for a certain
diagnosis if that diagnosis was specifically mentioned as an indication in the summary product
characteristic (SPC). Since no drugs are specifically registered for PIFP in the Netherlands we de-
fined on-label drugs as drugs with a broader indication for pain (i.e. ‘severe pain’ or ‘chronic pain’).
On-label drugs included: carbasalate calcium, fentanyl, pregabalin, gabapentin, paracetamol (with
or without codeine), tramadol or rofecoxib. All other use was classified as off-label. In addition we
described the type of pain medication, treatment regimen and failure of first therapy.
Treatment failure was defined as referral for invasive pain treatment, adverse events leading to ces-
sation of treatment, exacerbations of facial pain, suicide or dose adjustment (excluding titration
regimens)) (i.e. specified failure). Switching to another drug for pain treatment without reporting
of any of the aforementioned events was considered as unspecified treatment failure. Failures were
attributed to the drug if one of these events occurred during the legend duration or within the car-
ryover period of 30 days. The date of failure was defined as the date of starting the new episode
(within the carryover period) or the date of recorded event, whichever came first. Only failure of
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the first treatment episode was considered. In this analysis follow-up was right censored upon the
end of the treatment episode with 30 days carryover. 
Standard descriptive statistics were used to describe utilization patters (percentages, means and me-
dians). All statistical analyses were conducted using SPSS 15.0 (SPSS inc, Chicago, III).
Results
After completing the thorough review process, 41 out of 361 incident cases of facial pain were clas-
sified as PIFP. 2
First line pharmacological treatment
During follow-up 31 out of 41 (76%) PIFP patients were pharmacologically treated by a general
practitioner (90%) after a median delay of 15 days (Table 1). Anti-epileptic drugs and NSAIDs
were the most frequently prescribed drugs for the first line treatment (29% and 21% of patients re-
spectively) (Figure 1). 
Treatment persistence / failure
In the first six month-period, 63% of patients were treated with one of the study drugs; after six
months the proportion remaining on treatment stabilized to approximately 32% (Figure 2). 
First treatment failed in eight out of 31 treated patients within a month, seven because of switch for
unspecified reasons and one because of recorded lack-of-effectiveness. The one month failure rate
was 27% [95% confidence interval: 11.2 - 43.4] (Figure 3). 
Table 1 Characteristics of patients with persistent idiopathic facial 
pain and their treatment 
 
  Atypical Facial Pain 
Number of patients 41 
Mean age (SD) 45.4 (19.6) 
Male sex (%) 10 (24%) 
Number of treatment episodes  
Average number of episodes 4.6 (7.2) 
   At least 1 episode 31 (76%) 
2 or more episodes 17 (41%) 
Number of drugs used  
Single drug 28 (90%) 
Two drugs combined 3 (10%) 
Three or more drugs combined 0 (0%) 
Prescriber first treatment episode  
General practitioner 28 (90%) 
Anesthesiologist 1 (3%) 
Neurologist 2 (7%) 
Dosage regimen first treatment episode  
As needed 8 (26%) 
Titration regimen 1 (3%) 
   Fixed dose 22 (71%) 
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Figure 1: First and subsequent type of drug prescribed in patients 
with persistent idiopathic facial pain 
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The Y-axis shows the percentage of patients with the number of 
patients with persistent idiopathic facial pain treated with a single drug 
(n=28 for first episode, n=13 for subsequent episodes) as the 
denominator. Persons can contribute to more than one subsequent 
episode. 
NSAID = non-steroidal anti-inflammatory drug 
Figure 2: Percentage of people on treatment for persistent 
idiopathic facial pain during follow-up 
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This figure displays the percentage of patients receiving at least one 
prescription in each six month period with the number of patients in 
follow-up in the denominator (at least one day in concerned period) 
during consecutive six months periods. Six month periods start on the 
date of first symptoms (t=0). Error bars represent upper 95% 
confidence intervals. 
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Discussion
This study reported treatment patterns for persistent idiopathic facial pain in a primary care setting.
The pattern of use was directed towards treatment of neuropathic facial pain since anti-epileptic
drugs were relatively frequently used. Treatment was mostly initiated by the general practitioner,
was mostly off-label and given for a short period of time. 
Drug utilization studies in chronic pain syndromes in a primary care setting are rare and to our
knowledge no information is available on treatment patterns of idiopathic facial pain in particular.
A study performed in a primary care setting in the UK in patients with neuropathic pain in general
reported that 46-66% of all patients were treated at first diagnosis, usually with one drug. 16 Anti-
depressants were given in 30% of the cases, anti-epileptics and opioids in 20%. 16 Our finding that
20% of patients received anti-epileptics and 15% opioids is in line with these results. A study sur-
veying the impact of chronic pain in general also reported slightly different treatment patterns. 114
Two-thirds of chronic pain patients were taking prescription drugs, 44% NSAIDs, 28% opioids and
18% paracetamol. 114 In our PIFP patients we observed a smaller percentage of use of NSAID and
opioid use. This difference can be explained by the fact that PIFP may be considered of neuropathic
origin, which impacts on treatment choices (e.g. anti-epileptics). We previously reported drug uti-
lization patterns in patients with neuropathic facial pain, mainly consisting of trigeminal neuralgia.
101 The study on neuropathic facial pain showed that anti-epileptics were frequently used (55%)
while opioids were used less frequently (7%). 101 The percentage of patients treated with NSAIDs
in neuropathic facial pain was comparable to that of PIFP (16%). 101
96
Figure 3: One month failure rate of first treatment episode (n=31)  
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The strengths of this study are the extensive case validation process, the availability of information
from general practice and specialists and the possibility to follow patients over time. Limitations are
potential misclassification of disease which was limited due to extensive validation, and misclas-
sification of exposure. Misclassification of the exposure might occur due to over-the-counter use of
paracetamol and NSAIDs leading to an underestimation of its use. In addition, we may have missed
adverse events and exacerbations which were not reported by the patient or GP leading to an un-
derestimation of our reporting of adverse events and to a possible underestimation of the failure rate.
To compensate for this, we considered any switch in treatment regimen as failure of treatment as-
suming a switch to be due to adverse events or loss of effectiveness. 
This study showed that persistent idiopathic facial pain is mostly treated by the GP with anti-epilep-
tic drugs, similar to neuropathic pain syndromes. Failure rates were limited and mostly caused by
treatment switching. Whether or not anti-epileptics are efficacious in treating PIFP requires further
research.
97
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Abstract
Background: Some forms of facial pain are rare but severe. There is a lack of data on healthcare
consumption and diagnostic work-up of these rare forms. We studied healthcare consumption and
diagnostic work-up of trigeminal neuralgia (TN), postherpetic neuralgia (PN) in the facial area,
cluster headache (CH), occipital neuralgia with referred facial pain (ON), local facial neuralgias
(LN), persistent idiopathic facial pain (PIFP), glossopharyngeal neuralgia (GN) and paroxysmal
hemicrania (PH).
Methods: Patients with facial pain were identified in the Integrated Primary Care Information-
database with electronic GP records using an extensive validation procedure. All electronic records
were manually evaluated for secondary causes, GP and specialist visits, diagnostic delay, delay
until first referral, (time until first) investigations performed and (invasive) treatment. Specialists
included dentists, physiotherapists and psychologists.
Results: We identified 362 cases of facial pain (118 TN, 36 PN, 117 CH, 30 ON, 17 LN, 2 GN, 1
PH). Only 6 (2%) patients had a secondary form. The median diagnostic delay was 0 days with the
GP diagnosing 77% of cases. Of all cases, 98% visited a GP for their pain, the median number of
visits was three. During the first visit pharmacological treatment was initiated in almost all patients,
only half of all patients was referred to a specialist with a median time until referral of 14.5 days.
One third underwent some form of additional investigation. These investigations concerned X-rays
or laboratory tests.
Conclusions: Most patients are seen and treated in primary care, there should be a shift of focus on
treatment and research from secondary care to primary care.
100
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Introduction
Severe non-traumatic facial pain conditions include trigeminal neuralgia, postherpetic neuralgia in
the facial area, cluster headache, occipital neuralgia with referred pain, local facial neuralgias, per-
sistent idiopathic facial pain (atypical facial pain), glossopharyngeal neuralgia and paroxysmal hem-
icrania. These conditions often come together in the differential diagnosis of a general practitioner
(GP) as they share common clinical features. The overall frequency of these forms of facial pain in
the general population is low but the impact on quality of life is high. 2-5 Available studies on clus-
ter headache showed a large diagnostic delay of up to 6.6 years from first symptoms and specialist
care in 70% of cases with many receiving dental or phsyical threapy. 5, 138 The aetiology of these
forms can be either primary (idiopathic) or secondary (symptomatic) to diseases such as multiple
sclerosis (MS), tumors and infarctions. 6-13 Based on hospital data it was estimated that 10-15% of
all trigeminal neuralgia cases are secondary to other diseases. 36 However, the proportion of sec-
ondary facial pain in primary care is at present unknown. Being a debilitating disease which is dif-
ficult to diagnose the burden on health care consumption per facial pain is probably high.
Information on diagnostic work-up and resource consumption of facial pain conditions are sparse.
The available data are often based on information from secondary or tertiary care centers possibly
representing only a special part of the patient population. 5, 114, 138-140 Moreover, all reported studies
relied on questionnaires or interviews of patients which may have suffered from recall bias. Accu-
rate primary care data about healthcare consumption may help to get a better view on the impact
and burden of disease. We therefore studied the diagnostic work-up and healthcare consumption of
facial pain patient by performing a cohort study in a general practice research database.
Methods
The study was conducted in the Integrated Primary Care Information (IPCI)-database, a GP re-
search database with electronic patient records of more than one million patients throughout the
Netherlands. The source population of the IPCI database is representative for the general Dutch
population regarding age and sex and has been proven valid for pharmacoepidemiological research.
24, 25 In the Dutch healthcare system, everyone is registered with one GP who acts as gatekeeper for,
and receiver of information from secondary care. 26
Electronic records contain coded (anonymized) information on patient demographics, symptoms and
diagnoses (using the International Classification for Primary Care (ICPC)-codes) and free text nar-
ratives, referrals, clinical findings, laboratory assessments, drug prescriptions and hospitalizations
27. Summaries of hospital discharge letters or additional information from medical specialists are en-
tered as narratives and hard copies can be requested from the GP. To maximize completeness of elec-
tronic data, GPs participating in the IPCI-project are requested not to use additional paper-based
records. The system complies with European Union guidelines on the use of medical data for re-
search. The scientific and ethical advisory board of the IPCI project approved this study (project
number 07/03).
Source population
The source population comprised of persons with at least one year of valid history in the IPCI-data-
base and contributing person time to the database during the study period (January 1996–Septem-
ber 2006). One year of valid history meant that a practice had been contributing data to the
IPCI-database for at least one year and that the person had been registered with the GP for at least
one year. The one year run-in period was required to have sufficient background information on all
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subjects and to exclude existing (prevalent) facial pain. Follow-up started at the beginning of the
study period or on the date that one year of valid history was available, whichever date was latest.
Follow-up ended upon transferring out of practice, date of last data supply by the GP, death or end
of the study period, whichever came first. Since additional data collection was required for valida-
tion of diagnoses, we excluded practices from the source population that could not be contacted for
additional data collection. In addition, we excluded non-responding practices and patients with a di-
agnosis of facial pain prior to the start of follow-up (prevalent cases) from the source population.
The study population comprised all incident cases of facial pain. Facial pain included trigeminal
neuralgia, postherpetic neuralgia in the facial area, cluster headache, occipital neuralgia with referred
facial pain, local facial neuralgias, persistent idiopathic facial pain, glossopharyngeal neuralgia and
paroxysmal hemicrania.
Identification and validation of cases
Case selection and validation has been described elsewhere. 2 In brief, potential cases of facial pain
were identified using a broad and sensitive free text search in the computerized records followed
by a three step approach for case ascertainment. Firstly, in order to exclude false positive records
and to assess the index date (date of first symptoms), all potential cases were manually evaluated
by a medical doctor (JK) using the complete electronic medical records and applying the criteria of
the International Society for the Study of Pain (IASP). 21 Potential cases were divided into ‘proba-
ble’, ‘possible’ or ‘improbable’ depending on the number of disease episodes, mentioned symp-
toms and specialist confirmation. Improbable cases were excluded as a case. Secondly, additional
information was requested from the GP for all ‘possible’ cases. This was achieved using a ques-
tionnaire in which criteria from the IASP were mentioned per type of facial pain. 21 The GP was
asked to confirm or reject the diagnosis. If specialist letters were present, anonymized hard copies
were requested. All case information (including returned questionnaires) of all ‘probable’ and ‘pos-
sible’ cases was independently evaluated by two medical doctors. Discrepancies were arbitrated by
a pain specialist (FH). Thirdly, to further ensure validity of the diagnosis, a random sample of 250
patients of all initial cases from step one was reviewed by a neurologist with ample experience in
pain treatment. In case of disagreement, a case was discussed until agreement was reached. At the
end of the case validation each case was classified as either ’case’ or ‘no case’. The index-date was
set at the date of first symptoms of facial pain. Incident cases of facial pain were included in the
study population. Follow-up started on the index date. Since there is controversy in literature re-
garding the definition of postherpetic neuralgia in the facial area, we have chosen to set the index
date at date of first herpes zoster symptoms. 
Outcome parameters
Diagnostic work up
As part of diagnostic work-up we assessed the diagnostic investigation delay (i.e. time lapse between
first symptoms and first investigation), and treatment delay (i.e. time lapse between diagnosis and
first symptoms). As diagnostic investigations we included computed tomography (CT)-scans, mag-
netic resonance imaging (MRI)-scans, laboratory investigations and X-rays. 
Health care consumption
Healthcare consumption included the number of GP visits pertaining to facial pain, actions taken
by the GP (treatment initiation, switch or continuation of treatment or referral), specialist referrals
and treatment given. Referrals could be to any specialist including dentists, physiotherapists and psy-
chologists. Treatment was categorized as invasive (i.e. surgery), drugs and non-invasive treatment
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(i.e. dentist, physiotherapy). Treatment given by a dentist was always considered to be non-invasive
treatment (including tooth removal). 
All outcome measures were validated by manual review of the full medical records and all other
available information like specialist letters and questionnaires which were obtained from the GPs.
Analyses
Standard descriptive statistics were used to describe various outcome measures (percentages, means
and medians) with standard deviations (SD) or interquartile ranges (IQR), whichever was applica-
ble. The diagnostic delay, the delay between index date and date of first diagnostic investigation (in-
vestigation delay) and between index date and date of first treatment (treatment delay) were
calculated as the median number of days between index date and the applicable date (date of first
diagnosis, of first investigation or of first treatment). Investigation and treatment delay were cal-
culated within people undergoing an investigation or any form of treatment. All statistical analyses
were conducted using SPSS 15.0 (SPSS inc, Chicago, III).
Results
In the source population of 479,949 (1,898,417 PY) patients in the IPCI-database who had at least
one year of valid history, 362 incident cases with facial pain were identified. Of these, 118 cases had
trigeminal neuralgia, 36 had postherpetic neuralgia in the facial area, 117 had cluster headache, 30
had occipital neuralgia with referred facial pain, 17 had local facial neuralgias, 41 had persistent id-
iopathic facial pain, two had glossopharyngeal neuralgia and one had paroxysmal hemicrania. The
average follow-up time after the index date was 3.4 years (SD 2.5). The mean age at diagnosis was
49.1 years (SD: 18.0) and 158 (44%) were male (Table 1). 
Diagnostic work-up
The diagnosis was made by a GP in 77% of all cases followed by neurologists diagnosing 16% of
all cases. The two cases of glossopharyngeal neuralgia were exclusively diagnosed by a neurolo-
gist, the one case of paroxysmal hemicrania by a GP (Figure 1). Overall, the median diagnostic
delay was 0.0 days (IQR: 0.0 – 43.5). The diagnostic delay was longest for patients with glos-
sopharyngeal neuralgia (median: 323.0 days) and lowest for patients with postherpetic neuralgia in
the facial area (median: 0.0; IQR: 0.0 – 0.0). Of all 362 patients, one third (n = 120) underwent in-
vestigations as part of the diagnostic work-up. First investigations mostly included an X-ray (n =
47) or laboratory tests (n = 36). In total, 54 X-rays were performed, 49 laboratory investigations,
19 CT-scans and 37 MRI-scans (Figure 2). 
Most patients had a primary form of facial pain. Only six (2%) patients had secondary facial pain
(TGN:4, CH: 2) due to multiple sclerosis (n=4), Sjogrens disease (n=1) and meningioma (n=1).
Most secondary causes were already known at date of first symptoms of facial pain. 
Healthcare consumption:
Of all 362 cases, 355 (98%) visited a GP with a median number of facial pain related visits of 3.0
(IQR: 1.0 – 6.0) during follow-up after the date of first symptoms (Table 1). During first GP visits
pharmacological treatment was initiated in the majority of cases (n = 248, 70%) (Table 1). Subse-
quent visits usually led to either a change or a prolongation of the prescription (n = 76, 30% and n
= 75, 29% respectively). 
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Figure 1: Diagnosing physician 
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The figure displays the percentage of cases per specialist who 
diagnosed the disease and per disease. The general practitioner 
diagnosed most of the cases except for persistent idiopathic facial pain 
and glossopharyngeal neuralgia. E.N.T. Specialist: ear, nose and 
throat specialist. 
Figure 2: Total investigations performed 
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The total number of investigation per disease is presented here divided 
by type of test performed. For postherpetic neuralgia, 
glossopharyngeal neuralgia and paroxysmal hemicrania there were no 
investigations performed.  
CT-scan = computed tomography scan; mri-scan = magnetic 
resonance imaging scan 
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Glossopharyngeal neuralgia had the longest treatment delay (median: 315.0 days; IQR: 0.0 - ) of
all diseases (Table 1). Pharmacotherapy was given to 297 patients at any time after diagnosis (82%).
Besides glossopharyngeal neuralgia and paroxysmal hemicrania, of which all patients were treated,
cluster headache patients were most frequently treated pharmacologically (90%) followed by
trigeminal neuralgia patients (86%). Patients with trigeminal neuralgia were mostly treated with
anti-epileptics (55%), patients with cluster headache with anti-migraine drugs (41%) (Figure 3). 
In total, 182 (50%) of all patients visited a specialist, a dentist, physiotherapists or psychologists for
facial pain. If only first referrals to medical specialists were studied, 135 (37%) patients were re-
ferred (Table 2). If all referrals during follow-up were taken into account, 160 (44%) patients were
seen in secondary care at some point in time during follow-up. People were referred to a specialist
a median of 1.0 (IQR: 0.0 – 2.0) time. The median time until first referral was 14.5 (IQR: 0.0 – 87.8)
days (Table 2). 
Overall, 26 (7%) patients with a form of facial pain received non-invasive treatment. Dental ex-
traction and other dental therapies were performed in ten cases (3%). Most dental extractions (n =
6, 5% of cases) were performed in patients with trigeminal neuralgia. Physiotherapeutic interven-
tions were used in nine cases (2%). In persistent idiopathic facial pain, a disease known for the
many dental extractions performed, only one extraction was performed (2% of cases).
Only 37 patients (10%) received a form of invasive therapy. Local anesthetics (n = 13, 4%) were
mostly given followed by percutaneous radiofrequency thermocoagulation of either ganglion of
Gasser (n = 7, 2%) or the sphenopalatinum ganglion (n = 1, 0.3%). Of all studied forms of facial
pain, patients with local facial neuralgias were most frequently treated invasively (24%); exclu-
sively with local anaesthetics. Patients with trigeminal neuralgia were treated invasively in eight
(7%) cases mainly with percutaneous radiofrequency thermocoagulation (n = 4, 3%). Similarly,
only ten (9%) cluster headache patients were treated invasively, mostly with local anaesthesia (n =
6, 60%). Patients usually did not receive more than one form of treatment (Figure 3).
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Figure 3: First and second form of treatment initialized 
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The first and second form of treatment initialized per disease is presented here. Many people 
undergo only one treatment, mostly pharmacologically. Non-invasive treatment includes 
dental interventions, physiotherapist interventions, homeopathy and gamma-knife. 
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Discussion
This study showed that diagnostic workup was usually quick with 75% being performed within 44
days. Diagnosis was most quickly made by a GP without using additional investigations. Most pa-
tients had a form of primary facial pain. A GP was visited a median number of three times. This fre-
quently lead to treatment initiation (first visit) or treatment prolongation or switch (subsequent
visits). A minority was referred to secondary care. Treatment was mostly initiated immediately and
pharmacologically. The main findings of our study include extensive data on healthcare consump-
tion and diagnostic work-up of eight forms of facial pain, namely trigeminal neuralgia, cluster
headache, postherpetic neuralgia in the facial area, occipital neuralgia with referred facial pain,
glossopharyngeal neuralgia, local facial neuralgias, glossopharyngeal neuralgia or persistent idio-
pathic facial pain. Most people are treated in primary care and only half is ever referred to a spe-
cialist, dentist, physiotherapist or psychologist. 
Literature regarding the burden of disease and health care use of facial pain is scanty and mostly
concerns trigeminal neuralgia and cluster headache. Secondary trigeminal neuralgia has been re-
ported in 10-20% of trigeminal neuralgia. 36, 111, 141-146 A pooled analysis yielded an estimate of 15%
[95% CI: 11% - 20%]. 147 This differs substantially from our finding of secondary causes in 3%. This
discrepancy may be explained by the different settings. Previous reports studied a secondary care
population which cannot be generalized to a primary care setting. 12, 141-146 Alternatively, our num-
bers might be an underestimation since not all patients underwent additional investigations. 
Forty-three percent of cluster headache patients visiting their GP in the last year. 5 The same per-
centage visited a specialist in the last year and 1.2% underwent a hospital admission. 5 In other
studies, the average delay between start of symptoms and diagnosis in cluster headache has been
reported to be 2.6 - 6.6 years. 138, 139 Furthermore, 5-13% of patients underwent a form of surgery
related to cluster headache and 58% underwent a form of non-medical treatment (physical therapy,
acupuncture, etc). 5, 138, 139 Additional investigations were done in 58-75% undergoing either a CT-
scan or MRI-scan. 138, 139 The proportion referred to a specialist was 70% with 42% visiting a den-
tist. 5, 138 We reported the diagnostic delay to be zero days, 8.5% received a form of invasive
treatment and 15% undergoing a CT- or MRI-scan. Furthermore, patients visited their GP a median
of three times during the course of their disease which agrees well. However, we did find a lower
numbers for specialist referrals (50% total) and neurologist as diagnosing specialist (16%). Only 3%
underwent non-invasive treatment either as first or as second treatment. There are some possible ex-
planations for this difference. Firstly, it might be a difference in study design and data sources (in-
ternet questionnaires vs electronic GP records). Questionnaires may be subject to recall bias and
patient recruitment through a website may cause selection bias. Recall bias might have led to a dif-
ferential misclassification of the outcome since more severe patients might remember their proce-
dures more accurately and might have undergone more procedures. Selection bias might have led
to inclusion of more (or less) severe patients since these are more likely to participate and these pa-
tients might differ substantially from patients in primary care. We might underestimate the number
of paramedical visits because these might not be documented by a GP, although we performed a
manual free text search. Furthermore, time trends may explain differences. A decrease in mean time
to diagnosis from 12 years (before 1950) to 2.6 years (1990-1999) was reported. 138
A large multicountry study in Europe about the impact of chronic pain showed 60% of patients to
visit their doctor for their pain 2-9 times in the last six months. 114 Only 2% were currently treated
by a pain management specialist. 114 66% used non-medical treatments such as massage (30%),
physical therapy (21%) or acupuncture (13%). 114
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Regarding trigeminal neuralgia, a study about the burden of disease in primary care reported that
78% of trigeminal neuralgia patients visited their physician at least once during the past four weeks.
148 Almost half (45%) even visited their GP two or more times while 53% were evaluated by a pain
specialist. 148 Almost one-third (30.5%) received physical therapy. 148 This is comparable to our
finding that 50% visits a specialist. 
Our study possibly has some limitations besides the ones already mentioned above. To ensure a
complete case series we performed a broad and sensitive search algorithm followed by extensive
validation including revisions by a neurologist to ensure the validity of a diagnosis. Nevertheless,
since accurate description of symptoms was sometimes lacking, there might be some misclassifi-
cation of the index date and diagnostic delay, and misclassification of facial pain. To minimize mis-
classification of facial pain we employed an extensive validation process including GP confirmation
and double review of electronic patient records. Furthermore, given the nature of our database, we
rely on the accuracy of GP registration. Assuming GPs have an under registration of investigations
and treatment performed and depend on specialist communication / letters, we may underestimate
the number of procedures and investigations performed. To minimize this, we manually evaluated
specialist letters and GP questionnaires in which GPs were asked to supply us with investigations
performed. Since only half the patients are referred to a specialist and 37 patients underwent either
a CT- or MRI-scan, we might severely underestimate the number of patients with secondary facial
pain. On the other hand, one might question the validity of this underestimation since most people
apparently do not suffer severe adverse effects from missed underlying diseases.
Despite the above mentioned limitations we think our report offers a valuable contribution with
sound epidemiological data on healthcare consumption and diagnostic work-up of eight rare forms
of facial pain. We can conclude that many patients are primarily treated by a GP without being re-
ferred to secondary case and without undergoing additional investigations. Given our low percent-
age of secondary trigeminal neuralgia, additional investigations might not be required to exclude
secondary causes although further investigations are needed to give a definitive answer.
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Abstract
Background: Invasive procedures for treatment of trigeminal neuralgia (TGN) consist namely of
percutaneous radiofrequency thermocoagulation (PRT), partial sensory rhizotomy (PSR) and mi-
crovascular decompression (MVD). 
Methods: We described the frequency of use, patient characteristics and evaluated treatment fail-
ure. For this we used a nationwide discharge registry from the Netherlands. Each patient undergo-
ing a PRT, PSR or MVD between 1-1-2002 and 31-12-2004 and without a procedure in the year
prior were included. Primary outcome was readmission for repeat procedures for TGN or known
complications within one year. Comparability of patient populations was assessed through propen-
sity scores based on hospital, age, sex and comorbidity. Conditional logistic regression matched on
propensity score was used to calculate relative risks (RR) with 95% confidence intervals (95% CI)
for repeat procedures or complications. 
Results: During our study period, 672 patients with TGN underwent PRT, 39 underwent PSR and
87 underwent MVD. Hospital was the predominant determinant of the type of procedure while age,
sex and comorbidity were weak predictors. The RR for repeat procedures for PSR was 0.21 [95%
CI: 0.07 - 0.65] and the RR of MVD 0.13 [95% CI: 0.05 - 0.35]. For complications, the RR of PSR
was 5.36 [95% CI: 1.46 - 19.64] and of MVD 4.40 [95% CI: 1.44 - 13.42]. Sex, urbanization and
comorbidity did not influence prognosis but hospital and surgical volume did. 
Conclusions: MVD and PSR are associated with a lower risk of undergoing a repeat procedure
compared to PRT. However, MVD and PSR seem to be more prone to complications requiring read-
mission in hospital.
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Introduction
Trigeminal neuralgia is a severe form of facial pain presenting with paroxysmal, unilateral pain in
one or more branches of the fifth cranial nerve. 36 It has an estimated annual incidence of 12.6 per
100,000 person years. 2 It can be either idiopathic or secondary to diseases such as tumors, infarc-
tion and multiple sclerosis. 12, 149-152 Idiopathic trigeminal neuralgia is currently hypothesized to be
caused by neurovascular contact between an aberrant vein or artery and the fifth cranial nerve at the
root entry zone. 39 The three most common invasive modalities for the treatment of idiopathic
trigeminal neuralgia are microvascular decompression, partial sensory rhizotomy and percutaneous
radiofrequency thermocoagulation. During microvascular decompression a teflon patch is placed be-
tween the nerve and vascular structure using an open brain surgical approach. 153 Partial sensory rhi-
zotomy and percutaneous radiofrequency thermocoagulation are both destructive techniques aiming
to destroy a part of Gasserians ganglion by respectively a neurosurgical or a minimal invasive rönt-
gen-guided approach. 154, 155
Partial sensory rhizotomy is sometimes used as an alternative for microvascular decompression if
arterial contact cannot be found, but it is also an open neurosurgical procedure with risks compa-
rable to those of microvascular decompression. 155 A literature study describing long term outcomes
of individual treatment modalities indicate that microvascular decompression has a better effec-
tiveness than percutaneous radiofrequency thermocoagulation, but also a higher rate of adverse
events. 156 Studies included in this review concerned mainly cohort studies of individual procedures
with more than five years of follow-up. These studies, however, have not been performed in one data
source and therefore do not allow for a direct comparison of procedures. To our knowledge no ran-
domized clinical trials have been performed. 
At present the frequency of use of the individual invasive treatment modalities for trigeminal neu-
ralgia in daily practice is not known and comparisons of the safety and effectiveness of the differ-
ent treatment modalities on a population-based scale are lacking. Direct comparisons between the
treatment modalities using one data source have not been reported. Furthermore, reports on prog-
nostic factors for the success rate of individual treatment modalities remain contradictory. 157 In
order to describe the frequency of use of microvascular decompression, partial sensory rhizotomy
and percutaneous radiofrequency thermocoagulation and to compare the complication and failure
rate of these modalities on a nationwide scale, we performed a cohort study using a database with
hospital discharge diagnoses with complete coverage of the population in the Netherlands.
Methods
Source population
Data were retrieved from a nationwide electronic database with hospital discharge records, that
covers admissions in nearly all general and university medical centers in the Netherlands (Lan-
delijke Medische Registratie). The database includes, among others, demographics, date of admis-
sion and discharge, main intervention (coded), medical specialism (coded) and the main and
secondary diagnoses at discharge, based on the ICD-9-CM coding system. 158 Characteristics of
hospitalizations are recorded by medical specialists or residents and coded by professional code
clerks on the basis of hospital discharge letters. For every admission, one discharge/main diagno-
sis (mandatory), and up to nine secondary diagnoses (optional) are registered. This is done similarly
for interventions. The coding is independent of reimbursement of hospital or specialist. Patients
and hospitals are anonymized to allow for secondary use and processing of the data. All diagnoses
are submitted in the same format, mostly electronically. The database used for this study comprised
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data from 1 January 2001 up to and including 31 December 2005. More recent data are not avail-
able due to a change in the registration system in the Netherlands, which has resulted in incom-
pleteness of the registry after 2005.
Cohort definition
For incidence rate calculations, the study base comprised the entire population of the Netherlands
during the study period between 1 January 2002 and 31 December 2004. For all other analyses we
generated a cohort of patients admitted for microvascular decompression (ICD-9 codes: 5-014.0),
partial sensory rhizotomy (intervention code (ICD-9 codes): 5-014.1, 5-014.2) or percutaneous ra-
diofrequency thermocoagulation (ICD-9 codes: 5-043.2) all with trigeminal neuralgia as main di-
agnosis during the study period. Patients who had one of the procedures in the year prior to study
entry were excluded from the cohort. Each cohort member was followed until the earliest of one of
the following events: admission for a complication, repeat procedure (any of the three studied) or
end of a one year follow-up period, whichever came first. 
Outcome definition
The primary outcome parameters in this study were frequency of use, plus complications and treat-
ment failure leading to hospital readmission within one year of the initial admission. Complica-
tions included hospitalizations for hearing loss, dysaesthesia, persistent neurological deficit, death,
cerebrospinal fluid leakage, facial hypaesthesia, meningitis, ataxia, heamatoma, infarctions, pul-
monary embolisms, herpes labialis, vertigo, tinnitus, an- or hypacusis, facial spasms, trochlear and
acoustic palsy, facial paresis, severe brain damage, keratitis, sensory loss, corneal hypaesthesia, ar-
teriovenous fistula, bleeding, loss of sight, corneal anesthesia, facial asymmetry and all ICD-9 codes
specifically specifying complications of procedures (appendix C). 153, 155, 156, 159-165 Complications
were identified based on the ICD-9 codes of the main or secondary diagnoses. Treatment failure was
defined as a readmission for one of the studied procedures for treatment of trigeminal neuralgia or
for other reasons (e.g. pharmacological treatment) with trigeminal neuralgia mentioned as primary
or secondary diagnosis. The index date for complications and failure was the date of hospital ad-
mission. 
In addition to readmission rates for first complication or repeat procedure, we examined the dura-
tion of hospital stay of the initial procedure (index hospitalization) and in-hospital mortality of the
index hospitalization as secondary outcomes. To evaluate complications and treatment failure after
discharge, patients were linked by patient number (same hospital) and gender, date of birth and
postal code (other hospitals). 
Covariates
We considered the patient related (age, sex, urbanization level, comorbidity, specialism performing
the procedure) and hospital related variables (surgical procedure volume per hospital, type of hos-
pital) as potential confounders and prognostic factors. These factors might be related to treatment
choice and outcome based on either clinical judgment or literature. The year prior to the index hos-
pitalization was used to assess the presence of comorbidity (leading to hospital admission) on the
basis of discharge diagnoses during that year. Comorbidity was categorized according to the Charl-
son comorbidity index adapted for ICD-9 CM. 166, 167 During the study period, there were 105 hos-
pitals in the Netherlands, of which eight were university medical centers. To compare the experience
with a specific procedure between hospitals we classified the surgical volume (i.e. number of pro-
cedures performed) for each procedure in each hospital into quintiles. Quintiles were based on the
distribution of surgical volumes in the population. A surgical volume category of one meant that the
hospital belonged to the 20% hospitals with the lowest surgical volume in a certain procedure (in-
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cluding zero procedures). A score of five meant that the hospital belonged to the group of 20% hos-
pitals with the highest surgical volume. The scores related to the three different procedures were then
added together in one overall score ranging from 3 to 15, under the assumption that all types of
procedures add to the experience of hospitals and surgeons. 153 Urbanization of the home address
was evaluated using postal code data from Statistics Netherlands. 1 Very urban indicated more than
2500 houses per squared kilometer. Moderately urban is between 1500 and 2500, normal between
1000 and 1500, moderately rural between 500 and 1000 and very rural below 500 houses per
squared kilometer.
Analysis
For each treatment modality we calculated the incidence rate by dividing the number of procedures
by the total Dutch population for that year according to Statistics Netherlands. 1
Failure and complication risks were calculated for each type of intervention at 1 month, 1-2 months,
2-3 months and 3-12 months after the initial hospitalization by Kaplan-Meier analysis. Rates of
failure and complication were calculated by dividing the number of readmissions by the total num-
ber of person years (patients could count multiple times). 95% Confidence intervals (95% CI) were
calculated based on a binomial distribution.
To study whether we could compare outcomes between treatment groups we calculated propensity
scores for each procedure with percutaneous radiofrequency thermocoagulation as reference cate-
gory. 168 Overlapping propensity scores of different procedures would indicate comparable treatment
groups allowing for calculation of relative risks for complications and repeat procedures. Propen-
sity scores were calculated for each procedure separately. The following variables were included in
the model: the Charlson comorbidity score, sex, age and the type of treating hospital using logisti-
cal regression analysis. The final propensity score included all of these covariates for all proce-
dures. Since we expected the treating hospital to be a very large predictor for type of procedure, we
calculated a second propensity score model including age, sex and chronic disease score. Condi-
tional logistic regression with matching on propensity score (including age, sex and comorbidity
within bins of 0.1) was used to yield relative risks (RR) for partial sensory rhizotomy and mi-
crovascular decompression. Percutaneous radiofrequency thermocoagulation was taken as refer-
ence category. A Cox proportional hazards model was used to analyze prognostic factors for
treatment failure. 
A sensitivity analysis was performed including only specific complications described in literature
(all of the above except the ICD-9 codes specifically specifying complications of procedures). 153,
155, 156, 159-165 Furthermore, to ensure complications were due to the index hospitalization and not due
to other interventions after the index hospitalization a sensitivity analysis was performed in patients
without hospitalizations between the index hospitalization and the first complication. Further sen-
sitivity analyses included only patients operated in 2004 and taking into account only complications
and readmissions stated as primary discharge diagnosis (not as additional diagnoses). Hospitaliza-
tion data only provide information on in-hospital death and death may impact on the failure rates.
Therefore we conducted a survival analysis with imputed survival data to take into account deaths
occurring during follow-up. Survival data was imputed using the age and gender specific mortal-
ity data of the general Dutch population from 2003 as provided by Statistics Netherlands (CBS). 1
Imputation of survival data was done using R (version 2.7.12). 123 Five possible dates of death were
imputed based on age and gender. The Kaplan Meier analyses were redone using this imputed sur-
vival data. In compliance with the method of multiple imputations the rates and the standard errors
were averaged. 169 All statistical analyses were conducted in SPSS 15.0 (SPSS inc, Chicago, III).
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Results
Incidence
Between 1 January 2002 and 31 December 2004, 87 microvascular decompressions, 39 partial sen-
sory rhizotomies and 672 percutaneous radiofrequency thermocoagulations were performed. The in-
cidence rate of the three studied invasive procedures for trigeminal neuralgia in the Dutch population
was 16.4 per million persons per year [95% CI: 15.3 - 17.6] (Table 1). The rates were highest be-
tween the age of 70 and 79 for all procedures and the rate remained more or less stable over calen-
dar time (Figure 1a + b).
Baseline characteristics
Patients undergoing an intervention for trigeminal neuralgia during the study period were on ave-
rage 65.8 years of age (standard deviation (SD): 13.4) and a minority was male (43%) (Table 1). Pa-
tients were generally healthy with a mean Charlson comorbidity index of zero. The average num-
ber of procedures performed per hospital per year was 5.54 (SD: 8.94). Percutaneous radiofrequency
thermocoagulation was the most widely applied procedure with a high average relative surgical
volume level compared to that of partial sensory rhizotomy and microvascular decompression (1.17,
0.44 and 0.31 procedures per hospital respectively). Finally, patients undergoing percutaneous ra-
diofrequency thermocoagulation were on average older and had a shorter hospital stay than patients
admitted for the other procedures. There were large differences in hospital and physician charac-
teristics between the three procedures (Table 1).
Complications / therapeutic failure
In total, 33.8% of patients were readmitted for a repeat procedure (2.4%) or a complication (31.6%)
within one year following the initial procedure (Table 2). The one year readmission risk derived from
Kaplan-Meier analysis was 34% [95% CI: 30 - 37%] for all procedures together. The one year read-
mission risk was lowest with microvascular decompression (9%; [95% CI: 3% - 15%]) and high-
est for percutaneous radiofrequency thermocoagulation (38%; [95% CI: 34% - 42%]) (Table 2 &
Figure 2). 
Most complications occurred within the first month (31.6%) after the initial procedure. The risk of
complications was lowest for percutaneous radiofrequency thermocoagulation (2% versus 8% and
6%). The majority of complications were unspecific procedure complication codes (61%). Speci-
fied complications included Bell’s palsy (11%), infections (5%), anaphylactic shock (6%), hemi-
plegia (6%), aspiration (6%), hematoma (6%) and respiratory complications (6%). Most repeat
procedures took place between the third and ninth month (36.5%) after the initial procedure. 
A propensity score model based on hospital, age, sex and comorbidity could accurately predict
which treatment was given (Figure 3a) (c-statistic 0.99). There was, however, poor overlap. If hos-
pital was excluded from the propensity score the model performed worse (c-statistic 0.70) but there
was considerable overlap showing that actually the hospital was important for the decision which
treatment to perform and not so much the patient (Figure 3b). After matching on propensity score
(not considering hospital), the relative risk of partial sensory rhizotomy for readmission (both com-
plications or repeat procedures) was 0.40 [95% CI: 0.18 - 0.90], 5.36 [95% CI: 1.46 - 19.64] for
complications and 0.21 [95% CI: 0.07 - 0.65] for repeat procedures. Microvascular decompression
had a relative risk of 0.25 [95% CI: 0.12 - 0.52] for total readmission, 4.40 [95% CI: 1.44 - 13.42]
for complications and 0.13 [95% CI: 0.05 - 0.35] for undergoing a repeat procedure. Most people
undergoing a percutaneous radiofrequency thermocoagulation underwent a percutaneous radiofre-
quency thermocoagulation as repeat procedure while most people undergoing a partial sensory rhi-
zotomy underwent this procedure again as repeat procedure. In contrast, after microvascular
117
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Figure 1a: Incidence of individual treatments 
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Figure 1b: Incidence rate per calendar year 
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decompression most people had a percutaneous radiofrequency thermocoagulation as second pro-
cedure (Table 2). 
Sensitivity analyses considering only patients operated in 2004, or only healthy patients (Charlson
comorbidity index of zero), or only in literature specified complications, or only main diagnoses or
using imputed survival data showed that the results and conclusions did not materially change
(p>0.05).
Concerning our secondary outcomes; the admission duration of the index hospitalization was 2.62
days (SD: 3.38). No patients died during hospital stay [95% CI: 0.0% - 0.4%]. 
Prognostic factors
Sex, age, comorbidity, surgical volume, urbanization and hospital (aggregated) were evaluated as
prognostic factors for treatment failure. Cox regression analysis, stratified by the type of first pro-
cedure showed surgical volume and type of hospital to be associated with failure (Table 3). Only
the second and fifth group of surgical volume were associated with an increased risk of failure (OR:
1.54; [95% CI: 1.10 - 2.16]) and 1.53 [95% CI: 1.07 - 2.20] respectively). However, no clear vol-
ume-success relationship (i.e. dose-effect) could be shown. Being treated in a general hospital was
associated with an increased risk of failure (OR: 4.81; [95% CI: 2.47 - 9.34]) compared to being
treated in a university hospital.
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Figure 2: Survival curve 
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Of the three studied treatment modalities, the percutaneous 
radiofrequency thermocoagulation had the highest risk of readmission. 
PRT: percutaneous radiofrequency thermocoagulation PSR: partial 
sensory rhizotomy MVD: microvascular decompression. 
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Figure 3a: Propensity scores including treatment hospital 
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The propensity scores of partial sensory rhizotomy and microvascular 
decompression are shown with percutaneous radiofrequency 
thermocoagulation as reference category. Treating hospital, age, sex 
and the Charlson comorbidity were entered in the propensity score 
model. There is little overlap in the propensity scores of the different 
treatment modalities. This means that we can accurately predict 
treatment received. 
Figure 3b: Propensity scores excluding hospital  
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The same is shown as in figure 3a except we only included age, sex 
and Charlson comorbidity index. Although we can not predict 
treatment given there is overlap between the different treatment 
modalities. This shows that the hospital patients are referred to mainly 
determined the chosen procedure and not patient characteristics like 
age, sex and comorbidity. This enables a direct comparison of 
treatment modalities. 
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Discussion
This study showed that percutaneous radiofrequency thermocoagulation was the most frequently ap-
plied invasive procedure for trigeminal neuralgia with 13.8 procedures per 1 million person years
per calendar year. The rate of invasive procedures did not materially change over time. Given an es-
timated prevalence of trigeminal neuralgia in the Netherlands of 1600 per 1 million persons ap-
proximately 1% of persons with trigeminal neuralgia undergo a first invasive procedure each year.
170 The type of procedures performed were strongly hospital, age and specialist dependent. Partial
sensory rhizotomy and microvascular decompression were more likely to be carried out in spe-
cialized centers than percutaneous radiofrequency thermocoagulation. Percutaneous radiofrequency
thermocoagulation was mostly performed by anesthesiologists while partial sensory rhizotomy and
microvascular decompression were almost exclusively carried out by neurosurgeons. Microvascu-
lar decompression had the lowest relative risk for readmission (either complications or repeat pro-
cedures), mainly because of a lower risk for repeat procedures. Microvascular decompression had,
however, a higher complication risk compared to percutaneous radiofrequency thermocoagulation.
Readmission was not associated with sex, urbanization and comorbidity, which is in line with pre-
vious reports. 171 It was, however, positively associated with surgical volume (low and high) and re-
ceiving treatment in a general hospital. Our finding that younger patients more frequently underwent
microvascular decompression is in line with current practice. 172 This is presumably due to the al-
legedly longer effect of microvascular decompression and presence of comorbidity in older patients
which makes it difficult to conduct that intervention. 172
Percutaneous radiofrequency thermocoagulation showed the lowest absolute complication rate but
the highest failure rate which is in line with recent reviews. 156, 157, 164, 173, 174 One study compared mi-
crovascular decompression to percutaneous radiofrequency thermocoagulation and reported an
122
Table 3: Prognostic factors 
 
 Percutaneous radiofrequency thermocoagulation Partial sensory rhizotomy Microvascular decompression Total 
Age 0.92 [0.72; 1.18] 1.30 [0.24; 7.08] 7.18 [0.88; 58.39] 1.01 [0.79; 1.28] 
Sex 1.01 [1.00; 1.02] 0.96 [0.00; 1.02] 1.00 [0.95; 1.05] 1.01 [1; 1.02] 
Comorbidity index     
  0 Ref NA Ref Ref 
  1 1.21 [0.62; 2.36] NA 0.05 [0.00; ] 1.33 [0.68; 2.58] 
  2 4.19 [1.34; 13.12] NA 0.05 [0.00; ] 2.92 [0.94; 9.13] 
  3 0.73 [0.18; 2.92] NA NA 0.85 [0.21; 3.4] 
Hospital     
  University Ref Ref Ref Ref 
  General 4.56 [1.13; 18.32] 0.03 [0; 32.85] 10.35 [1.27; 84.12] 4.81 [2.47; 9.34] 
Surgical volume     
  1 Ref NA Ref Ref 
  2 1.49 [1.06; 2.08] Ref 98257.15 [0.00; ] 1.54 [1.1; 2.16] 
  3 0.76 [0.33; 1.78] 0.85 [0.05; 13.68] 86540.31 [0.00; ] 0.8 [0.38; 1.68] 
  4 0.94 [0.60; 1.48] NA NA 0.99 [0.63; 1.56] 
  5 1.50 [1.04; 2.15] 1.42 [0.15; 13.64] NA 1.53 [1.07; 2.2] 
  6 0.49 [0.23; 1.02] 0.19 [0.01; 3.05] 15163.02 [0.00; ] 0.29 [0.17; 0.52] 
Urbanization     
  Very urban Ref Ref Ref Ref 
  Moderately urban 0.97 [0.66; 1.44] 0.59 [0.08; 4.20] 0.70 [0.10; 4.99] 0.94 [0.64; 1.36] 
  Normal 0.84 [0.55; 1.29] 0.43 [0.04; 4.80] 0.86 [0.14; 5.16] 0.82 [0.54; 1.22] 
  Moderately rural 0.88 [0.59; 1.31] 0.68 [0.06; 7.55] 0.20 [0.02; 2.19] 0.82 [0.56; 1.2] 
  Very rural 0.89 [0.59; 1.33] NA 0.00 [0.00; ] 0.8 [0.54; 1.19] 
 
In bold are the statistically significant predictors of treatment failure. Ref is reference category, NA is not 
assessable (no cases in that group). 
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equal effect but a lower long-term complication rate for microvascular decompression. 175 Our study
shows a difference in effect, but this may be because we only assessed serious complications re-
quiring a readmission, which do not represent the total range of adverse events. Assuming that neu-
rosurgical interventions have a higher percentage of adverse events requiring hospitalization, this
will lead to a selective underestimation favoring percutaneous radiofrequency thermocoagulation.
The high failure rate of percutaneous radiofrequency thermocoagulation might have several reasons.
Compared to microvascular decompression which is usually performed by experienced neurosur-
geons, percutaneous radiofrequency thermocoagulation is also performed by less experienced doc-
tors. Furthermore, to avoid anesthesia dolorosa, doctors will be careful to apply too much
coagulation. They prefer to conduct the operation in two stages instead of risking adverse events.
The low complication rate of percutaneous radiofrequency thermocoagulation is especially note-
worthy since it is more often performed in high risk (older) patients.
Limitations
Being an observational study using a hospital registry we have to consider the influence of poten-
tial misclassification and confounding. There are several sources of misclassification. Firstly, the
failure rate may be an underestimation, since not every failure requires readmission as some re-
currences may be treated conservatively. Our study did not focus on failure that could be addressed
in an outpatient setting. Secondly, admission for complications after the intervention may have been
the result of other hospitalizations during follow-up, this issue was explored by exclusion of patients
with other hospitalization during follow-up. This did not change the results substantially. Thirdly,
since the database only captures in-hospital deaths and not the outpatient deaths, people dying the
year after readmission are lost to follow-up and cannot count in the numerator which may lead to
an underestimation of risks. Due to differences in age, this is less likely to happen for microvascu-
lar decompression and more for the other interventions. People undergoing a MVD are younger
and thus less likely to die out of the hospital. To minimize this bias, we imputed age and gender spe-
cific survival data from the general Dutch population, the relative risk estimated did not change
substantially. 
The fourth limitation of our study is the low number of prognostic variables and the lack of specific
prognostic factors such as disease severity. Previous destructive surgery, a known risk factor for an
unfavorable outcome of microvascular decompression and partial sensory rhizotomy, could not be
considered in our analyses since we only had one year of history available. 153, 155 Patients undergoing
a destructive procedure in that year were excluded from the analysis to minimize possible con-
founding. To further limit residual confounding due to the fact that we had limited prior history
data we performed a sensitivity analysis amongst people undergoing a procedure in 2004, for these
persons we had three years of prior history, the results in these patients were consistent with the main
analysis showing that residual confounding due to a short availability of information is limited. Fi-
nally, known prognostic factors such as having a clear-cut and marked vascular compression at sur-
gery, type of vessel compressing, duration of complaints, involvement of all three branches and
postoperative pain relief could not be evaluated given the nature of our database. 155, 164, 171, 176, 177
Despite its limitations the results of our study are unique in that they capture a large nationwide study
sample which provides a comprehensive overview of the application of invasive procedures for
trigeminal neuralgia in daily practice. The study further gives a valid estimate of the absolute and
relative risks (complications requiring admission) and effectiveness (readmission for repeat proce-
dure) of individual surgical procedures in patients with trigeminal neuralgia. Previous reports show-
ing a higher success rate of microvascular decompression compared to percutaneous radiofrequency
rhizotomy have now been confirmed in a single data source. Finally, we have shown that the choice
for a certain treatment modality is, at least in the Netherlands, largely institutionalized practice and
not based on a nationwide consensus. 
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Chapter 5
General discussion
125
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In this thesis we present several studies on the occurrence and disease course of facial pain. Facial
pain refers to a group of painful conditions affecting the face. Among the rarest and most severe
types of facial pain are trigeminal neuralgia, postherpetic neuralgia in the facial area, cluster
headache, occipital neuralgia with referred facial pain, local facial neuralgias, persistent idiopathic
facial pain, glossopharyngeal neuralgia and paroxysmal hemicrania. Facial pain can be caused by
many different diseases or occur without direct cause. The aetiology varies across different types
of facial pain and is mostly unknown.
Available epidemiological data on facial pain conditions mostly concern secondary care facial pain
patients. In this thesis we studied incidence rates (chapter two), aetiology and risk factors (chapter
three) and treatment (chapter four) using data from a population based general practitioners’ data-
base.
Main findings
Incidence rate of facial pain
We estimated the incidence of facial pain to be 38.7 per 100.000 person years [95% CI: 34.9 - 42.9].
2 Trigeminal neuralgia and cluster headache were the most frequently occurring types with inci-
dence rates of 12.6 and 12.5 per 100.000 person years. Glossopharyngeal neuralgia and paroxys-
mal hemicrania were the least frequent. 2 Studies based on hospital data estimated incidence rates
of 4.7 cases of trigeminal neuralgia per 100.000 persons per year. 17 On the other hand studies using
less well validated primary care data reported an incidence rate of trigeminal neuralgia of 26.8 – 28.9
per 100.000 person years. 15, 16 While our incidence rates were obtained from general practice data,
we employed a more rigorous validation process including general practitioner verification and
double review. The false positive rate of the initial diagnosis after initial validation turned out to be
around 40%. This high rate may have several explanations. Firstly, the clinical presentation of some
of these facial pain syndromes might mimic other diseases such as sinusitis. This complicates the
differentiation between different forms of facial pain at first presentation. Secondly, revision of the
diagnosis of, for example, trigeminal neuralgia and cluster headache occurs especially if the parox-
ysmal nature of facial pain cannot be confirmed in subsequent clinic visits. 14, 36 The results of our
study and its discrepancies with previous incidence rate estimates suggest that not all patients with
facial pain are referred to secondary care and that there is substantial over recording of facial pain
diagnoses in primary care medical records. Hence, we argue that the most accurate incidence rate
estimates for facial pain conditions result from population based primary care databases with a thor-
ough facial pain case ascertainment process.
Aetiology and risk factors
To learn more about the aetiology of facial pain and in search of (modifiable) risk factors we stud-
ied risk factors for the most common types of facial pain (trigeminal neuralgia and cluster headache)
in our facial pain cohort. 
Cluster headache
We confirmed the previously suggested association between smoking and cluster headache. 83 While
head trauma was reported as a risk factor for cluster headache in some studies and not in others, our
study suggests that a possible association is confined to only recent head trauma (eg. less than 3
years ago). 79, 84 In line with previous research hypertension was not associated with cluster headache.
88 We did, however, show that anatomical diseases of internal organs and the locomotoric tract, my-
coses, mixed infectious diseases, allergies, menstrual cycle related diseases and climacterium related
126
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diseases were significantly associated with first cluster headache occurrence. These findings may
shed further light on the underlying pathophysiological pathway for cluster headache. They support
the hypothesis that complex trigemino-vascular and cranial parasympathic pathways are involved
in the development of cluster headache. 33 In this hypothesis, stimulation of the trigeminal ganglion
results in cerebral vasodilatation by activating afferent trigeminal branches and by stimulating
parasympathic outflow. The latter is also accomplished by a functional reflex between the caudalic
nerve (trigemino-vascular system) and the superior salivatory nucleus (cranial parasympathic sys-
tem). 33 Activation of the trigemino-vascular system will lead to pain in the first branch of the trigem-
inal nerve while activation of the parasympathic system will lead to symptoms of lacrimation or
decreased nasal passage as seen in cluster headache and paroxysmal hemicrania. 33 In addition, in-
volvement of the hypothalamus has been suggested. 33 This could explain the association between
cluster headache and the longest and shortest day of the year as well as the association with men-
strual cycle related diseases as we observed in our study. 33 The influence of menstrual cycle related
disease may also be mediated through lower melatonin levels, which have been implemented in
the aetiology of cluster headache risk previously. 33, 97 Finally, it has been hypothesized that substance
P, calcitonin gene related peptide and neurokinin A play an important role in the aetiology of clus-
ter headache. 33, 96, 178 This could be an explanation for the higher risk of cluster headache with my-
coses and infections that we observed in our study. 94, 95 Although the role of neuropeptides in cluster
headache and in the different disease categories that were associated with cluster headache in our
study has not been fully clarified, our data support this as a possible mechanism.
Trigeminal neuralgia
In our study we confirmed the previous finding that hypertension is associated with trigeminal neu-
ralgia. 17, 22 At variance with a previous study reporting a protective effect of smoking, smoking was
not a risk factor in our study which supports our impression that the previous study was subject to
selection bias. 40 Their selected control category might have been related to smoking leading to a
change in point estimate. New information provided by our study is the association between diseases
of the lipid and glucose mechanism, benign neoplasm and mixed infections with first trigeminal neu-
ralgia occurrence. Although the associations between these disease groups and trigeminal neural-
gia remain to be substantiated and further elucidated, they provide further anchors for a theory
regarding the aetiology underlying idiopathic trigeminal neuralgia. Idiopathic trigeminal neuralgia
is believed to be the consequence of compression of the trigeminal nerve at the root entry zone near
the brainstem by an aberrant blood vessel (neurovascular contact), which leads to local demyelin-
isation and spontaneous action potentials. 50-54 Many things about this theory, however, remain un-
clear including the exposure prevalence of this neurovascular contact. [35-42] Disorders in the lipid
and glucose mechanism, which include cardiovascular diseases such as atherosclerosis and dia-
betes mellitus type 2, may exert their effect on trigeminal neuralgia by arterial sacking thereby in-
creasing the risk of neurovascular contact. Central demyelinisation caused by diabetes mellitus type
2 might be an explanation for the association between diabetes mellitus 2 and trigeminal neuralgia.
56-60
Apart from neurovascular contact, other factors have been implicated in the development of trigem-
inal neuralgia. Recently, the role of neuropeptides, more specifically substance P, in trigeminal neu-
ralgia has been put forward. 61, 62 Since benign prostatic hyperplasia and infections have been
associated with elevated plasma levels of neuropeptides including substance P, these conditions
might possibly be associated with trigeminal neuralgia through this pathway. 63
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Risk factors for exacerbation
Both cluster headache and trigeminal neuralgia are diseases that may exacerbate. Better insight into
the risk factors for exacerbations of cluster headache and trigeminal neuralgia may help to develop
better secondary prevention strategies. 
Previous studies have suggested an influence of alcohol, solstices, daylight saving time and weather
conditions. 34, 36, 83 None of these factors was associated with exacerbations of cluster headache of
trigeminal neuralgia in our study. Oral contraceptives and hormone replacement therapy did not in-
fluence the exacerbation risk in our study which confirmed previous findings. 85, 91 A major short-
coming of our analyses was the number of exacerbations which may explain the lack of statistical
power to confirm associations. 
Management of facial pain
The diagnosis of facial pain was made by the general practitioner in more than 75% of the cases.
The diagnostic process was usually short (median 0 days) and involved additional investigations in
only one third. In total, 50% of all patients were (eventually) referred to secondary care. 
Available literature suggests a longer diagnostic delay and a higher proportion of additional inves-
tigations performed. 5, 114, 138-140 Most available literature on this subject however was derived from
secondary or tertiary care populations or was obtained using internet questionnaires. 5, 114, 138-140 The
results are therefore difficult to generalize. These patient populations probably represent more se-
verely ill patients and represent almost 50% of our patient population since the other half was not
referred. Data from questionnaire studies may not be representative of the entire patient population.
Since we used electronic patient records from primary care physicians containing a well defined
population and data gathered irrespective of the research question our study does not suffer from
selection bias. 
Treatment of facial pain
Pharmacotherapy was given to 82% of all facial pain patients, 7% received a form of non-invasive,
non-pharmacological treatment and 10% received a form of invasive treatment. Anti-epileptic drugs
were most commonly used for neuropathic facial pain while anti-migraine drugs were mostly used
for cluster headache. Paracetamol and NSAIDs were frequently used in the treatment of both neu-
ropathic facial pain and cluster headache. This may account for the high treatment failure rate ob-
served in the first treatment episode (30% for cluster headache and 38% for neuropathic facial pain).
Persistent idiopathic facial pain, a disease with a badly understood aetiology, was mostly treated with
anti-epileptic drugs and NSAIDs. Only few drugs are registered in the Netherlands for the specific
diseases we studied. 107 Even the recommended drugs in the clinical treatment guidelines often are
not licensed for the indication. 106, 107, 129 Our studies showed that 34% of cluster headache and trigem-
inal neuralgia patients received drugs that were both off-label and off-guideline, indicating a gap be-
tween available treatment options and treatment needs.
Since treatment failure is a significant problem in the treatment of facial pain, even for recom-
mended drugs, we studied predictors for failure of the first level A recommended drugs for trigem-
inal neuralgia (carbamazepine) and cluster headache (sumatriptan, zolmitriptan and oxygen). For
trigeminal neuralgia, treatment delay and the carbamazepine dose were predictors for carbamazepine
treatment failure. In cluster headache, comorbidity, previous pain treatment, age, a fixed dose reg-
imen, treatment delay and the prescribed dose were associated with failure of sumatriptan, oxygen
or zolmitriptan treatment (level A drugs). 
The major limitation of these prognostic studies is the small sample size and poor model perfor-
mance (c-statistics of 0.6 - 0.7). The prediction models provide however a first step towards more
evidence on the determinants of failure. If confirmed in the future it may aid in tailored treatment.
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If pharmacological treatment fails, patients with trigeminal neuralgia can be invasively treated using
percutaneous radiofrequency thermocoagulation, partial sensory rhizotomy and microvascular de-
compression. We identified 672 patients in the Landelijke Medische Registratie database undergo-
ing a percutaneous radiofrequency thermocoagulation, 39 patients undergoing a partial sensory
rhizotomy and 87 patients undergoing a microvascular decompression. Using percutaneous ra-
diofrequency thermocoagulation as reference category, partial sensory rhizotomy had a relative risk
of 0.21 [95% CI: 0.07 - 0.65] for a repeat procedure (within one year) and 5.36 [95% CI: 1.46 -
19.64] for a complication. Microvascular decompression had a relative risk of 0.13 [95% CI: 0.05
- 0.35] for repeat procedures and 4.40 [95% CI: 1.44 - 13.42] for complications.
Methodological considerations
Setting
Most data used for this thesis came from the Integrated Primary Care Information (IPCI) database
which contains anonymized medical records of over one million general practitioner patients. The
database is representative for the Dutch population regarding age and sex. General practitioners act
as gatekeepers for secondary care in the Netherlands. 26 As such, their records can be considered to
hold most relevant medical information about a patient. No paper records are being kept by a gen-
eral practitioner participating in the project except specialist letters which were requested during the
validation process. Given the rarity of the studied diseases, using a large database ensured a con-
siderable dataset for most analyses. Yet, the sample size occasionally was too small to draw reliable
conclusions. Since data in the IPCI database was collected prospectively and irrespective of the re-
search question, no selection bias is present. 
Study population
All cases with facial pain were identified in the IPCI database. Controls, when applicable, were
drawn at random from the entire source population. Since we used routine electronic patient records,
we focused on an extensive validation process for our cases of facial pain. Since not all cases might
have been recognized by the general practitioner and since we were interested in the date of first
symptoms, we performed a broad and sensitive search on clinical symptoms, specific treatments,
diagnoses and diagnosis codes. To be as specific as possible as to not overestimate the incidence we
manually evaluated against the criteria of the International Association for the Study of Pain (IASP).
14 Cases were subsequently classified as ‘probable’ (specialist confirmation, two or more well de-
fined episodes), ‘possible’ (one well defined episode) or ‘improbable’ (none of the before men-
tioned). For all possible cases a questionnaire was sent to the general practitioners to confirm the
diagnosis according to the criteria of the IASP. 14 All case material (electronic patient records and
questionnaires) were evaluated independently by two medical doctors. A random sample (n=250)
was evaluated by a neurologist. This extensive case ascertainment process ensured a maximum sen-
sitivity and specificity. 
Confounders, covariates and predictors
Misclassification of exposure and covariates may cause residual confounding and spurious esti-
mates. We used both automated search and manual validation of confounders, covariates and pre-
dictors. For efficiency reasons we chose to automatically assess covariates for which previously
validated search algorithms were available and which are registered consistently by general prac-
titioners: hypertension, diabetes mellitus, concomitant drug use, patient demographics (age, sex),
smoking and alcohol abuse. 
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For evaluation of less commonly used covariates or suspected inconsistency of registration between
different general practitioners we performed manual validation using the entire electronic patient
record. Although one could argue that probable cases had less information since no questionnaires
were sent to the general practitioners in the validation process, these patients usually had special-
ist summaries in their electronic records. 
Landelijke medische registratie (LMR)
For our study on three commonly used invasive procedures for trigeminal neuralgia we used the na-
tional morbidity register (LMR). This database contains discharge diagnoses and admission details
of almost all Dutch hospitals. Discharge diagnoses and procedures are coded by trained personnel
in the hospital. In this database, we identified all patients undergoing a partial sensory rhizotomy,
microvascular decompression or percutaneous radiofrequency thermocoagulation for trigeminal
neuralgia. We looked at the relative risk for a hospitalization for repeat procedure for trigeminal neu-
ralgia (any of the three) or complication within one year. Our main concern in this study was mis-
classification of the outcome (since minor complications will not be captured) although this is
probably non-differential for the different procedures. Non-differential misclassification of the out-
come might lead to an underestimation of the effect. Furthermore, since we only have data on hos-
pitalizations, we could not evaluate the risk of minor complications and exacerbations not requiring
hospitalization. Since the complications of microvascular decompression and partial sensory rhi-
zotomy might be more severe than those of percutaneous radiofrequency rhizotomy misclassifica-
tion might lead to an overestimation of the risk for complications of microvascular decompression
and partial sensory rhizotomy.
Conclusions from this thesis
In this thesis we provided a population based estimate of the incidence rate of facial pain. In addi-
tion, we described the diagnostic work-up, health care use, drug utilization patterns, predictors of
treatment failure and risk factors for first occurrence and exacerbations. The higher incidence rate
compared to hospital data and the lower incidence compared to less stringently validated primary
care data emphasized the need to use study populations recruited from primary care settings but to
ensure proper case validation. The same applies to the assessment of the diagnostic delay, which was
shorter than previously suggested based on hospital data. 5, 138 Treatment failure is a frequent and
significant problem. We identified several possible predictors for treatment failure which need fur-
ther substantiation in larger datasets.
Furthermore, we identified several new risk factors for first occurrence of cluster headache and
trigeminal neuralgia. Based on these new risk factors we support the previously postulated hy-
pothesis of a neuropeptide mediated aetiology for both cluster headache and trigeminal neuralgia.
Given the hypothesis generating nature of this study, however, more research is needed to confirm
these associations and to identify a possible pathway. 
Recommendations for further research
The studies in this thesis may help to give direction to further research in the field of facial pain.
Our research is the first to provide information on incidence rates, patient management and treat-
ment failure based on a primary care population and profound case validation. 
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Replication of our studies in other primary care datasets would strengthen the conclusions. In ad-
dition, the findings on risk factors for trigeminal neuralgia and cluster headache need substantiation
in a larger population. More detailed information on individual diseases rather than groups of dis-
eases could give a better insight into the underlying pathophysiological mechanisms. Moreover,
treatable risk factors may provide options for preventive strategies in the treatment of facial pain.
Future studies are needed to elucidate the risk factors we identified and to investigate the role of neu-
ropeptides in the aetiology of facial pain.
Although this thesis presents new information on the risk of trigeminal neuralgia and cluster
headache, much remains unknown. Regarding trigeminal neuralgia, more research into the role of
neurovascular contact is needed before drawing definite conclusions. There are several ways to ac-
curately address this issue. One could be to establish neurovascular contact in incident cases or at-
tacks of trigeminal neuralgia and matched control persons. With the development of more
sophisticated computer algorithms of large datasets automatically assessing the presence of neu-
rovascular contact and superior MRI-scanners to detect neurovascular contact, this goal might be
reachable.
Given the high proportion of off-label and off-guideline use of treatment for facial pain and the
high treatment failure rate, research should focus on developing more effective treatment strate-
gies. For this, properly performed randomized controlled trials comparing frequently used drugs
with carbamazepine regarding effectiveness and safety should be performed. Performing these tri-
als will also enable the development of prediction models for failure and adverse events. Identify-
ing patients at high risk for failure will greatly improve treatment and might prevent adverse events. 
In this thesis we have shown the need to study facial pain in a primary care setting rather than a sec-
ondary or tertiary care setting. Since not everyone is referred to secondary care, results from research
performed in a secondary care setting might not be generalizable to primary care patients. Given the
low incidence, a large enough source population should be used to identify patients to ensure valid
results.
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Summary
Facial pain is a symptom of many different diseases. The differential diagnosis of some of the rarer
forms includes trigeminal neuralgia, postherpetic neuralgia in the facial area, cluster headache, oc-
cipital neuralgia with referred facial pain, local facial neuralgias, persistent idiopathic facial pain
(atypical facial pain), glossopharyngeal neuralgia and paroxysmal hemicrania. There is a lack of
knowledge on the aetiology, natural course, risk factors for development of first occurrence and
exacerbations, treatment algorithms and outcome of facial pain. Chapter 1.1 gives a brief intro-
duction in which the aim and background of this thesis is described. 
In chapter two a study about the estimation of the incidence of these eight forms of facial pain in
the Netherlands is described. Incidence rates are given per age category, gender, calendar year and
season. To estimate the incidence rates we used the Integrated Primary Care Information (IPCI)
database with electronic medical records of over 140 general practices throughout the Netherlands.
We showed that trigeminal neuralgia and cluster headache are the most frequently occurring types
of the studies facial pains with an incidence of 12.6 [10.5 – 15.1] and 12.5 [10.4 – 14.9] per 100,000
person years respectively. They were more frequent than previous studies using hospital data sug-
gested but less frequent than suggested by studies using less well validated primary care data. 
In chapter three we describe a study in which we evaluated risk factors for occurrence of trigemi-
nal neuralgia and cluster headache. We showed an association between smoking, recent head trauma
and cluster headache. Furthermore, we confirmed a previously shown association between hyper-
tension and trigeminal neuralgia. In addition to studying known associations, we also performed a
hypothesis generating study to identify new associations. We showed that some disease categories
are associated with trigeminal neuralgia and cluster headache. Disorders of the lipid and glucose me-
tabolism, benign neoplasm and mixed infections were related to trigeminal neuralgia. Diseases of
the internal organs, locomotoric tract, mycoses, mixed infections, allergies, menstrual cycle related
disorders and climacterium related disorders were related to cluster headache. A mechanism was
proposed to explain this possible association, namely via neuropeptides. Neuropeptides have pre-
viously been associated with trigeminal neuralgia, cluster headache and also with some of the dis-
eases that showed an association. Furthermore, we tried to identify predictors for an exacerbation
of cluster headache or trigeminal neuralgia. Although, based on literature, several risk factors were
of interest, we were not able to confirm these.
In chapter four we report four descriptive studies on treatment patterns in facial pain. Most patients
were treated rapidly after disease onset. The large majority was treated by a general practitioner. Fa-
cial pain was usually treated according to guidelines or in line with licensing data. In one third of
the cases, a drug was used which was neither registered for the indication nor recommended by
guidelines. Remarkably enough, almost one fifth of the first prescriptions included a non-opioid
analgesic. This is remarkable because these drugs are, in general, not recommended by guidelines
nor registered for the forms of facial pain we studied (with the exception of indomethacin for parox-
ysmal hemicrania). One third of the first treatment episodes failed within three months. We de-
scribe a study in which we evaluated several predictors for carbamazepine treatment failure.
Treatment delay, the dosage and comorbidity were associated with treatment failure. In chapter four
we also give a description of the diagnostic work-up and health care consumption of facial pain pa-
tients. In the majority of cases the diagnosis was made by the general practitioner. Overall, half of
all facial pain patients visited some kind of specialist (both medical and paramedical). A minority
underwent some form of additional investigation. Most patients were treated pharmacologically, a
minority invasively. Invasive procedures used for trigeminal neuralgia include microvascular de-
compression, partial sensory rhizotomy and percutaneous radiofrequency thermocoagulation. We
used the “Landelijke Medische Registratie” database to compare safety and effectiveness of these
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three procedures and determined that microvascular decompression and partial sensory rhizotomy
had a significantly better effectiveness compared to percutaneous radiofrequency thermocoagula-
tion but a worse safety profile. Hospital volume and type of hospital were prognostic factors for
treatment failure. 
Chapter five includes a general discussion on our findings and methodological aspects and con-
cludes with suggestions for further research.
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Samenvatting
Aangezichtspijn kan veroorzaakt worden door veel verschillende aandoeningen. Als een huisarts
denkt aan een zeldzame vorm van aangezichtspijn dan staan er verschillende specifieke syndromen
in de differentiaal diagnose. Dit zijn bijvoorbeeld trigeminus neuralgie, postherpetische neuralgie
in het gezicht, cluster hoofdpijn, occipitaal neuralgie met uitstralende pijn in het gezicht, persiste-
rende idiopatische aangezichtspijn (voorheen atypische aangezichtspijn), glossopharyngeus neu-
ralgie en paroxysmale hemicranie. Er is een groot gebrek aan kennis over de etiologie, het
ziektebeloop, risicofactoren voor het onstaan en exacerberen van de aandoening , behandel algo-
ritmes en voorspellende factoren voor het falen van de therapie.. Hoofdstuk I beschrijft het doel en
de indeling van het proefschrift.. In hoofdstuk wordt de geslacht en leeftijds-specifieke incidentie
van deze acht vormen van aangezichtspijn in Nederland beschreven. Hiervoor hebben we gebruik
gemaakt van de Integrated Primary Care Information (IPCI) database. Deze database bevat de ge-
anonimiseerde, elektronische, medische gegevens van meer dan 140 huisartsenpraktijken door heel
Nederland. In deze studie hebben we laten zien dat trigeminus neuralgie en cluster hoofdpijn het
meeste voorkomen van de acht door ons bestudeerde vormen van aangezichtspijn met respectieve-
lijk een incidentie van 12,6 [10,5 – 15,1] en 12,5 [10,3 – 14,9] per 100.000 persoonsjaren. Dit was
hoger dan verwacht kon worden op basis van getallen die vooral gebaseerd waren op data uit zie-
kenhuizen maar lager dan verwacht op basis van gegevens uit minder strikt gevalideerde huisart-
senstudies.
Risicofactoren voor het ontwikkelen van trigeminus neuralgie en cluster hoofdpijn worden be-
sproken in hoofdstuk 3. We hebben een verband aangetoond tussen roken, een recent hoofdtrauma
en cluster hoofdpijn. Ook hebben we de reeds bekende relatie tussen hypertensie en trigeminus
neuralgie bevestigd. Daarnaast hebben we ook gepoogd nieuwe associaties te ontdekken middels
een explorerende aanpak. Sommige categoriëen van ziektes zijn geassocieerd met trigeminus neu-
ralgie en cluster hoofdpijn. Ziektes die verband houden met het lipide en glucose metabolisme, be-
nigne neoplasmata en gemengde infecties (bacterieel en viraal) waren gerelateerd aan het
ontwikkelen van trigeminus neuralgie. Aandoeningen van de interne organen, van de tractus loco-
motorius, schimmelinfecties, gemengde infecties, allergiëen, aandoeningen van de menstruele cy-
clus en climacterium gerelateerde aandoeningen waren geassocieerd met de ontwikkeling van
cluster hoofdpijn. Mogelijk spelen neuropeptides een rol in deze relaties. Neuropeptides zijn eer-
der beschreven in de etiologie van cluster hoofdpijn en trigeminus neuralgie en ze zijn  in verband
gebracht met sommige van de ziektes die gerelateerd waren aan trigeminus neuralgie en cluster
hoofdpijn. Ook hebben wij geprobeerd voorspellende factoren voor een exacerbatie van trigeminus
neuralgie en cluster hoofdpijn te identificeren. Alhoewel enkele predictoren in de literatuur be-
schreven zijn, konden wij deze niet bevestigen in onze studies.
Hoofdstuk vier bevat vier beschrijvende studies over de behandeling van aangezichtspijn in de da-
gelijkse praktijk. De meeste patiënten worden snel na ontwikkeling van de eerste symptomen be-
handeld en het meestal door de huisarts. De meeste behandelingen waren geregistreerd voor de
specifieke pijn indicatie of waren conform de beschikbare richtlijnen voor behandeling. In een-
derde van de patiënten werd een medicijn voorgeschreven dat niet geregistreerd was, noch aanbe-
volen werd in de richtlijnen. Opmerkelijk genoeg werd eenvijfde van de patiënten behandeld met
paracetamol of een NSAID. Deze medicijnen worden over het algemeen niet aanbevolen voor de
aandoeningen die wij bestudeerden (met uitzondering van indometacine voor paroxysmale hemi-
cranie). Eenderde van de eerste behandelepisodes faalde binnen drie maanden. We hebben onder-
zocht of  falen van behandeling voorspeld kan worden aan het begin van de behandeling en vonden
dat het uitstellen van behandeling, de dosis en comorbiditeit geassocieerd waren met therapiefalen.
Daarnaast hebben we beschreven hoe het diagnostisch proces verloopt in patiënten met aange-
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zichtspijn en hoeveel beslag deze patiënten leggen op de gezondheidszorg. De huisarts stelde de di-
agnose in de meerderheid van de gevallen. De helft van alle patiënten werd doorverwezen naar een
medisch specialist (medisch en paramedisch), slechts een  minderheid onderging aanvullende on-
derzoeken. De meeste mensen werden pharmacologisch behandeld; een minderheid invasief. Mi-
crovasculaire decompressie, partiële sensore rhizotomie en percutane radiofrequente
thermocoagulatie zijn invasieve procedures die gebruikt worden voor trigeminus neuralgie. Wij
hebben de veiligheid en effectiviteit van deze procedures vergeleken in de “Landelijke Medische
Registratie”. Microvasculaire decompressie en partiële sensore rhizotomie waren effectiever dan
percutane radiofrequente thermocoagulatie maar ook onveiliger. Het aantal ingrepen per zieken-
huis en het type ziekenhuis (academisch of perifeer) waren predictoren voor falen van therapie.
Wij sluiten af in hoofdstuk vijf met een algemene discussie van onze bevindingen, methodologische
aspecten van onze studies en suggesties voor toekomstig onderzoek.
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Appendix A: Flowchart 
 
 
Cases: 
1466 patients
Search algorithm  
Source population: 
479,949 patients 
141 practices 
Questionnaires mailed to 
General Practitioners
Reply: 
481 patients 
52 practices 
Probable: 
180 
patients 
Possible: 
562 patients 
62 practices 
No-case: 
319 patients 
Case: 
121 patients 
No-case: 
9 patients 
Prevalent ***: 
23 patients 
Record validation 
Validation by two medical 
doctors (JK, MM)
Validation by a neurologist of a 
random sample 
Prevalent *: 
405 patients 
Incident: 
742 patients 
Case: 
247 patients 
No-case: 
200 patients 
Prevalent ***: 
34 patients 
Case: 
362 patients 
No-case: 
6 patients 
10 Non-replying practices 
removed ** 
Probable: 
153 
patients 
111,810 hits 
Manual validation
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Appendix B: Classification of morbidities (by pathogenesis) 
 
 Anatomic Degenerative Metabolic Neoplasm 
Internal Organs 
abdominal hernia 
cardiac valve deformity 
diaphragmatic hernia 
gastro-esophageal reflux  
   disease 
inguinal hernia 
nefrolithiasis 
spermatocèle 
umbilical hernia 
urinary tract reflux 
urogenital adhesions 
urogenital stricture 
urolithiasis 
torsio testis 
 
Neurologic tract 
meralgia paresthetica 
nerve entrapment 
radicular syndrome 
spina bifida occulta 
spinal disc herniation 
carpal tunnel syndrome 
 
Locomotoric tract 
anatomic disorder of any  
 extremity not futher defined 
cervicobrachial syndrome 
cervicogenic vertigo 
dysplasia of the hip 
 
Vascular tract 
hemorrhoids 
hypostatic eczema 
(trombogenic) varices 
venous insufficiency 
 
Other 
atrophy of the maxilla 
deviation of the nasal septum 
incarnated nail 
obstruction of the parotic 
   gland 
obstructive sleep apnea 
phimosis 
 
Internal organs 
diverticulosis 
urogenital prolaps 
 
Neurologic tract 
Alzheimer’s dementia 
benign paroxysmal position 
   dependent vertigo 
Parkinson’s disease 
psychogeriatric problems 
 
Locomotoric tract 
arthrosis 
chondromalacia 
chondropathy 
costoclavicular compression  
   syndrome 
discopathy 
stenosis of the vertebral  
   column 
tendinosis 
thoracic outlet syndrome 
vertebral weakness 
trigger finger 
 
Vascular tract 
aneurysm of the aorta 
 
Other 
ablatio retinae 
blepharochalazis 
cataract 
retraction of corpus vitreum  
ectropion 
keratoconjunctivitis 
luxation of the lens 
macula degeneration 
mamma involution 
mouches volantes 
 
Lipid and glucose 
metabolism 
amaneurosis fugax 
angina pectoris 
arterial stenosis 
atherosclerosis 
cerebrovascular accident 
cholelithiasis 
claudicatio intermittens 
cysteinuria 
diabetes mellitus type II 
diabetic nefropathy 
diabetic polyneuropathy 
diabetic retinopathy 
cardiovascular disease 
hepatic steatosis 
hypercholesterolemia 
hyperglycemia 
hypertensive retinopathy 
intracranial bleeding 
lipodystrophia 
transient ischemic attack 
thrombosis of the eye 
xantelasmata 
 
Excesses or deficiencies 
erythropoietic protoporphyria 
folic acid deficiency anemia 
hemochromatosis 
hemoglobinopathy 
hypokalemia 
iron deficiency anemia 
lactose intolerance 
leber opticus atrophy 
Lewy body dementia 
mitochondrial disease 
myositis ossificans 
syndrome of Bartter 
syndrome of Klippel-  
   Trenaunay 
thalassemia 
vitamine B12 deficiency 
vitamine B12 deficiency 
   anemia 
vitamine D deficiency 
vtiamine B1 deficiency 
Willibrand's disease 
 
Intoxications 
alcoholic gastritis 
alcoholic hepatitis 
   intoxication 
Korsakoff’s disease 
liver cirrhosis 
 
Other 
acute tubular necrosis 
cardia insufficiency 
decubitus 
disturbed kidney function 
gout 
hyperuricemia 
postoperative delirium 
Benign 
adenoma 
angioma 
benign brain tumor 
benign lung tumor 
benign mamma tumor 
benign nervous system tumor 
benign parotic tumor 
benign prostate hyperplasia 
benign skin tumor 
benign thyroid tumor 
cholesteatoma 
clavus 
cornu cutaneum 
dermatofibroma 
eccrien hidrocytoma 
exostosis  
feochromocytoma 
fibroadenoma 
fibroma 
granuloma 
hemangioma 
histiocytoma 
keloid 
lipoma 
meningeoma 
myoma 
naevus 
neurinoma 
neurofibroma 
osteoma 
papilloma 
polyp 
schwannoma 
 
Malignant 
astrocytoma 
Barret's esophagus 
Bowen's disease 
carcinoma of the bladder 
carcinoma of the colon 
carcinoma of the endometrium 
carcinoma of the kidney 
carcinoma of the lung 
carcinoma of the mamma 
carcinoma of the prostate 
carcinoma of the sinus 
carcinoma of the skin 
cervical dysplasia 
Hodgkin’s lymphoma 
keratosis actinica 
leucoplakia 
melanoma 
Non-Hodgkin’s lymphoma 
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bacterial 
abces 
acute rheumatic 
fever 
appendicitis 
axillar dermatitis 
bacterial 
conjunctivitis 
balantitis 
bartholinitis 
campylobacter 
infection 
cellulitis 
chlamydia 
cholangitis 
cholecystitis 
cystitis 
diverticulitis 
duodenic ulcer 
dysenteria 
epididymitis 
erysipelas 
erythema nodosum 
erytrasma 
flebitis 
folliculitis 
furuncle 
gardnerella infection 
giardiasis 
gingivitis 
gonorrhea 
helicobacter pylori 
gastric ulcer 
helicobacter pylori 
   gastritis 
hordeolum/chalazion 
hydradenititis 
impetigo 
Lymes’ disease 
orchiitis 
ostemylitis 
parodontitis 
paronychia 
parotitis 
pelvic inflammatory 
   disease 
phlegmon 
prostatitis 
pyelonefritis 
salmonelloses 
scarlet fever 
sexual transmittable 
   disease 
trichomonas 
infection 
tuberculosis 
urethritis 
urinary tract 
infection 
urosepsis 
Commonly viral 
Bornholm’s disease 
condylomata 
accuminata 
chorioretinitis 
croup 
cytomegalo virus 
hepatitis A 
herpes simplex 
herpes zoster 
Pfeiffer’s disease 
post viral fatigue 
syndrome 
varcella zoster 
infection 
dermatomycosis 
intertrigo 
onychomycosis 
oral mycosis 
perianal mycosis 
pharyngeal mycosis 
pityriasis 
rosacea 
tinea pedis 
urogenital mycosis 
candida 
 
Several types of 
microorganisms 
possible 
adenoiditis 
blepharitis 
bronchitis 
corneitis 
dacryocystitis 
dermatitis not further 
   defined 
endocarditis 
enteritis 
epiglottitis 
gastroenteritis 
upper airway tract 
   infection 
infection not further 
   defined 
infectious conjunctivitis 
infectious rhinitis 
laryngitis 
meibomitis 
meningitis 
otitis externa 
otitis media 
perforation of the 
   tympanum 
pharyngitis 
pneumonia 
respiratory tract infection 
sinusitis 
skin infection not further 
   defined 
stomatitis 
tonsilitis 
tracheitis 
ulcer of the cornea 
ulcer of the ear 
ulcer of the perineum 
vaginitis 
vulvitis 
 
Other 
headlice 
oxyuria 
scabies 
Autoimmune* 
autoimmune hepatitis 
Bechterew's disease 
Behcet's disease 
Chron's disease 
Churg Strauss’ disease 
colitis ulcerosa 
crest syndrome 
diabetes mellitus type I 
Graves disease 
lichen ruber planus 
lichen sclerosis et 
   atroficans vulvae 
mixed connective 
   tissue disease 
multiple sclerosis 
myasthenia gravis 
polymyalgia 
rheumatica 
psoriasis 
psoriatic arthritis 
Quervain's disease 
rheumatic syndrome 
rheumatoid arthritis 
sarcoidosis 
Sjögren' s disease 
Still's disease 
vasculitis 
vitiligo 
 
Asthma* 
asthma 
chronic aspecific 
   respiratory disorders 
 
Allergy* 
allergic conjunctivitis 
allergic rhinitis 
allergy not further 
   defined 
angioedema 
broncheal hyperactivity 
urticaria 
allergic vasculitis 
 
eczema 
atopic eczema 
constitutional eczema 
contact eczema 
seborrhoeic eczema 
 
Locomotoric tract 
arthritis 
bursitis 
capsulitis 
costochondritis 
lateral epicondylitis  
medial epicondylitis 
fasciitis plantaris 
synovitis 
tendinitis 
tendosynovitis 
tendovaginitis 
apexitis 
 
 
 
asthmatic bronchitis 
chronic bronchitis 
colitis not further 
   defined 
episcleritis 
esophagitis 
fibrosis of the lung 
interstitial pulmonary 
disorder 
iriits 
lymfadenitis 
lymfadenopathy 
mastitis 
neuritis 
neurodermatitis 
photodermatosis 
proctitis 
scleritis 
sigmoiditis 
thyroiditis 
uveitis 
chronic obstructive 
pulmonary 
   disease/ 
   emphysema 
keratitis 
duodenitis 
 
 
 
 
 
 
 
 
 
Infections Infections (contin.) Inflammation Inflammation 
(contin.) 
Commonly Mycoses Hypersensitivity Other 
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verrucae 
viral conjunctivitis 
undefined viral 
   infection 
 
Hormonal Psychological 
factors 
Trauma 
Sex hormones 
Menstrual Cycle 
   related* 
dysmenorhea 
irregular menstrual 
   cycle 
metro/menorrhagia 
polymenorhea 
premenstrual 
syndrome 
senundary 
amenorhea 
 
Climacteriu 
    related 
atrophic vaginitis 
Climacterial 
   symptoms 
climacterium 
praecox 
osteoporosis/ 
osteopenia* 
 
Other 
endometriosis 
hirsutism 
hypertrichosis 
 
Thyroid 
hormones 
athyroidism 
hyperthyroidism 
hypothyroidism 
struma 
 
Other 
hyperparathyroidism 
hyperprolactinaemia 
hypofyse related 
problems 
hypogonadism 
Depression* 
bipolar disorder 
depression not further 
   defined 
dysthymic disorder 
neurotic depression 
postnatal depression 
psychotic depression 
reactive depression 
 
Anxiety* 
anxiety/panic disorder 
anxious/nervous feelings 
hyperventilation 
hypochondria 
phobia 
 
Psychosocial* 
psychosocial problems 
 
Stress* 
burn out 
posttraumatic stress 
   syndrome 
stress 
 
Other 
alcohol abuses 
anorexia nervosa 
attention deficit 
   hyperactivity disorder 
bulimia 
drug abuse 
functional polyuria 
hallucinations 
impulse regulation 
disorder 
catatonia 
manic disorder 
medication abuses 
nervous dermatitis 
neurasthenia/surmenage 
neurosis 
nicotine abuse 
personality disorder 
psychiatric problems not  
   further defined 
psychogenic epilepsy 
psychosis 
schizophrenia 
Soft tissue 
ecchymosis 
fissura ani 
hematoma 
rontgen dermatitis 
syndrome of Mallory Weiss 
top injury of a finger 
wound 
 
Locomotoric tract 
frozen shoulder 
loge syndrome 
meniscus lesion 
muscle fascia defect 
patellofemoral pain syndrome 
perihumeroscapulair syndrome 
pseudoarthrosis of the arm 
pseudoarthrosis of the wrist 
repetitive strain injury 
rotator cuff syndrome 
spoke injury 
 
neurological tract 
commotion cerebri 
contusion cerebri 
post spinal headache 
posttraumatic tinnitus 
whiplash 
 
Other 
bleeding in the eye 
cornea erosion 
corpus alienum at any location 
orbital bleeding 
posttraumatic syndrome 
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Appendix C: ICD-9 Complication 
 
389  Hearing loss  
34981  Cerebrospinal fluid rhinorrhea  
7820  Disturbance of skin sensation  
38861  Cerebrospinal fluid otorrhea  
322  Meningitis of unspecified cause  
321  Meningitis due to other organisms  
320  Bacterial meningitis 
047  Meningitis due to enterovirus 
7813  Lack of coordination 
368  Visual disturbances 
998  Other complications of procedures, NEC 
997  Complications affecting specified body systems, not elsewhere classified  
996  Complications peculiar to certain specified procedures 
054  Herpes simplex 
7804  Dizziness and giddiness 
3883  Tinnitus 
3510  Bells palsy 
37853  Fourth or trochlear nerve palsy  
3885  Disorders of acoustic nerve 
78194  Facial weakness 
854  Intracranial injury of other and unspecified nature 
370  Keratitis 
9961  Mechanical complication of other vascular device, implant, and graft 
37181  Corneal anesthesia and hypoesthesia  
V410  Problems with sight 
E870  Accidental cut, puncture, perforation, or hemorrhage during medical care 
E871  Foreign object left in body during procedure 
E878  Surgical operation and other surgical procedures as the cause of abnormal reaction of 
patients, or of later complication, without mention of misadventrue at the time of 
operation 
E879  Other procedures, without mention of misadventure at the time of procedure, as the 
Cause of abnormal reaction of patient, or of later complication  
9954  Shock due to anesthesia 
9950  Other anaphylactic shock 
C2939  Unspecified transient mental disorder in conditions classified elsewhere 
C3209  Meningitis due to unspecified bacterium 
C3229  Meningitis, unspecified 
C3429  Hemiplegia, unspecified  
C3682  Diplopia 
C3899  Unspecified hearing loss 
C4340  Cerebral thrombosis 
C5070  Due to inhalation of food or vomitus 
C5990  Urinary tract infection, site not specified 
C9973  Respiratory complications  
C9981  Hemorrhage or hematoma or seroma complicating a procedure 
C9985  Postoperative infection 
Seppe proefschrift boek:Opmaak 1  01-04-2010  20:11  Pagina 158
Acknowledgements
Too many people helped me to finish my current work for me to name them all. Furthermore, the
risk of naming people includes the risk of forgetting people who might very well have been crucial
for completion of this work. I would sincerely like to thank each and every one of you who helped
me to accomplish this task.
159
Seppe proefschrift boek:Opmaak 1  01-04-2010  20:11  Pagina 159
Bibliography
Koopman JS, Kunthonluxamee A, Dieleman JP, Huygen FJ, Sturkenboom MC.
Cluster headache and head trauma: A Dutch population-based study.
Submitted
Koopman JS, Huygen FJ, Dieleman JP, de Mos M, Sturkenboom MC.
Pharmacological treatment of neuropathic facial pain in the Dutch General population.
2010 Mar;11(3):264-72
Koopman JS, Dieleman JP, Huygen FJ, de Mos M, Martin CG, Sturkenboom MC.
Incidence of facial pain in the general population.
Pain. 2009 Dec 15; 147(1-3):122-7
Koopman JS, Vrinten DH, van Wijck AJ.
Efficacy of microcurrent therapy in the treatment of chronic nonspecific back pain: a pilot study.
Clin J Pain. 2009 Jul-Aug ;25(6):495-9.
de Mos M, Huygen FJ, Dieleman JP, Koopman JS, Stricker BH, Sturkenboom MC.
Medical history and the onset of complex regional pain syndrome (CRPS).
Pain. 2008 Oct 15;139(2):458-66.
Koopman JS, Baoutou Y.
De betrouwbaarheid van troponine en CK-MB bij patiënten met een subarachnoidale 
bloeding (SAB)
NTvA. 2009 Feb; 21(1).
Koopman JS, Vrinten DH, van Wijck AJ:
Elektroanalgesie bij de behandeling van acute en chronische pijn: Mogelijkheden,
technieken, literatuur.
NTPP. 2008
Koopman JS.
Genetisch verbeteren en de doelen van de gezondheidszorg 
Verslag. 2005
160
Seppe proefschrift boek:Opmaak 1  01-04-2010  20:11  Pagina 160
